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Abstract 
Escherichia coli is a common human pathogen, capable of causing a wide range of 
infections. Some strains produce AmpC beta-lactamase, an enzyme able to affect 
the action of antibiotics. These strains are often resistant to cephalosporin 
antibiotics, causing problems for clinical treatment. The production of the enzyme 
can be mediated by either mutations in the chromosomal ampC promoter region, 
or through the acquisition of ampC plasmid genes from other species. 
In this study, SYBR Green real-time PCR was used to detect blaAmpC and blaCTX-M 
genes in E. coli isolates collected in Gloucester and four other laboratories in the 
South West region (Dorchester, Swindon, Taunton and Truro). Following a small 
pilot study, a larger study of 276 isolates collected from the five laboratories was 
undertaken. Isolates were tested for the presence of acquired blaAmpC genes and 
blaCTX-M extended-spectrum beta-lactamase (ESBL) genes. The ampC promoter 
region for each isolate was sequenced, and all isolates were typed using multi-locus 
sequence typing (MLST). 
AmpC plasmid genes were identified in 19 isolates (15 with CIT-type and 4 with 
DHA-type). The most common ampC promoter mutation was a T to A transition at 
position -32, seen in a total of 36 isolates. This was in contrast to other studies, in 
which the most common mutation is found at position -42. MLST confirmed the 
expected dominance of the ST131 clone (43.6% of isolates) within the cefpodoxime-
resistant isolates in the South West. There was no evidence for a dominant clone 
within the AmpC plasmid-carrying isolates, but some potential evidence for a 
dominant clone of ST12 with the -32 ampC mutation present. 
Overall, in 276 E. coli isolates with cefpodoxime-resistance, 25.8% were confirmed 
as having a genotype associated with AmpC resistance. The remaining isolates were 
largely carrying a blaCTX-M gene (57.1%) or another type of ESBL (16.4%). 
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1 Introduction 
Escherichia coli is a common bacterium that has, over time, developed into a 
successful human pathogen. Not only a common component of the normal 
intestinal flora in humans, it is capable of causing a wide range of extra-intestinal 
infections; from urinary tract infections to septicaemia and meningitis (Jaureguy et 
al., 2008). The impact of E. coli urinary tract infections alone globally is substantial. 
It is estimated that there are 130-175 million cases of uncomplicated cystitis in 
women, and 5.4 million cases of uncomplicated pyelonephritis each year 
worldwide. E. coli will be reported as the causative agent in 85-90% of these cases 
(Russo & Johnson, 2003), and other estimates suggest that half of all women in the 
United States will have a urinary tract infection at least once by the fourth decade 
of life (Foxman, 2002). 
E. coli is also the most common cause of bacteraemia reported in the UK, with a 
total of over 35,000 cases in England and Wales during 2014 (Public Health England, 
2015c). Mortality rates in these cases have been estimated to be in the region of 
15%; equating to 4,800 deaths annually (Davies, 2013), therefore making options 
for effective treatment essential. 
E. coli infections are usually easily treated with antibiotics. Some strains, however, 
produce beta-lactamase enzymes that inhibit the action of certain antibiotics. This 
can result in infections that are more difficult to treat, and which can be associated 
with a higher mortality rate (de Kraker et al., 2011). 
The beta-lactam group of antibiotics include the penicillins and cephalosporins, and 
represents the largest overall group of antimicrobials (Livermore & Woodford, 
2006). These antimicrobial agents contain a beta-lactam ring as an integral part of 
their structure, and target the synthesis of the bacterial cell wall as their mode of 
action. Beta-lactamase enzymes produced by bacteria break down the beta-lactam 
ring, rendering the antibiotic ineffective. 
The beta-lactamase enzymes represent a large and diverse collection of enzymes, 
including the extended spectrum beta-lactamases (ESBL) and AmpC beta-
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lactamases. Both types of enzyme confer resistance to the cephalosporin 
antibiotics. ESBL enzymes are characterised by a broad pattern of resistance to 
cephalosporin antibiotics that has expanded to include the third-generation 
antibiotics (e.g. cefotaxime) (Pfaller & Segreti, 2006). Phenotypic detection in the 
laboratory is possible by demonstrating reversal of resistance using an inhibitor 
compound such as clavulanic acid. Clinical laboratories in the UK are recommended 
to screen all significant E. coli isolates for the presence of ESBLs using the third-
generation cephalosporin cefpodoxime (Andrews & Howe, 2011). 
The main difference between AmpC and ESBL enzymes is a lack of activity in the 
AmpC enzymes against fourth-generation cephalosporins (e.g. cefepime) and a 
failure to have the resistance reversed using clavulanic acid (Woodford et al. 2007). 
The presence of an AmpC enzyme, however, can still be confirmed phenotypically 
using an alternative inhibitor compound, such as cloxacillin (Babini & Livermore, 
2000) or boronic acid (Coudron, 2005). 
1.1 Extended-Spectrum Beta-Lactamases (ESBL) 
The first beta-lactamases with an extended spectrum of activity were mutations of 
the TEM-1 and SHV-1 enzymes; commonly found as native enzymes in 
Enterobacteriaceae. Minor amino acid substitutions were sufficient to expand the 
hydrolyzing activity beyond the penicillins (Cantón et al., 2008). These new enzymes 
(e.g. SHV-2 and SHV-5) were called extended-spectrum beta-lactamases due to their 
ability to hydrolyze the third-generation cephalosporins, but not the cephamycins. 
Over the last decade, there has been a significant shift in the prevalence of different 
ESBL types, with the TEM and SHV ESBL enzymes being largely replaced by CTX-M 
enzymes (Livermore et al., 2007). 
Although the CTX-M enzymes were first discovered in 1989 (Bauernfeind, Grimm & 
Schweighart, 1990), they did not reach prominence until early in the 21st century. 
The first CTX-M enzyme was detected in an E. coli strain isolated from an ear in a 4-
month old child with otitis media. The CTX refers to the enhanced activity against 
cefotaxime and the –M refers to Munich, the city of first isolation. Phylogenetic 
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analysis indicates that the CTX-M enzymes originated from chromosomal genes 
from various Kluyvera spp. (Cantón et al., 2008). 
In the UK, CTX-M genes were first reported in 2000 (Alobwede et al., 2003), but by 
2004 were the predominant cause of cephalosporin resistance in E. coli and 
Klebsiella pneumoniae (Potz et al., 2006). A later study of E. coli bacteraemia 
isolates in Leeds between 2010 and 2012 found 68% of ESBL-producing isolates 
were carrying CTX-M Group 1 genes (Horner et al., 2013). 
The CTX-M enzymes are characterised by enhanced activity against cefotaxime, and 
are classified into five main groups according to amino acid sequence similarities. 
The Group 1 enzymes include CTX-M-1, -3, -10, -12 and CTX-M-15. Group 2 enzymes 
include CTX-M-2, -4, -5, -6, -7 and -20. Group 8 includes CTX-M-8. Group 9 enzymes 
include CTX-M-9, -13, -14, -16, -17, -19, -21 and -27. Group 25 includes the CTX-M-
25 and CTX-M-26 enzymes (Bonnet, 2004). 
There are >170 different recorded variants of CTX-M enzymes 
(http://www.lahey.org/studies) (last checked 02/10/15). The most common are 
CTX-M-14 and CTX-M-15; found in human, animal and environmental sources 
worldwide (Cantón et al., 2008). The predominant reason for the increase in the 
prevalence of CTX-M ESBL enzymes is the global dissemination of the ST131 
pandemic E. coli clone that carries the gene for CTX-M-15 production (Coque et al., 
2008) (See Section 1.5). 
1.2 AmpC Beta-Lactamases 
E. coli strains produce AmpC beta-lactamase enzymes using two separate 
mechanisms. Firstly, all strains have genes encoded in the chromosome for enzyme 
production (Olsson et al., 1983). The level of production is tightly controlled and at 
a level so low as to not cause detectable resistance. Mutations can occur in the 
ampC promoter region that affect the level of control, leading to hyper-production 
of the AmpC enzyme and potential treatment failures (Caroff et al., 2000). 
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E. coli strains can also acquire the genetic material coding for AmpC enzyme 
production from other species. Plasmids carrying ampC genes are derived from 
species such as Enterobacter sp. and Citrobacter sp. 
1.2.1 Plasmid-Mediated AmpC Resistance 
Although there is some evidence of AmpC-carrying plasmids as early as 1976 
(Bobrowski et al., 1976), the first credible report was in 1989 in the United States, 
when Bauernfeind et al. (1989) reported the isolation of a K. pneumoniae strain 
from a patient’s wound site. This first plasmid gene was called CMY-1, after its 
cephamycinase activity. Later, Papanicolaou et al. (1990) identified a plasmid gene 
named as MIR-1, with the inhibition profile indicative of a beta-lactamase enzyme. 
Sequencing a short (150bp) region found 90% identity with the ampC chromosomal 
gene of Enterobacter cloacae, but only 71% identity with the ampC gene in E. coli. 
The first reported UK case was in 1989 (Woodford et al., 1990), in a patient 
originating from Pakistan. The plasmid was isolated from an E. coli strain and was 
subsequently shown to transfer resistance to three different genera (Payne, 
Woodford & Amyes, 1992). The plasmid was originally named BIL-1, but with the 
advent of more sophisticated sequencing methods has been confirmed to be 
identical to the CMY-2 plasmid gene (Barlow & Hall, 2002). By 2009, CMY-2 was the 
most commonly reported AmpC plasmid gene worldwide (Jacoby, 2009). 
In 2002, Perez-Perez and Hanson published a set of primers for detecting and 
classifying the AmpC plasmid genes into six groups (Perez-Perez & Hanson, 2002). 
Using traditional end-point PCR methods, with a multiplexed primer set, isolates 
could be placed into one of six groups: ACC, FOX, MOX, DHA, CIT and EBC. The six 
groups were based on the sequences derived from similar species: Hafnia alvei 
(ACC), Morganella morganii (DHA), Citrobacter freundii (CIT) and Enterobacter 
cloacae (EBC).  
CMY-2 (part of the CIT group) has a wide geographic spread, and is often reported 
as the most common AmpC plasmid-mediated gene in surveillance studies 
(European Centre for Disease Prevention and Control, 2014). The potential 
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reservoirs for the CMY-2 plasmid genes are numerous and widespread. Voets et al. 
(2013) screened retail chicken products in the Netherlands and compared resistant 
E. coli isolates with human isolates. In the chicken isolates, 12.2% carried a CMY-2 
plasmid gene, compared to 5.2% of the human isolates. Overall, the study results 
indicated that 68% of human AmpC plasmid-carrying E. coli isolates have the same 
ampC plasmid gene as that found in poultry meat. 
In a UK study of raw chicken products imported into the UK from South America, 
42% of the 141 cefpodoxime-resistant E. coli isolates carried a CMY-type AmpC 
plasmid (Dhanji et al., 2010). The majority of the other isolates had CTX-M-type 
ESBL genes, with two isolates shown to have both CMY-type and CTX-M-type genes. 
Another Dutch study (Dierikx et al., 2012) investigated the presence of antibiotic 
resistance genes in veterinary isolates of Enterobacteriaceae; isolated from dogs, 
cats, horses and a turtle. Most of the isolates came from cases of urinary tract 
infections in the animals. CMY-2 plasmid genes were found in 13.8% of the 
cephalosporin-resistant isolates, with other isolates mainly having CTX-M type 
genes present. The presence of blaAmpC genes in cefoxitin-resistant E. coli strains 
isolated from water sources and beaches across Canada was investigated in 2009 
(Mataseje et al., 2009). CMY-2 AmpC plasmid genes were found in 77.5% isolates 
examined. 
Plasmids carrying genes for AmpC beta-lactamases can also carry multiple other 
resistance genes, including those for resistance to the aminoglycosides, quinolones 
and other beta-lactamases (Jacoby, 2009). Also, the co-occurrence of multiple 
AmpC plasmid genes in the same strain has been reported in a number of species, 
including E. coli (Chérif et al., 2015). Resistance genes can also occur alongside 
virulence genes. The large outbreak in Germany in 2011 of E. coli serotype O104 
was found, after whole genome analysis, to be carrying genes for shiga-toxin 
production and also the CTX-M-15 gene (Rasko et al., 2011). The outbreak had a 
reported total number of 4075 cases and 50 deaths. 
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1.2.2 Chromosomal AmpC Resistance in E. coli 
The promoters for E. coli RNA polymerase have two highly conserved regions, 
located 10 and 35 base pairs upstream from the transcription start site. This is the 
case in a number of different promoters for the organism, including the ampC 
promoter. The two conserved sequences for the -10 and -35 regions are TATAAT 
and TTGACA, respectively (Hawley & McClure, 1983). In addition to the sequences 
of these regions, the actual distance between them is important for promoter 
strength, with a 17bp distance creating a stronger promoter. Promoters with 
distances of 15bp and 20bp have been reported to retain only partial function 
(Hawley & McClure, 1983). The -10 and -35 box regions are key to the success of the 
transcription process, and are responsible for the fixation of the sigma factor 
subunit of RNA polymerase (Busby & Ebright, 1994). The ampC promoter for E. coli 
is different by a single base pair in each of the two boxes, and has an inter-box 
distance of 16 base pairs (Figure 1-1). It is these small changes that reduce the 
power of the promoter and the associated level of enzyme production (Corvec et 
al., 2007). Mutations that affect either of the two box regions, or the distance 
between them, can have an impact on promoter strength, and the corresponding 
level of enzyme production. 
All E. coli strains have the chromosomal ampC gene encoding for AmpC beta-
lactamase production (Hawley & McClure, 1983). In most cases, the gene is under 
tight regulation and is expressed constitutively in low amounts; rarely producing 
enough enzyme to cause clinical resistance. The potential role of the ampC gene in 
causing an increase in the production of beta-lactamase enzymes was first 
suggested in 1979 (Bergstrom & Normark, 1979), when six isolates of E. coli were 
investigated due to unusual resistance. The first report in a clinical isolate was in 
1982 (Olsson, Bergstrom & Normark, 1982), when four single base pair mutations in 
the ampC promoter region were described that resulted in a 40-fold increase in 
AmpC enzyme production. One of the mutations was located near the -35 box 
region, at position   -42. This mutation is the most frequently reported in studies, 
and creates a displaced -35 box with a sequence closer to that of the E. coli 
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consensus sequence (TTGACA) (Figure 1-1b) (Mulvey et al., 2005; Mammeri et al., 
2008; Jorgensen et al., 2010; Bogaerts et al., 2010). 
 
 
Figure 1-1: Section of the ampC promoter region in E. coli, with examples of mutations. 
(a) The wild-type hexameric -10 and -35 boxes 
(b) C->T transition at position -42 creates a displaced -35 box with a sequence identical to the E. coli 
standard promoter (TTGACA) 
(c) T->A transition at position -32 creates an altered wild-type -35 box with a sequence identical to 
the E. coli standard promoter (TTGACA) 
(d) Insertion of a single nucleotide at position -13 increases the spacer distance from 16bp to 17bp. 
Numbering of positions is according to Jaurin et al. (1981). 
Figure adapted with permission from Lewis et al. (2013). 
 
Other mutations in the ampC promoter region have been reported to cause a 
significant increase in enzyme production (Caroff et al., 2000). Mutations are 
usually grouped into those that create a displaced promoter region and those that 
change the existing promoter region. In addition to the -42 mutation (C to T), 
commonly reported mutations include a T to A transition at position -32 (Figure 1-
1c) and a 1 or 2 bp insertion at position -13 (Figure 1-1d) (Tracz et al., 2007). 
The -32 mutation (T to A) was first described by Kobayashi et al. (1990), and has 
since been reported to increase enzyme expression by a factor of 46-fold (Tracz et 
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al., 2007). This mutation changes the existing -35 box region to one with a sequence 
closer to the E. coli consensus sequence. 
The insertion of one or two bases in position -13 increases the distance between 
the -10 and -35 regions. The importance of the spacer distance between the -10 and 
-35 box regions in the ampC promoter was confirmed by Ayers et al. (1989). 
Moreover, Tracz et al. (2007) demonstrated that isolates with a single base pair 
insertion at position -13 had a 24- to 61-fold increase in enzyme expression. 
The -42, -32 and -13ins mutations are often found together with mutations at other 
locations in the promoter region. In a large Canadian study, Mulvey et al. (2005) 
found mutations at 29 different locations in the 271bp sequenced ampC promoter 
region. In the 166 E. coli isolates investigated, a total of 49 different mutation 
patterns were found; all but one of which had multiple locations involved. Other 
mutations have been reported, including mutations in the attenuator and coding 
regions, but these have been shown to have a lesser impact on the level of enzyme 
production (Tracz et al., 2007). 
1.3 Epidemiology of AmpC-Mediated Resistance 
European surveillance data indicate that the mean rate of resistance for third 
generation cephalosporins in invasive E. coli isolates (from blood and CSF) was 
12.6% for the participating countries in 2013 (European Centre for Disease 
Prevention and Control, 2014). The individual country rates varied from 5.0% for 
Iceland to 39.6% for Bulgaria, with the UK having a rate of 14.7%. Overall, the 
adjusted population mean rate increased significantly from 9.5% to 12.6% over the 
four-year period up to 2013. Although some European data exist for ESBL 
prevalence rates, this does not include UK strains or the inclusion of data for the 
prevalence of AmpC-producing strains. 
The incidence of AmpC-mediated resistance in most areas of the UK is unknown. 
Although a national surveillance programme exists for E. coli bacteraemia strains, 
this does not extend to characterising the mechanisms of resistance or to include 
other sample types (e.g. urine). Laboratory surveillance data submitted to Public 
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Health England (Public Health England, 2014) indicate that 10.9% of E. coli 
bacteraemia isolates in the UK were phenotypically determined as being resistant 
to cephalosporins during 2013. The percentage of cephalosporin-resistant cases 
was seen to vary in regions throughout the UK, with London and Cheshire, 
Warrington, Wirral having the highest at 15% and Devon, Cornwall having the 
lowest rate at 6%. This suggests that the types of resistance mechanisms found in E. 
coli may also vary between regions. There are no national data, however, for the 
actual presence of ESBL or AmpC resistance genes. 
In 2006, Potz et al. (2006) tested 1253 cephalosporin-resistant Enterobacteriaceae 
isolates that had been submitted to the English national reference unit (Colindale, 
London). Of these, 16.9% were high-level AmpC producers. Another study reported 
in 2006 (Hopkins et al., 2006a), investigated a different collection of E. coli isolates 
submitted to the national reference laboratory between 1995 and 2003. In one of 
the few studies to investigate ampC chromosomal mutations in the UK, 103 
cephalosporin-resistant E. coli isolates were examined. A total of 37 isolates were 
confirmed as having possible AmpC genes, based on cefoxitin resistance, with 
67.6% carrying an AmpC plasmid gene and 29.7% having chromosomal ampC 
mutations. However, as these isolates had been submitted to the national reference 
laboratory, they may not truly reflect the populations of strains circulating in clinical 
samples. 
Woodford et al. (2007) investigated 135 E. coli isolates for the presence of AmpC 
plasmid genes. All isolates had been selected from those referred to the reference 
laboratory as having a phenotype suggestive of an AmpC plasmid-mediated 
resistance (cephalosporin resistance without potentiation by clavulanic acid). A 
total of 67 (49.6%) isolates were confirmed as carrying an AmpC plasmid gene, 59 of 
which were of the CIT group, 4 were of the ACC group, 3 were of the FOX group and 
1 was from the DHA group. 
Studies investigating the normal human carriage of E. coli strains with ampC 
chromosomal mutations are rare. Van Hoek et al. (2015b) investigated 1033 rectal 
swabs from volunteers in Denmark. In 65 E. coli isolates with cephalosporin-
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resistance, 8 isolates (0.77% prevalence) had mutations in the ampC chromosomal 
promoter region. Four isolates had a -42 mutation, 3 isolates had a -32 mutation 
and one isolate had a nucleotide insertion at position -14. 
1.4 Clinical Impact of Cephalosporin Resistance 
There were over 35,000 reported cases of E. coli bacteraemia in England and Wales 
in 2014, with the incidence rate per 100,000 population increasing by 16.7% 
between 2010 and 2014 (Public Health England, 2015c). E. coli strains represent 
about one-third of all bacteraemia cases (Davies, 2013), and evidence published by 
de Kraker et al. (2011) suggests that patients with septicaemia due to a 
cephalosporin-resistant E. coli strain have a mortality rate of 30%, compared to 15% 
for patients with a susceptible strain. Other estimates of increased mortality vary, 
but most authors agree that there is an increase. 
UK data for 2011 indicate that 45% of E. coli bacteraemia cases have a urinary tract 
infection as the primary source (Davies et al., 2012). It is in these systemic cases 
that infection with a cephalosporin resistant strain is more significant, with length 
of hospital stay and mortality both frequently being reported as adversely affected. 
In a Spanish study, Peralta et al. (2007), reported the results of a retrospective 
study of 663 E. coli bacteraemia cases from 1997 to 2005. They demonstrated that 
patients with a multi-drug resistant strain were less likely to receive correct 
empirical treatment and had a higher mortality rate. The definition of a multi-drug 
resistant strain was phenotypic evidence of ESBL or AmpC production, with 
resistance to 3 or more antibiotics.  
In a UK prospective study of E. coli bacteraemia cases (Melzer & Petersen, 2007), 
the proportion of patients who died within 30 days following onset of bacteraemia 
illness was significantly higher in the ESBL-producing isolates at 60.9%, compared to 
23.7% for the non-ESBL isolates. This increased risk of death from an ESBL-
producing E. coli infection was actually associated with the delay in appropriate 
treatment. Once the delay in appropriate treatment had been excluded from the 
dataset, the ESBL cases actually had a longer time to death (7 days instead of 5 
days) and a shorter inpatient stay (9 days instead of 12 days). Rottier et al. (2012) 
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suggest that the outcomes of observation studies of this nature are highly 
susceptible to confounding factors, which may mislead investigators. Patients with 
an increased severity of illness will generally require a longer stay in hospital and 
more antibiotics for treatment. Moreover, the likelihood of colonisation remaining 
and subsequent infection happening is higher with resistant bacteria. 
Not all studies have found a significant difference between ESBL-producing and 
non-ESBL-producing strains. In a retrospective study of five years’ bacteraemia data 
in France, Denis et al. (2015) found that the presence of an ESBL-producing E. coli 
isolate was not associated with a longer stay in hospital; and although there was a 
higher mortality rate, it was not significant (30% vs 27%). Another study (Ofner-
Agostini et al., 2009) also failed to determine a significance difference in mortality 
rates between cephalosporin-resistant and susceptible isolates of E. coli and K. 
pneumoniae (13% vs 7%) in Canada. 
The number of studies investigating the impact of AmpC-mediated resistance on 
the clinical outcome of E. coli infections is less common. Most studies have focussed 
on the impact of strains with an inducible AmpC enzyme, such as Enterobacter spp. 
(Kaye et al., 2001; Choi et al., 2008). Rand et al. (2011) investigated AmpC-
producing Enterobacteriaceae in a case-control study against non-AmpC isolates. 
The presence of an AmpC enzyme was only determined using phenotypic methods, 
and the case group only included three isolates of E. coli. However, the study did 
identify a slightly higher 30-day mortality rate for the AmpC group (9% vs 6%), but 
this was not found to be significant. In a study not linked to bacteraemia cases, 
Sidjabat et al. (2009) determined in a retrospective cohort study that patients with 
infections caused by isolates with CMY-type enzymes were significantly more likely 
to have a symptomatic infection, when compared with ESBL-producing isolates. 
1.5 E. coli ST131 is a Successful Global Strain 
The dominance of CTX-M genes as the primary cause of ESBL-mediated resistance in 
E. coli is due to the global expansion of one particular clone, called ST131 after its 
multi-locus sequence type (MLST). The ST131 clone has spread extensively across 
the world since it was first reported in 2008 (Nicolas-Chanoine et al., 2008), and has 
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been reported in multiple countries and continents (Peirano & Pitout, 2010), 
including the UK (Lau et al., 2008; Gibreel et al., 2012; Horner et al., 2013). Studies 
on retrospective isolates in America and Canada suggest that the clone may have 
first appeared earlier, probably around 2003 (Johnson et al., 2012; Peirano et al., 
2012). Although MLST was not in use at the time, a UK study in 2004 (Woodford et 
al., 2004) described the likely presence of the ST131 clone, with 37.8% of CTX-M-
producing isolates identified as a single clone using pulsed-field gel electrophoresis. 
The reason for this degree of global spread is not clear. Possibilities include higher 
transmissibility, enhanced virulence or increased antibiotic resistance (Banerjee & 
Johnson, 2014). Transmissibility studies for E. coli ST131 have shown that cases of 
intra-familial spread can occur: between mother and daughter (Johnson et al., 
2010), between two sisters (Price et al., 2013) and even between household pets 
(Johnson et al., 2009). 
The case for enhanced virulence is supported by the fact that ST131 strains are 
more common in cases of invasive disease (e.g. sepsis) than non-invasive disease. 
Alhashash et al. (2013) demonstrated that the prevalence of ST131 isolates in blood 
cultures was 21%, compared to 7% for urine cultures. Other studies have shown 
that the prevalence of ST131 isolates is higher in cases of pyelonephritis than 
routine cystitis and also when compared with healthy faecal carriage (Kudinha et 
al., 2013b, 2013a). Banerjee et al. (2013) suggest that ST131 strains are more likely 
to cause recurrent or persistent urinary tract infections, and ST131 strains are also 
associated with a higher frequency of sepsis (Tchesnokova et al., 2013). 
Antibiotic resistance is a key feature of the ST131 clone, with strains accounting for 
70-80% of all fluoroquinolone-resistant E. coli isolates and two-thirds of ESBL-
producing isolates (Banerjee & Johnson, 2014). Banerjee et al. (2013) demonstrated 
that the prior use of a fluoroquinolone or third-generation cephalosporin antibiotic 
was significantly associated with the acquisition of a ST131 strain. Colpan et al. 
(2013) reported that ST131 isolates accounted for 78% of the fluoroquinolone-
resistant isolates and 64% of the ESBL-producing isolates, but only 7% of 
fluoroquinolone-sensitive isolates, in a multi-centre study in the US. 
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1.6 Principal Methods Used in this Study 
1.6.1 Real-time PCR / SYBR Green 
This study made use of real-time SYBR Green PCR technology with melting curve 
analysis. The use of fluorescence to monitor the progress and outputs of PCR 
reactions was first described in 1992 (Higuchi et al., 1992). This enabled the real-
time detection of PCR products, without the need for a separate detection stage 
such as gel electrophoresis. It also meant that reactions could be contained within a 
single tube, removing the risk of environmental contamination with PCR amplicons. 
The use of real-time PCR in this study was driven by the availability of equipment. 
Many clinical microbiology laboratories have real-time PCR instruments for 
diagnostic purposes, some of which can be used for melting curve analysis (personal 
observation).  
In 1997, the use of melting curve analysis was highlighted as a means to confirm the 
presence of intended PCR products and also to differentiate between products 
based on the melting points (Ririe, Rasmussen & Wittwer, 1997). The melting point 
of a particular PCR product is determined by its GC content and the length of the 
target sequence. As fluorescence is monitored continuously during a temperature 
cycle, the melting point is observed as a rapid loss of fluorescence at a particular 
temperature. The melting curves can be transformed into a graph of melting peaks 
using a first-derivative calculation (Figure 1-2). Assuming that the GC content of two 
sequences was the same, a 40bp product would melt at a temperature 12oC lower 
than a 400bp product, thus allowing the presence of primer dimers to be identified 
(Ririe, Rasmussen & Wittwer, 1997). The presence of a melting peak in the expected 
melting temperature range is analogous to the presence of bands on gel 
electrophoresis (Giglio, Monis & Saint, 2003; Boot et al., 2013). 
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Figure 1-2: Real-time PCR melting curves (a) and melting peaks (b) for mixtures of amplification 
products. 
Sample A represents a purified 180bp fragment from the Hepatitis B gene. Sample C represents a 
536bp fragment from the human b-globin gene. Sample B is a mixture of Samples A and C. The 
melting curves were transformed into first derivative melting peaks. Reproduced with permission 
from Ririe et al. (1997). 
 
Although early papers still used ethidium bromide as the fluorescent dye, this has 
since been replaced with less-hazardous chemicals such as SYBR Green (Wittwer et 
al., 1997). SYBR Green is an intercalating dye that binds preferentially to double-
stranded DNA. Its use in clinical diagnostic and research assays has been well 
reported, particularly for detecting virulence genes and antibiotic resistance genes 
in Enterobacteriaceae isolates. Mendes et al. (2007) used SYBR Green assay to 
detect the presence of metallo-beta-lactamase genes in Enterobacteriaceae isolates 
in Brazil. Guion et al. (2008) developed a SYBR Green assay to detect and 
characterise the presence of eight virulence genes in isolates of diarrhoeagenic E. 
coli in the US.  
Chandramohan and Revell (2012) used a SYBR Green melting curve analysis to 
detect blaESBL genes in a range of Enterobacteriaceae isolates from paediatric 
patients in the US. Boot et al. (2013) demonstrated that a SYBR Green assay could 
be used to detect blaESBL genes in Enterobacteriaceae isolates. The assay was 
reported as having a sensitivity ten-fold higher using melting curve analysis when 
compared to gel electrophoresis. 
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Molecular methods for detecting AmpC plasmid genes have developed since the 
first publication in 2002 (Perez-Perez & Hanson, 2002). More recently, Brolund et al. 
(2010) reported using a SYBR Green real-time PCR method for detecting the six 
AmpC plasmid groups. The method also used melting curve analysis to differentiate 
the PCR products in multiplexed reactions. Geyer and Hanson (2014) have also 
reported using real-time PCR and melting curve analysis for the detection and 
differentiation of AmpC plasmid genes. 
1.6.2 Multi-Locus Sequence Typing (MLST) 
First described in 1998, multi-locus sequence typing is a method of typing bacteria 
using the sequences of housekeeping genes at a number of different loci (Maiden et 
al., 1998). The first scheme published was for Neisseria meningitidis, in which six 
housekeeping genes were selected from a panel of eleven to create a typing 
method. The DNA sequence of each gene locus is determined and then assigned an 
allele profile number. The final sequence type (ST) number is derived from the 
profile of the six allele numbers. For example, the allelic profile of N. meningitidis 
ST1 is 1, 1, 1, 1, 3, 3 (Maiden et al., 1998).  
Maiden et al. (1998) describe the principal advantage of MLST as being the 
portability of the results, with data being truly comparable between laboratories. 
This is in contrast to typing methods such as pulsed-field gel electrophoresis, which 
rely on the interpretation of gels. Maiden et al. (1998) also suggested the creation 
of global databases for each species, so that data from MLST studies can be 
standardised to facilitate global epidemiology. This has subsequently been 
completed, with the creation of the PubMLST website, in which 75 MLST schemes 
are hosted for different bacterial species (www.pubmlst.org) (Jolley & Maiden, 
2010). 
Strains can be grouped into clonal complexes, based on sharing the same allele 
sequences at a number of the different loci. Clonal complexes are usually comprised 
of a single dominant sequence type, with a number of less common close relatives. 
Usually, the members of a complex will share identical allele sequences at all but 
one locus. The emergence of clonal complexes within a population occurs as a 
Page 28 of 188 
 
particular sequence type increases in frequency and as a result of genetic changes 
over time becomes the dominant founder of the complex (Feil et al., 2004). 
There are two MLST schemes for E. coli. The first was described by Wirth et al. 
(2006), and is widely known as the Achtman scheme. In this scheme, seven 
housekeeping genes are used to generate the allelic profile: adk (adenylate kinase); 
fumC (fumarate hydratase); gyrB (DNA gyrase); icd (isocitrate dehydrogenase); mdh 
(malate dehydrogenase); purA (adenylosuccinate dehydrogenase) and recA 
(ATP/GTP binding motif). The use of housekeeping genes helps to ensure that the 
measured variation is neutral, as any nucleotide changes will be constrained by the 
need to retain essential biochemical functions (Spratt & Maiden, 1999). 
The second scheme was developed at the Pasteur Institute in 2008 (Jaureguy et al., 
2008), and is known as the Pasteur method. The Pasteur method uses eight loci to 
generate the sequence type profile, one of which (icdA) is at the same locus as the 
Achtman scheme. The two schemes have broadly compatible results, although the 
Pasteur scheme has fewer registered sequence types and has been mainly used for 
investigating animal and environmental strains (Bae et al., 2014) 
Before the advent of whole-genome sequencing, pulsed-field gel electrophoresis 
(PFGE) was generally considered the gold standard for analysing outbreaks of 
infections (Padmanabhan et al., 2013). A few studies have compared the resolving 
power of PFGE against that of MLST. Nemoy et al. (2005) investigated 40 ESBL-
producing E. coli isolates, finding 19 different PFGE subtypes. One of the PFGE types 
was dominant, comprising 30% of isolates. This single PFGE type, however, was 
separated into five different sequence types using MLST. Overall the MLST scheme 
used in the study found 22 MLST sequence types, but it was a modified scheme 
using eight housekeeping genes supplemented with two antibiotic resistance genes. 
Although the MLST scheme was shown in this particular study to have a higher level 
of discrimination compared to the PFGE method, it is worth noting that this was 
only the case when the two antibiotic resistance genes were included in the allele 
profile. In general, however, PFGE is considered to be more discriminatory than 
MLST.  
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Tartof et al. (2005) used the Achtman MLST scheme to examine 45 E. coli isolates 
from human, animal and environmental sources. Of 19 isolates confirmed as being 
ST69 type by MLST, a total of 14 different subtypes were identified by PFGE. 
Another example of the difference between the two methods is provided by Gibreel 
et al. (2012), in which 8 different PFGE profiles were found in isolates of ST73 and 9 
PFGE profiles were found in the ST131 isolates.  
Although MLST may not be as good as other techniques at resolving outbreak 
situations, the fact that it can reveal relationships among isolates that appear to be 
different could also be considered a benefit. Woodford (2008) suggests that the 
ability to group isolates together that have previously been shown as distinct by 
other methods is important in the identification of potential epidemic clones. 
Highlighting potential relationships between strains can be an important initial step 
in identifying the need for interventions. It is the use of MLST that identified the 
presence of the global ST131 E. coli strain. 
1.7 Study Design 
1.7.1 Aim 
The principal aim of this study was to determine the molecular characteristics of 
clinical E. coli isolates producing AmpC beta-lactamase enzymes in the South West 
of England. 
1.7.2 Objectives 
a) To confirm the utility of SYBR Green real-time PCR as a method for the detection 
of bla genes in E. coli 
b) To determine whether a dominant AmpC-producing clone of E. coli exists within 
the South West population 
c) To determine the genotypic characteristics of AmpC-producing E. coli isolates 
present in the South West population 
d) To determine whether there is evidence that the E. coli populations differ 
between the five laboratories studied. 
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1.7.3 Ethics 
The study was approved by the South West (Central Bristol) National Research 
Ethics Service (NRES) Committee, under reference 11/SW/0224. Local site approval 
was also obtained for the Gloucester laboratory, and for each of the other four 
participating laboratories. 
1.7.4 Funding 
The study was part-funded by two research grants from the Institute of Biomedical 
Science (IBMS). 
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2 Materials & Methods 
2.1 Principal Equipment Used 
The principal equipment used in this study is shown in Table 2-1. 
Table 2-1: List of principal equipment used in the study, with manufacturer and model/version 
details 
Equipment Function Model / Version Manufacturer 
Smart Cycler II Real-Time PCR DX 2.0 Cepheid, US 
Geneious DNA Analysis Software 7.1.7 Biomatters, NZ 
Vortexer Vortexer SO 200 Labnet 
Mini-Centrifuge Centrifugation Mikro 200 Hettich 
Qubit 2.0 Fluorimeter 2.0 Invitrogen 
 
2.2 Bacterial Control Strains 
A set of six bacterial control strains was obtained from Public Health England 
(Colindale, UK), representing each of the six AmpC plasmid groups. The six control 
strains were those used by the PHE laboratory as positive controls for their in-house 
PCR assay for AmpC plasmid genes (Woodford, 2010 personal communication), but 
have not been registered with the National Collection for Type Cultures (NCTC). A 
further control strain was used as a positive control in the CTX-M ESBL PCR assays, 
and a wild type control strain known to lack blaAmpC and blaESBL genes was used for 
comparison of promoter sequences. Details of all the control strains used in the 
study are given in Table 2-2. 
2.3 SYBR Green PCR / General PCR Methods 
2.3.1 Preparation of DNA Template 
DNA templates were prepared using a mechanical lysis method (Woodford, 2010). 
Each control strain was inoculated onto a Columbia Horse Blood Agar plate (Oxoid, 
UK) and incubated overnight at 37oC in air. A heavy bacterial suspension, equivalent 
to MacFarland Standard 4.0 (Biomerieux, UK), was prepared in 100µl water (PCR 
grade) in 1.5ml PCR tubes (Sarstedt, UK). Tubes were vortex-mixed for 2 minutes 
and then centrifuged for 5 minutes at 8000g. The resulting supernatants were used 
as the DNA template. Templates were stored for up to 1 month at 4oC. 
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Table 2-2: Bacterial control strains used for the AmpC plasmid gene PCR assays, CTX-M PCR assays 
and for the comparison of E. coli ampC promoter regions. 
Organism Purpose 
Citrobacter freundii CIT PCR Assay Control 
Hafnia alvei ACC PCR Assay Control 
Klebsiella pneumoniae DHA PCR Assay Control 
Escherichia coli FOX PCR Assay Control 
Escherichia coli MOX PCR Assay Control 
Enterobacter cloacae EBC PCR Assay Control 
Escherichia coli (NCTC 12241) Reference strain for wild-type  
Escherichia coli (NCTC 13441) CTX-M (Group 1) PCR Assay Control 
 
The amount of DNA present in the templates was established for a selection of 
isolates during the optimisation stage. A Qubit 2.0 fluorimeter was used to calculate 
the amount of DNA present in 2.0µl of the templates. A total of 10 isolates, selected 
at random, were tested in triplicate. The average quantity of DNA present was 
calculated from the triplicate results (data available in the appendices; Section 9.1). 
2.3.2 SYBR Green Real-Time PCR 
SYBR Green PCR methodology was used throughout this study. The assay 
parameters were based on those recommended by the master-mix manufacturer 
(Qiagen, Manchester, UK). All PCR reactions were completed on the Smart Cycler II 
Real-Time PCR instrument (Cepheid, Sunnyvale, US), using the Smart Cycler DX 
software (Version 3.0). 
Fluorescence was read after each cycle, at the analyser settings for FAM dye 
(Channel 1). This equated to an excitation wavelength of 450-495nm and an 
emission wavelength of 510-527nm. The cycle threshold values (CT) were 
determined by the instrument software, as were the melting temperatures (TM) of 
the amplified products. 
The Quantifast SYBR Green master-mix kit (Qiagen, Manchester, UK) was used due 
to the fast-start property of the Taq DNA polymerase. This meant that a short initial 
holding stage (5 minutes) was required and enabled easier handling and stability of 
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reagents at room temperature during preparation. The master-mix was aliquotted 
and kept at -18oC to prevent deterioration from repeated freeze-thaw cycles 
(Qiagen Ltd, 2010). 
2.3.3 PCR Protocols 
The standard PCR protocol (Table 2-3) used initially for method development and 
for the simplex assays was based on that recommended in the master-mix kit insert 
(Qiagen Ltd, 2010). The melting curve stage was added to confirm the presence of a 
PCR product at the end of the amplification stage. The annealing and extension 
stages were combined into a single stage (60oC for 30 seconds), as recommended in 
the master-mix instructions. 
Table 2-3: PCR protocol used for the simplex real-time PCR assays, and for initial assay 
development. 
Stage Protocol 
Initial hold stage 95oC for 5 minutes 
Denaturation stage 95oC for 10 seconds (35 cycles) 
Annealing / extension stage 60oC for 30 seconds (35 cycles) 
Melting curve stage 60oC to 95oC, increasing at 0.5oC / sec 
 
The melting curve was used to confirm the presence of a PCR product post-
amplification. The peaks observed on the melting curve graph were analogous to 
those seen in conventional end-point PCR by gel electrophoresis (Giglio, Monis & 
Saint, 2003). The peaks generated by intended products could easily be 
differentiated from peaks caused by non-specific amplification, due to the 
differences in melting temperatures. 
2.3.4 Optimisation of Primer Concentration 
The primers used initially for detecting the ampC-carrying plasmids were those 
published by Perez-Perez and Hanson (2002). Primers were purchased from an 
external supplier (Invitrogen, Paisley, UK), and were re-constituted on receipt in 
Tris-EDTA pH8.0 buffer (Tris 10mM, EDTA 1mM) (A0386,0500, VWR, Lutterworth, 
UK) to a working concentration of 100µM. Stock vials were stored at -18oC for up to 
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12 months. Working stock solutions (2.5µM) of each primer were made up in Tris-
EDTA buffer, and stored at 4oC for up to 3 months. 
The initial optimisation of primer concentrations was done by testing each of the six 
primer pairs at five different concentrations. The amount of primer solution added 
to each reaction tube was varied, so that primers were tested at 0, 0.08, 0.15, 0.25, 
0.35 and 0.45µM final concentrations (Table 2-4). 
Table 2-4: Reaction mixtures for primer optimisation, with each of the six AmpC plasmid primers 
tested at six different concentrations. 
 0µM 0.08µM 0.15µM 0.25µM 0.35µM 0.45µM 
Master-mix 12.5µl 12.5µl 12.5µl 12.5µl 12.5µl 12.5µl 
Primer - F - 0.8µl 1.5µl 2.5µl 3.5µl 4.5µl 
Primer - R - 0.8µl 1.5µl 2.5µl 3.5µl 4.5µl 
Water 12.5µl 10.9µl 9.5µl 7.5µl 5.5µl 3.5µl 
Total 25.0µl 25.0µl 25.0µl 25.0µl 25.0µl 25.0µl 
 
Each reaction mixture comprised primers, 12.5µl SYBR Green master-mix and water 
making up the final volume to 25µl. Water was used in the place of a DNA template, 
so that any amplification present would be non-specific in nature. The assay PCR 
protocol described in 2.3.3 was used. CT and TM values for each assay were 
recorded, and the presence of non-specific product amplification was noted from 
the dissociation curve. 
2.3.5 Specificity of Primers for Detecting ampC-Carrying Plasmids  
In order to confirm the absence of cross-reactivity between the six AmpC plasmid 
control strains, each strain was tested against each of the six primer sets. Reaction 
mixtures comprised 12.5µl SYBR Green master-mix, 2.0µl each primer (0.2µM), 2.0 
DNA template, made up to 25µl with water. The PCR assay protocol described in 
Section 2.3.3 was used. 
2.3.6 Validation of Amplification Product 
To ensure the amplification of intended products, the PCR amplification products 
were referred for sequencing at an external laboratory (Eurofins Genomics, 
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Germany). Each control strain was tested against its respective primer pair, using 
the PCR protocol described in 2.3.3 and primers at 0.2µM concentration. PCR 
products were sent for sequencing at the external laboratory, using the forward 
amplification primer as the sequencing primer. The reported sequence of each 
product was compared against the GenBank entry for each control strain (Table 
2-5). Sequences were aligned using ClustalW2 software 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) and the degree of sequence identity 
between sequences was determined by calculating the number of non-consensus 
nucleotides. 
Table 2-5: The GenBank sequence entries used for the comparison of target product sequences for 
each of the bacterial control strains. 
Control Strain Gene / Enzyme GenBank Acc No. 
C. freundii (CIT) LAT-1 X78117 
H. alvei (ACC) ACC-1 AJ133121 
K. pneumoniae (DHA) DHA-1 Y16410 
E. coli (FOX) FOX-1 X77455 
E. coli (MOX) MOX-1 D13304 
Ent. cloacae (EBC) MIR-1 M37839 
E. coli (NCTC 12241) ampC AY899338 
E. coli (NCTC 13441) CTX-M-15 AY463958 
 
2.4 Detection of AmpC Plasmid Genes 
2.4.1 Review of Primers 
Since the original AmpC plasmid primer sequences were published in 2002, the 
number of registered AmpC plasmid-mediated enzymes had increased significantly. 
Current plasmid-mediated enzymes are listed on a central, curated, website 
(www.lahey.org/studies/). At the time of checking (November 2011), there were 
119 recorded AmpC plasmid-mediated enzymes, of which 94 had a registered 
GenBank sequence. Since November 2011, the number of registered plasmid-
mediated enzymes has increased further, to 239 (last accessed 2nd February 2015). 
A full list of the current AmpC plasmid-mediated enzymes is provided in the 
appendices (Section 9.2). 
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The 94 AmpC plasmid gene sequences were downloaded from the GenBank website 
and aligned using the ClustalW2 software. Aligned sequences were checked against 
the original primers, to determine whether the more recently registered plasmid 
genes would continue to be detected. Potential new primers were identified from 
the consensus regions in the aligned sequences, and were checked using the 
Primer-BLAST software (www.ncbi.nlm.nih.gov/tools/primer-blast/) for specificity, 
product size, GC content and melting temperatures (Ye et al., 2012). 
The new primers (shown in Table 2-6) were validated by testing against the 
respective control strains using simplex PCR assays, using the same protocols as 
described in Section 2.3.6. Products were referred to the external laboratory for 
sequencing (Eurofins Genomics, Germany) to confirm the correct target had been 
amplified. Sequences were compared against the reference sequences for each of 
the AmpC plasmid gene groups (Table 2-5) using ClustalW2. 
Table 2-6: Primers used for the two multiplex PCR assays for the detection of AmpC plasmid genes. 
Primers Sequences (5’ to 3’) Product 
Size (bp) 
Source 
CIT2-F TGA TGC AGG AGC AGG CTA TTC 417 ++ 
CIT2-R ACA GAC CAA TGC TGG AGT TAG   
ACC-F AAC AGC CTC AGC AGC CGG TTA 346 ** 
ACC-R TTC GCC GCA ATC ATC CCT AGC   
DHA-F AAC TTT CAC AGG TGT GCT GGG T 405 ** 
DHA-R CCG TAC GCA TAC TGG CTT TGC  
FOX-F AAC ATG GGG TAT CAG GGA GAT G 175 Forward ++ 
Reverse ** FOX2-R GAT TGG CCT GGA AGC TCA CCG  
MOX-F GCT GCT CAA GGA GCA CAG GAT 322 Forward ++ 
Reverse ** MOX2-R CAC CTC CTC GGG GAA TTG CAG  
EBC2-F AAC TGG CAG CCG CAG TGG AAG 572 ++ 
EBC2-R GCC ACG TAG CTG CCA AAC CC  
++
 This study 
**
 Perez-Perez & Hanson (2002) 
 
 
2.4.2 Multiplex Assay for Detecting AmpC Plasmid Genes 
Using the updated primers, multiplex assays were developed from a combined 
primer solution, made up with 5µl of each primer (100µM) added to 100µl of Tris-
EDTA buffer. A 4.0µl volume of the pooled primer solution was used in the assay, 
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together with 12.5µl master-mix, 2.0µl template and 6.5µl water. Primer 
combinations used were for CIT/ACC/DHA and FOX/MOX/EBC plasmid gene groups. 
Assays were run for each of the relevant control strains. Initially, the same PCR 
protocol was used as for the simplex assays. However, a protocol with a longer 
extension / annealing time (Table 2-7) was subsequently found to give more 
consistent results. Each primer solution was tested against all of the relevant 
control strains. 
Table 2-7: PCR assay protocol used for the AmpC plasmid gene multiplex assays 
Stage Protocol 
Initial hold stage 95oC for 5 minutes 
Denaturation stage 95oC for 10 seconds (35 cycles) 
Annealing / extension stage 60oC for 60 seconds (35 cycles) 
Melting curve stage 60oC to 95oC, increasing at 0.5oC / sec 
 
The presence of AmpC plasmid genes in clinical isolates was determined using the 
two multiplex real-time SYBR Green assays as an initial screen. The screening assays 
were designed to detect groups of plasmid genes: CIT/DHA/ACC and FOX/MOX/EBC. 
Primers for the plasmid gene groups were as shown in Table 2-6. Multiplex assays 
with positive dissociation curves were confirmed using the same primers in three 
separate simplex reactions, to identify the individual AmpC plasmid gene present. 
2.5 Sequencing the E. coli ampC Promoter Region 
A 271bp region of the ampC gene, including the promoter region, attenuator region 
and part of the coding region was amplified for each isolate, using previously 
published primers (Caroff et al., 2000) (Table 2-8). 
Table 2-8: Primers used for the amplification of the E. coli ampC promoter region. 
Primers Sequences (5’ to 3’) Product 
Size (bp) 
Source 
AMPC-F GAT CGT TCT GCC GCT GTG 271 Caroff et al. 
(2000) AMPC-R GGG CAG CAA ATG TGG AGC AA  
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Primers were used at a 0.1µM concentration. The simplex PCR protocol described in 
Section 2.3.3 was used. A melting curve protocol was run to confirm the presence of 
an amplified product prior to sequencing. PCR products were sent to an external 
company (Eurofins Genomics, Germany) for purification and sequencing. The 
forward amplification primer was used for sequencing. 
The reported sequence of each product was compared against the GenBank entry 
for E. coli NCTC 12241 (GenBank Accession No AY899338), a laboratory control 
strain. Sequences were aligned using the ClustalW alignment tool in the Geneious 
software package (Version 7.1.7) (Biomatters, New Zealand). The sequence 
visualisation tool in Geneious was used to identify the nature and position of each 
mutation, with each polymorphism recorded according to the numbering system of 
Jaurin et al. (1981). 
2.6 Detection of ESBL Resistance Genes 
The presence of blaCTX-M genes was determined by using two simplex assays for 
CTX(M) Group 1 specific primers and universal CTX-M primers. The primers used for 
the assays are shown in Table 2-9. 
Table 2-9: Primers used for the detection of CTX-M ESBL resistance genes. 
CTX-M(P) indicates the universal primers and CTXM(1) indicates the Group 1-specific primers. 
 
Primers Sequences (5’ to 3’) Product 
Size (bp) 
Source 
CTX-M(P)-F TTT GCG ATG TGC AGT ACC AGT AA 544 Edelstein 
(2003) CTX-M(P)-R CGA TAT CGT TGG TGG TGC CAT A  
CTX-M(1)-F AAA AAT CAC TGC GCC AGT TC 415 Woodford 
(2010) CTX-M(1)-R AGC TTA TTC ATC GCC ACG TT  
 
The Group 1 CTX-M specific primers were used as the initial screening assay. 
Isolates with a negative CTX-M Group 1 assay were also then tested for the 
presence of other CTX-M genes using the universal CTX-M primers (Edelstein et al., 
2003). 
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2.7 Multi-Locus Sequence Typing  
The method developed by M. Achtman and others was used to determine the 
sequence type of each isolate (Wirth et al., 2006). Fragments of seven 
housekeeping genes were amplified and sequenced (Table 2-10).  
Table 2-10: The seven housekeeping genes used in the MLST method for E. coli. 
(Wirth et al., 2006) 
Locus Gene 
adk adenylate kinase 
fumC fumarate hydratase 
gyrB DNA gyrase 
icd isocitrate/isopropylmalate dehydrogenase 
mdh malate dehydrogenase 
purA adenylosuccinate dehydrogenase 
recA ATP/GTP binding motif 
 
DNA was extracted from each isolate using the mechanical lysis method described 
in Section 2.3.1. Each gene was amplified using the primers shown in Table 2-11.  
Amplification was carried out in 25µl volumes; with 12.5µl master-mix, 3.0µl of each 
primer (2.5µM), 2.0µl of DNA template and 4.5µl of water. The primers used were 
those published on the central website, available at 
http://mlst.warwick.ac.uk/mlst/dbs/Ecoli/documents/primersColi. 
The PCR protocol was adapted from that used by Wirth et al. (2006) and is shown in 
Table 2-12. Due to the larger sizes of the amplicons, and the need to have longer 
extension times and different temperatures, the protocol differs to those used in 
earlier sections. A melting curve protocol was run to confirm the presence of an 
amplified product prior to sequencing. 
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Table 2-11: Primers used to amplify the genes at each of the seven loci used for the E. coli MLST 
scheme. 
(Wirth et al., 2006) 
Primer Sequences (5’ to 3’) Product Size 
(bp) 
ADK2-F TCA TCA TCT GCA CTT TCC GC 583 
ADK2-R CCA GAT CAG CGC GAA CTT CA  
FUMC-F TCA CAG GTC GCC AGC GCT TC 806 
FUMC-R GTA CGC AGC GAA AAA GAT TC  
GYRB-F TCG GCG ACA CGG ATG ACG GC 911 
GYRB-R ATC AGG CCT TCA CGC GCA TC  
ICD-F ATG GAA AGT AAA GTA GTT GTT CCG GCA CA 878 
ICD-R GGA CGC AGC AGG ATC TGT T  
MDH-F ATG AAA GTC GCA GTC CTC GGC GCT GCT GGC GG 932 
MDH-R TTA ACG AAC TCC TGC CCC AGA GCG ATA TCT TTC TT  
PURA-F CGC GCT GAT GAA AGA GAT GA 816 
PURA-R CAT ACG GTA AGC CAC GCA GA 
RECA-F CGC ATT CGC TTT ACC CTG ACC 780 
RECA-R TCT CGA TCA GCT TCT CTT TT  
 
Table 2-12: PCR protocol for the amplification of the seven housekeeping genes in the E. coli MLST 
scheme. 
Stage Protocol 
Initial hold stage 95oC for 5 minutes 
Denaturation stage 95oC for 30 seconds (30 cycles) 
Annealing stage 56oC for 30 seconds (30 cycles) 
Extension stage 72oC for 30 seconds (30 cycles) 
Melting curve stage 60oC to 95oC, increasing at 0.5oC / sec 
 
PCR products were sent to an external company (Eurofins Genomics, Germany) for 
purification and sequencing. The forward amplification primer was used first for 
sequencing. The reported sequence of each product was entered onto an online 
database (Jolley & Maiden, 2010) (at http://pubmlst.org/) to obtain the allele 
profile. A profile number was accepted only if the database result indicated an exact 
match to the designated sequence. Once a full set of seven alleles had been 
identified, the sequence type was obtained from entering the 7-digit number into 
the same database. If a valid allele profile was not obtained for a locus, the process 
would be repeated again using the forward amplification primer and then (if still 
required) using the reverse amplification primer. Potential new alleles were 
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sequenced at least twice, and the raw data files submitted to the database curator 
for inclusion in the database and the generation of a new allele number. Isolates 
with a new sequence type were registered on the database website, so a new 
sequence type profile number could be generated. 
2.8 Data Analysis 
This study made use of the PubMLST website (available at http://.pubmlst.org/), 
developed by Keith Jolley and sited at the University of Oxford. The development of 
the website was funded by the Wellcome Trust. 
Patient demographics and sample data were held in a MS Access database and 
analysed using MS Excel spreadsheets. The significance of differences between 
categorical variables was calculated using either Chi-square tests or Fisher’s exact 
test. The online statistics software GraphPad QuickCalcs (available at 
www.graphpad.com/quickcalcs/) was used to calculate P values. A P value of <0.05 
was considered to be an indicator of statistical significance. 
The web-based ClustalW2 software (www.ebi.ac.uk/Tools/msa/clustalw2/) was 
used to compare the sequences of amplified products with known sequences 
downloaded from GenBank. All sequences were imported into the Geneious 
software package (Version 7.1.7). The package includes an alignment and 
visualisation tool for DNA sequences. The package also includes a plugin tool based 
on the ClustalW2 algorithm. 
The web-based eBURST software (V3) was used to cluster the MLST sequence types 
into related groups (Feil et al., 2004). The software is available at 
http://eburst.mlst.net/v3/. The eBURST software analyses the relationship between 
isolates grouped as clonal complexes, assigning sequence types as potential 
founders for a particular complex (Feil et al., 2004). Clonal complexes were defined 
as a population of isolates with MLST alleles identical at six or more loci.  
The Simpson’s Index of Diversity (Hunter & Gaston, 1988) was used to determine 
the level of diversity between different bacterial populations. The 95% confidence 
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intervals for diversity indices were calculated using the method described by 
Grundmann et al. (2001). 
2.9 Clinical Laboratories 
A total of eight laboratories in the South West region were approached to 
participate in the study: Dorchester, Gloucester, Swindon, North Bristol, Bristol PHE, 
Torbay, Plymouth and Truro. These laboratories were selected to ensure a good 
geographic coverage of the region, and were of a size to ensure the number of 
isolates collected would meet the study requirements. 
 
Figure 2-1: Locations of the five participating laboratories in the South West region: Gloucester, 
Swindon, Taunton, Dorchester and Truro. 
Participating laboratories are indicated by a large black circle. Other laboratories in the region are 
indicated by a small yellow circle. 
Map image used under the fair-use policy of Google Maps ©2012 
  
Five of the laboratories were able to participate in the study (Figure 2-1). Local 
Trust approval was obtained for each laboratory via their Research & Development 
teams. The five final laboratories were Dorchester, Gloucester, Swindon, Taunton 
and Truro. Each laboratory was provided with an information sheet explaining the 
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purpose of the study and the instructions for submitting isolates (included in the 
appendices; Section 9.3). 
2.10 Collection of Clinical Isolates 
Clinical isolates of E. coli were collected from the five laboratories. Isolates for the 
pilot study (Gloucester only) were collected during the period June and November 
2011. Isolates for the larger regional study were collected during the period April 
and May 2013. 
Isolates were eligible for inclusion in the regional study provided the routine disc 
susceptibility testing indicated resistance to cefpodoxime (Public Health England, 
2012). Laboratories were asked to submit only E. coli isolates for the study, but 
could submit isolates from any sample type. Laboratories were asked to exclude 
isolates if the same species had previously been isolated from the same patient 
within a 28-day period. This was to exclude the introduction of sampling bias from 
testing identical isolates from the same patient. Laboratories were asked to submit 
the first 50 isolates during the collection period; with the exception of the 
Gloucester laboratory, which collected 100 isolates. 
Eligible isolates were allocated a unique study number by the local laboratory staff, 
with a prefix used to identify the laboratory of origin (DO- for Dorchester, G- for 
Gloucester, SW- for Swindon, TA- for Taunton and TR- for Truro). Laboratories were 
asked to submit the isolates on a suitable medium (usually a 3ml nutrient agar 
slope) and to provide basic demographic data for each isolate. A copy of the isolate 
information sheet for data collection is included in the appendices (Section 9.4). The 
information provided for each isolate included: specimen type, date of isolation, 
patient birth year, patient gender and whether the patient was an inpatient or 
outpatient / GP at the time the sample was taken. All isolates were anonymised at 
the point of collection, with the isolates identified subsequently only using the 
study reference number. 
On receipt in the testing laboratory (Gloucester), isolates were sub-cultured onto a 
chromogenic urine media plate (Becton Dickinson, UK), to confirm the identity of 
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the isolate and the purity of the culture. This medium had previously been reported 
as having 99.3% specificity for E. coli based on the colour of the colonies (Merlino et 
al., 1996). If required, further identification to species level was done using API20E 
identification strips (Biomerieux, UK). All isolates were then stored on cryobeads 
(Pro-Lab, UK) at -80oC until required.  
Isolates were excluded from the study if they were found not to be cefpodoxime-
resistant or did not confirm as being E. coli when tested at the central laboratory. In 
the case of mixed cultures, a selection (up to three) of E. coli colonies was tested for 
cefpodoxime resistance. If present, a single resistant isolate was then included in 
the study. 
2.11 Susceptibility Testing 
Isolates were tested for a range of cephalosporins using a standardised disc 
susceptibility method, including the antibiotics cefpodoxime, cefuroxime, cefoxitin, 
cefotaxime and cefepime. Testing was performed according to the British Society of 
Antimicrobial Chemotherapy (BSAC) published guidelines (Andrews & Howe, 2011). 
To achieve a semi-confluent growth, a 0.5 MacFarland suspension was made and 
diluted to a 1:100 concentration. The final suspension was inoculated onto an 
Isosensitest agar plate (Oxoid) using a cotton-tipped swab. Antibiotic discs (Oxoid) 
were applied to the surface of the agar and the plate was incubated for 18-24 hours 
at 37oC in air. Following incubation, the zone size for each antibiotic disc was 
recorded. The disc concentrations and respective zone sizes for result 
interpretations are shown in Table 2-13. Isolates were also tested for the presence 
of phenotypic ESBL activity using clavulanic acid synergy discs, with cefpodoxime as 
the indicator antibiotic (M’Zali et al., 2000). 
Gradient antibiotic strips (Oxoid) were used to test the cefotaxime minimum 
inhibitory concentration (MIC) within the range 0.002-32mg/L. A 0.5 MacFarland 
suspension was made and inoculated directly onto an Isosensitest agar plate 
(Oxoid) using a cotton-tipped swab. The gradient strip was placed on the surface of 
the agar and the plate was incubated for 18-24 hours at 37oC in air. Following 
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incubation, the point of intersection of the zone to the strip was recorded as the 
MIC for the isolate. 
Table 2-13: Antibiotic disc concentrations and recommended interpretive zone sizes (BSAC 
guidelines) for the five cephalosporins tested. 
(Andrews & Howe, 2011) 
Antibiotic Disc Content 
(µg) 
Resistant 
(mm) 
Intermediate 
(mm) 
Sensitive 
(mm) 
Cefpodoxime 10 ≤19 - ≥20 
Cefuroxime 30 ≤19 - ≥20 
Cefotaxime 30 ≤23 24-29 ≥30 
Cefoxitin 30 - - ≥23 
Cefepime 30 ≤26 27-31 ≥32 
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3 Development of PCR and Sequencing Methods 
3.1 Introduction 
This first stage of the study started in 2010, and was to develop and validate a 
suitable method for detecting beta-lactamase genes by real-time PCR. As a working 
clinical laboratory, the Gloucester laboratory had real-time PCR instruments already 
installed for diagnostic purposes. As this is the case for most clinical laboratories, 
and potential future utility was a consideration, it was decided that real-time SYBR 
Green PCR would be the primary DNA amplification and detection method. Offering 
a good alternative to traditional end-point PCR methods, key benefits of SYBR 
Green PCR chemistry include speed of assay times, ease of use and safer handling of 
reagents (Tong & Giffard, 2012).  
Although real-time PCR can be used most effectively with fluorescent-labelled 
probes, Giglio et al. (2003) suggest that SYBR Green PCR chemistry is often used due 
to its relative inexpensive cost when compared to other detection methods. First 
used for monitoring PCR reactions in 1997 (Wittwer et al., 1997), SYBR Green is an 
intercalating fluorescent dye that binds preferentially to double-stranded DNA. The 
use of melting curve analysis to visualise PCR products after the amplification stage 
gives melting curves that are analogous to the bands seen using gel electrophoresis 
(Giglio, Monis & Saint, 2003). 
The original work on detecting the six AmpC plasmid gene groups used conventional 
PCR methods and gel electrophoresis (Perez-Perez & Hanson, 2002). Since then, 
Brolund et al. (2010) have demonstrated that real-time PCR using a SYBR Green dye 
and melting curve analysis can be used effectively to detect and classify the six 
AmpC plasmid gene groups in two multiplex assays. 
The aim of this stage of the study was to develop a specific assay for the detection 
of blaAmpC and blaCTX-M genes. A further aim was to develop the under-pinning 
methods and assays for the general amplification of PCR products prior to 
sequencing. 
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3.2 Methods 
SYBR Green PCR methodology was used to develop a number of assays for the 
detection of key resistance genes in E. coli, and also for amplifying target genes 
prior to sequencing. All assays were run using the Smart Cycler II real-time PCR 
instrument (Cepheid, Sunnyvale, US), and the Quantifast SYBR Green master-mix 
(Qiagen, Manchester, UK).  
A number of bacterial control strains were obtained, to act as PCR controls for the 
assays. Six strains (various species) were purchased from the national reference 
laboratory (Colindale, UK) for the six AmpC plasmid gene groups. Two further 
strains of E. coli were purchased from the National Collection of Type Cultures 
(NCTC); one to act as a positive control for the CTX-M PCR assays, and one to act as 
a reference wild type strain. Details of all control strains used are given in Table 2-2. 
A crude lysis method for extracting bacterial DNA from isolates of E. coli was used 
for all assays (Woodford, 2010). The detection of the six AmpC plasmid gene groups 
was done initially using the primers published by Perez-Perez and Hanson (Perez-
Perez & Hanson, 2002). These primers were later reviewed against the current list 
of AmpC plasmid gene sequences available in GenBank. The detection of CTX-M 
ESBL genes was done using a previously published universal set of CTX-M primers 
(Edelstein et al., 2003) and also a set of Group 1 CTX-M specific primers (Woodford, 
2010). 
The amplification and sequencing of the ampC promoter region was done using the 
primers previously published by Caroff et al. (2000). These primers amplified a 
271bp region of the E. coli ampC gene, including the promoter region, attenuator 
region and part of the coding region. Amplified PCR products were sent to an 
external company (Eurofins Genomics, Germany) for sequencing, using the forward 
amplification primer. 
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3.3 Results 
3.3.1 Optimisation of DNA Template 
The crude lysis method described by Woodford (2010) indicated that 2µl of the 
resulting DNA template would be sufficient for use with PCR assays. However, as 
this was originally based on using traditional end-point PCR, the optimum 
concentration level was established for the AmpC plasmid gene assays using real-
time PCR. DNA quantification using the Qubit fluorimeter indicated an average 
amount of 2.4ng/µL in the lysate, with a range of 0.74 to 8.38ng/µL (see Appendices 
– Section 9.1). Although the DNA amount was not adjusted for each run, the same 
lysate was used within control strains.  
Each control strain was tested against its respective primer pair, with the DNA 
template volume varied between 0µl and 4.0µl. The master-mix and primer 
concentrations (0.2µM) were kept consistent for all experiments, but the water was 
varied to make the final volume up to 25µl for each reaction. The CT values for the 
six control strains amplified with different template amounts are shown in Table 
3-1. 
Table 3-1: Cycle threshold (CT) values for the six AmpC plasmid gene assays; testing each bacterial 
AmpC plasmid control strain at six different DNA template amounts. 
Primers used were those corresponding with each relevant bacterial control strain. 
 
 DNA Template Volume 
Controls 0µl 0.5µl 1.0µl 2.0µl 3.0µl 4.0µl 
CIT - 29.6 27.8 26.9 26.7 25.9 
ACC - 25.5 24.2 22.5 22.2 20.9 
DHA - 26.7 25.5 24.9 23.9 23.1 
FOX - 23.7 20.2 19.4 18.4 18.2 
MOX - 33.7 26.8 26.0 23.5 22.8 
EBC - 22.5 20.9 19.5 18.8 18.1 
 
The data demonstrate that all assays had a CT value of <30 when tested at the 
proposed template volume of 2.0µl. The melting temperatures for the products 
were consistent within each strain (Table 3-2), with <0.5oC variation from the mean 
value for each control strain. 
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Table 3-2: Melting temperature (TM) values for the products of the bacterial AmpC plasmid 
control strains when tested at six different template amounts. 
The value for CIT at 1.0µl (indicated in green) did not register a specific product peak at >80
o
C. This 
value was not included in the average TM value calculation. Ave = average. 
 
 DNA Template Volume 
Controls 0.5µl 1.0µl 2.0µl 3.0µl 4.0µl Ave 
CIT 87.9 68.8 87.9 88.0 87.6 87.6 
ACC 87.0 86.9 86.7 87.1 86.9 86.9 
DHA 89.3 89.3 89.2 89.4 89.4 89.3 
FOX 89.0 88.9 89.2 89.3 89.2 89.1 
MOX 91.4 91.0 91.0 90.9 90.7 91.0 
EBC 89.8 89.3 89.3 89.6 89.9 89.6 
 
3.3.2 Optimisation of Primer Concentrations for AmpC Plasmid Gene PCR 
A series of experiments was undertaken to determine the optimum initial 
concentration for the primers in the AmpC plasmid gene PCR assays. Primers for 
each of the six AmpC plasmid gene groups were tested at five different 
concentrations, using water as a blank template. The purpose of the experiments 
was to assess the level of background amplification caused by the non-specific 
binding nature of SYBR Green (Ririe, Rasmussen & Wittwer, 1997). The 
concentrations of primers ranged from 0.08µM to 0.45µM (Table 3-3). 
Table 3-3: Cycle threshold (CT) values indicating non-specific amplification in the six AmpC plasmid 
gene assays. 
Cycle threshold values are given for the six AmpC plasmid gene PCR assays at different primer 
concentrations. Assays were run with water as the template. 
 
Primers 0.08µM 0.15µM 0.25µM 0.35µM 0.45µM 
CIT 0 0 32.1 33.5 31.3 
ACC 0 0 0 33.3 0 
DHA 0 0 32.1 33.8 27.9 
FOX 0 0 0 0 0 
MOX 0 0 0 28.1 33.1 
EBC 0 33.2 31.4 29.1 30.3 
 
The purpose of optimising a single concentration for all primers was to develop a 
single protocol base for all assays, in which only the primers would differ. This 
would simplify the protocol for future clinical utility. Overall, the amount of non-
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specific amplification increased with the rising concentration of primers. None of 
the primers demonstrated non-specific amplification at the 0.08µM concentration, 
and this was also the case for the majority of primers at the 0.15µM concentration. 
The FOX primers were the only primers not to exhibit non-specific amplification 
throughout the concentration range. A concentration of 0.2µM was chosen as the 
mid-point between the two tested concentrations of 0.15µM and 0.25µM. 
The presence of a non-specific product could clearly be identified through the use 
of the dissociation graph (Figure 3-1). The range of melting temperatures observed 
for all primer groups was 65.8oC to 81.9oC for the non-specific amplification, with an 
average temperature of 79.2oC. The height of the melting curve peak was higher in 
the assays with a greater primer concentration. 
 
 
Figure 3-1: Evidence of non-specific amplification in a CIT plasmid gene real-time PCR assay using 
SYBR Green chemistry. 
Primers were tested at five different concentrations (0.08µM to 0.45µM), with water used as the 
template. The melting curves for 0.25, 0.35 and 0.45µM are shown. 
 
3.3.3 Validation of AmpC Control Strains 
Having selected an initial primer concentration of 0.2µM from the experiments in 
Section 3.3.2, the set of six bacterial control strains for the AmpC plasmid gene 
groups was checked to confirm specificity for each of the relevant primer sets. Each 
control strain was tested against each of the six primer sets. This also confirmed 
0.45µM 
 
0.35µM 
0.25µM 
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that the primer concentration of 0.2µM enabled detection of all control strains at 
that level. 
The CT values for the primers tested against each control strain are shown in Table 
3-4. With the exception of the CIT primers, each assay produced a CT value of <30 
when tested against the respective control strain. The presence of a non-specific 
amplification product was noted in 9 of the 30 expected “negative” assays, although 
the average CT values were significantly higher (31.6 versus 26.7, p=0.007, 2 test). 
The assay for the FOX control strain tested with the MOX primers did give a CT 
value of 27.2. However, the melting temperature of this product was 69.1oC and 
was due to non-specific amplification. 
Table 3-4: Cycle threshold (CT) values for the six AmpC plasmid gene assays; testing each control 
strain against all of the six primer sets. 
The values shaded in green are those were a true positive result was expected. The presence of CT 
values in the other assays was the result of non-specific amplification. 
 
 Bacterial Control Strains (CT values) 
Primers CIT ACC DHA FOX MOX EBC 
CIT 31.3 0 0 32.3 0 30 
ACC 0 24.7 0 32.8 0 32.9 
DHA 0 0 26.5 0 0 30.2 
FOX 0 0 0 28.4 0 33.9 
MOX 0 0 0 27.2 28.9 31.2 
EBC 34.1 0 0 0 0 20.5 
 
The presence of a non-specific product could be clearly differentiated from the 
target product using the dissociation curve (Figure 3-2). Not only is there a clear, 
and higher peak for the true positive peak, but there is also a significant shift to the 
left for the non-specific products. Non-specific amplification often results in smaller 
products with lower melting temperatures (Ririe, Rasmussen & Wittwer, 1997). 
All melting temperatures (TM) for the true positive products were >85oC, with a 
range of 86.8oC to 91.3oC (Table 3-5). Non-specific amplification was observed in 
some tubes, but within the range 65.4 to 81.5oC. 
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Figure 3-2: Melting curve graphs of an EBC plasmid gene assay testing each of the six AmpC 
bacterial control strains with the EBC primers. 
Some evidence is present of low-level non-specific amplification at a TM in the region of 81
o
C 
compared to the target EBC plasmid gene product at 89.5
o
C. 
 
Table 3-5: Melting temperature (TM) values for the amplified products of control strains when 
tested against all six of the AmpC plasmid gene primer sets. 
The values shaded in green are those where a true positive result was expected. The presence of a 
TM value in the other assays indicates the presence of non-specific amplification. 
 
 Bacterial Control Strains (TM) 
Primers CIT ACC DHA FOX MOX EBC 
CIT 87.6 65.4 0 80.2 68.1 80.9 
ACC 0 86.8 0 79.2 65.8 81.4 
DHA 0 0 89.2 0 66 81.5 
FOX 0 0 65.4 89.2 70.4 80.1 
MOX 0 0 0 69.1 91.3 81.1 
EBC 80.4 0 0 0 66.6 89.5 
 
3.3.4 Validation of Amplification Product 
To confirm that the AmpC plasmid gene assays were detecting and amplifying the 
correct product, the resulting PCR products were referred for sequencing by an 
external company (Eurofins Genomics, Germany). All products were sequenced 
using the respective forward amplification primer. Sequencing was performed using 
the dideoxy chain termination method on ABI3730XL instruments (Applied 
Biosystems). The resulting DNA sequences were compared against the relevant 
sequences in GenBank, using the online ClustalW software: 
(www.ebi.ac.uk/Tools/msa/ClustalW2/).  
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The sequences of all six AmpC plasmid gene products showed a good degree of 
sequence identity (>92%) when compared to the GenBank sequence (Table 3-6). An 
example of one of the ClustalW analysis reports is shown in Figure 3-3, with the 
other reports provided in the appendices (Section 9.5). 
Table 3-6: Degree of sequence identity of each of the six sequenced AmpC plasmid gene products, 
when compared with the respective reference sequence. 
GenBank accession numbers are given for each reference sequence. 
 
Control Strain GenBank Acc. Total Bases Consensus 
Bases 
% Identity 
CIT X78117 356 335 94.1 
ACC AJ133121 306 302 98.7 
DHA Y16410 335 335 100.0 
FOX X77455 142 131 92.3 
MOX D13304 472 469 99.4 
EBC M37839 261 258 98.9 
 
 
 
The process was repeated for the two sets of CTX-M primers used (universal and 
Group 1-specific). Both sets of primers were used to amplify the respective regions 
in the control strains E. coli NCTC 13441. The PCR products were referred for 
sequencing, using the forward amplification primers. The resulting sequences were 
aligned with the GenBank sequence for the CTX-M-15 gene (Accession No. 
AY463958) using the ClustalW online software. The alignment output for the 
universal CTX-M primers is shown in Figure 3-4. The ClustalW alignment report for 
the Group 1- specific primers is provided in the Appendices (Section 9.6).  The 
degree of sequence identity for the universal and Group 1-specific primers was 
99.6% and 98.2%, respectively. 
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CIT-1_CIT-F                  -----------------------GTTACGGATAAAGCCGAATTACTGCGC 27 
CIT-2_CIT-F                  TGCCGCTGCAGATCCCCGATGACGTTACGGATAAAGCCGAATTACTGCGC 83 
gi|496632|emb|X78117.1|      TACCGCTGCAGATCCCCGATGACGTTAGGGATAAAGCCGCATTACTGCAT 600 
                                                    **** *********** ********   
 
CIT-1_CIT-F                  TTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTA 77 
CIT-2_CIT-F                  TTTTATCAAAACTGGCAACCACAATGGACTCCGGGCGCTAAGCGTCTTTA 133 
gi|496632|emb|X78117.1|      TTTTATCAAAACTGGCAGCCGCAATGGACTCCGGGCGCTAAGCGACTTTA 650 
                             ***************** ** *********************** ***** 
 
CIT-1_CIT-F                  CGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACATTCAG 127 
CIT-2_CIT-F                  CGCTAACTCCAGCATTGGTCTGTTTGGTGCGCTGGTGGTAAAACATTCAG 183 
gi|496632|emb|X78117.1|      CGCTAACTCCAGCATTGGTCTGTTTGGCGCGCTGGCGGTGAAACCTTCAG 700 
                             *************************** ******* *** **** ***** 
 
CIT-1_CIT-F                  GTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAA 177 
CIT-2_CIT-F                  GTATGAGCTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAA 233 
gi|496632|emb|X78117.1|      GAATGAGTTACGAAGAGGCAATGACCAGACGCGTCCTGCAACCATTAAAA 750 
                             * ***** ****************************************** 
 
CIT-1_CIT-F                  CTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGC 227 
CIT-2_CIT-F                  CTGGCGCATACCTGGATTACGGTTCCGCAAAGCGAACAAAAAAATTATGC 283 
gi|496632|emb|X78117.1|      CTGGCGCATACCTGGATTACGGTTCCGCAGAACGAACAAAAAGATTATGC 800 
                             ***************************** * ********** ******* 
 
CIT-1_CIT-F                  CTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGGCAACTTG 277 
CIT-2_CIT-F                  CTGGGGCTATCGCGAAGGGAAGCCTGTACACGTTTCTCCGGGGCAACTTG 333 
gi|496632|emb|X78117.1|      CTGGGGCTATCGCGAAGGGAAGCCCGTACACGTTTCTCCGGGACGACTTG 850 
                             ************************ ***************** * ***** 
 
CIT-1_CIT-F                  ACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGG 327 
CIT-2_CIT-F                  ACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATCGATATGGCCCGCTGG 383 
gi|496632|emb|X78117.1|      ACGCCGAAGCCTATGGCGTGAAATCCAGCGTTATTGATATGGCCCGCTGG 900 
                             ********************************** *************** 
 
CIT-1_CIT-F                  GTTCAGGCCAACATGGACGCCAGCCACGTTCAGGAGAAA----------- 366 
CIT-2_CIT-F                  GTTCAGGCCAACATGGACGCCAGCCACGTCAAAG---------------- 417 
gi|496632|emb|X78117.1|      GTTCAGGCCAACATGGATGCCAGCCACGTTCAGGAGAAAACGCTCCAGCA 950 
                             ***************** ***********  * * 
                
Figure 3-3: ClustalW alignment report for the sequenced products of the CIT control strain tested 
in duplicate using the CIT primers. 
The GenBank sequence X78117 is included for comparison. 
* indicates agreement at that position with all three nucleotides. 
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gi|39545937|gb|AY463958.1      GCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAA 450 
EC-13441_ctxmp-f               ------------------------------------------GAAGTGAA 8 
                                                                          ******* 
 
gi|39545937|gb|AY463958.1      AGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCT 500 
EC-13441_ctxmp-f               -GCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCT 57 
                                ************************************************* 
 
gi|39545937|gb|AY463958.1      TGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCAC 550 
EC-13441_ctxmp-f               TGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCAC 107 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      TGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATG 600 
EC-13441_ctxmp-f               TGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATG 157 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      AATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGC 650 
EC-13441_ctxmp-f               AATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGC 207 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      CCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGT 700 
EC-13441_ctxmp-f               CCGACAGCTGGGAGACGAAACGTTCCGTCTCGACCGTACCGAGCCGACGT 257 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      TAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCA 750 
EC-13441_ctxmp-f               TAAACACCGCCATTCCGGGCGATCCGCGTGATACCACTTCACCTCGGGCA 307 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      ATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAG 800 
EC-13441_ctxmp-f               ATGGCGCAAACTCTGCGGAATCTGACGCTGGGTAAAGCATTGGGCGACAG 357 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      CCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAG 850 
EC-13441_ctxmp-f               CCAACGGGCGCAGCTGGTGACATGGATGAAAGGCAATACCACCGGTGCAG 407 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      CGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACC 900 
EC-13441_ctxmp-f               CGAGCATTCAGGCTGGACTGCCTGCTTCCTGGGTTGTGGGGGATAAAACC 457 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      GGCAGCGGTGGCTATGGCACCACCAA-CGATATCGCGGTGATCTGGCCAA 949 
EC-13441_ctxmp-f               GGCAGCGGTGGCTATGGCACCACCAAACGATATC---------------- 491 
                               ************************** *******                 
Figure 3-4: ClustalW alignment report for the sequenced product of the CTX-M control strain 
tested using the universal CTX-M primers. 
The GenBank reference sequence (AY463958) for the CTX-M-15 gene was used for comparison.  
* indicates agreement at that position for both nucleotides. 
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3.3.5 Review of AmpC Plasmid Gene Primer Sequences 
When the original AmpC plasmid gene primers were published in 2002 (Perez-Perez 
& Hanson, 2002), there were 29 genes recorded and available for download from 
GenBank. At the time of this current review in November 2011, the number had 
increased to 119 recorded plasmid genes (94 available for download). Since then, 
the number has increased further still, with 239 AmpC plasmid genes currently 
recorded on the central website (www.lahey.org/studies/, last accessed 2nd 
February 2015). The full list of current plasmid genes is included in the appendices 
(Section 9.2). The list of 94 plasmid genes with available GenBank sequence entries 
at the time of the review is given in Table 3-7. The sequences for the 55 available 
CMY plasmid genes were aligned in ClustalW and checked for suitability against the 
original primers. It was clear that the original primers for the CIT group were no 
longer suitable, as the forward and reverse primers were not consensus with the 
sequence derived from the combined alignment (see Appendices, Section 9.7). The 
sequence for CMY-13 (GenBank Accession X92520) was not included in the 
ClustalW alignment analysis, as it had a large number of additional nucleotides 
throughout the sequence and therefore made full alignment difficult. It was 
possible from the remaining 54 CMY plasmid gene sequences to select new forward 
and reverse primers (Table 3-8), using new consensus regions in the alignment. 
In contrast to the large number of additional CIT plasmid genes recorded since 
2002, there had been only two plasmid genes added to the ACC group (ACC-3 and 
ACC-4). The ClustalW analysis of the four ACC sequences together indicated that no 
suitable consensus sequences were available for primer selection. The longest 
region of sequence agreement in the alignment was 6 base pairs in length, making 
the selection of suitable primers impossible. The ClustalW analysis for the review of 
the ACC plasmid genes is included in the appendices (Section 9.8). 
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Table 3-7: List of 94 plasmid ampC genes recorded on the www.lahey.org/studies/ website (Nov 
2011) that were available for download from GenBank, together with relevant accession numbers. 
Plasmid Gene GenBank  Plasmid Gene GenBank 
CMY-1 X92508  CMY-54 HM544039 
CMY-2 X92509  CMY-55 HM544040 
CMY-3 X92510  CMY-56 HQ322613 
CMY-4 X92511  CMY-57 HQ285243 
CMY-5 X92512  CMY-58 HQ185697 
CMY-6 X92513  CMY-59 AB587082 
CMY-7 X92514  CMY-64 HQ832678 
CMY-8 X92515  CMY-73 GQ351345 
CMY-9 X92516  ACC-1 AJ133121 
CMY-10 X92517  ACC-2 AF180952 
CMY-11 X92518  ACC-3 AF180958 
CMY-12 X92519  ACC-4 EF504260 
CMY-13 X92520  ACT-1 U58495 
CMY-14 X92521  ACT-2 AM076977 
CMY-15 X92522  ACT-3 EF125013 
CMY-16 X92523  ACT-4 EU427302 
CMY-17 X92524  ACT-5 FJ237369 
CMY-18 X92525  ACT-6 FJ237366 
CMY-19 X92526  ACT-7 FJ237368 
CMY-20 X92527  CFE-1 AB107899 
CMY-21 X92528  DHA-1 Y16410 
CMY-22 X92529  DHA-2 AF259520 
CMY-23 X92530  DHA-3 AY494945 
CMY-24 X92531  DHA-5 JF273491 
CMY-25 X92532  DHA-6 HQ322612 
CMY-26 X92533  DHA-7 HQ456945 
CMY-27 X92534  FOX-1 X77455 
CMY-28 X92535  FOX-2 Y10282 
CMY-29 X92536  FOX-3 Y11068 
CMY-30 X92537  FOX-4 AJ277535 
CMY-31 X92538  FOX-5 AY007369 
CMY-32 X92539  FOX-6 AY034848 
CMY-33 X92540  FOX-7 AJ703795 
CMY-34 EF394370  FOX-9 JF896803 
CMY-35 EF394371  LAT-1 X78117 
CMY-36 EU331426  MIR-1 M37839 
CMY-37 AB280919  MIR-2 AY227752 
CMY-38 AM931008  MIR-3 AY743435 
CMY-39 AB372224  MIR-4 EF417572 
CMY-40 EU515251  MIR-5 FJ237367 
CMY-41 AB429270  MOX-1 D13304 
CMY-43 FJ360626  MOX-2 AJ276453 
CMY-44 FJ437066  MOX-3 EU515248 
CMY-45 FN546177  MOX-4 FJ262599 
CMY-47 HM046998  MOX-5 GQ152600 
CMY-48 HM569226  MOX-6 GQ152601 
CMY-49 GQ402541  MOX-7 GQ152602 
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Table 3-8: Updated primers for the CIT, FOX, MOX and EBC AmpC plasmid gene assays, following 
the review of aligned sequences for the six AmpC plasmid gene groups.  
F indicates a forward primer, and R indicates a reverse primer. 
(2) indicates an updated version of the primer. 
 
Primers Sequences (5’ to 3’) Product 
Size (bp) 
CIT(2)-F TGATGCAGGAGCAGGCTATTC 417 
CIT(2)-R ACAGACCAATGCTGGAGTTAG 
FOX-F As original primer 175 
FOX(2)-R GATTGGCCTGGAAGCTCACCG  
MOX-F As original primer 322 
MOX(2)-R CACCTCCTCGGGGAATTGCAG  
EBC(2)-F AACTGGCAGCCGCAGTGGAAG 572 
EBC(2)-R GCCACGTAGCTGCCAAACCC  
 
The original DHA primers were found to still have full sequence agreement with the 
six aligned DHA plasmid gene sequences. For the FOX and MOX plasmid gene 
groups, although the forward primers were found to still be suitable, the reverse 
primers were both non-consensus with the alignment of the newer plasmid genes. 
New reverse primers for both FOX and MOX were identified from their respective 
alignment sequences (Table 3-8) 
As with the FOX and MOX primers, the review of the EBC primers showed that one 
primer was no longer suitable (forward primer in this case). An alternative primer 
pair was identified using the original reverse primer as a new forward primer. A new 
reverse primer was then identified from the remaining aligned sequence. The two 
new primers are shown in Table 3-8. The largest region of consensus sequences was 
20bp in length, which restricted the selection of primers.  
The four new primer pairs were tested against their respective control strains. All 
the primer pairs gave a good clear product peak on the dissociation curves. The 
corresponding CT and TM values are shown in Table 3-9. The melting temperatures 
were slightly different to those using the original primers. CIT, FOX, MOX and EBC 
originally had melting temperatures of 87.6oC, 89.1oC, 91.0oC and 89.6oC, 
respectively. All potential new primers were tested using the Primer-BLAST 
software (available at www.ncbi.nlm.nih.gov/tools/primer-blast/) to confirm the 
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accuracy of the primers, the melting temperatures of the products and the GC 
content of the primers and products. 
Table 3-9: Cycle threshold (CT) and melting temperature (TM) values for the AmpC plasmid gene 
simplex assays using the updated primers for CIT, FOX, MOX and EBC plasmid gene groups.  
Control Primer Conc (µM) CT  TM (oC) 
CIT 0.2 23.7 88.9 
FOX 0.2 20.3 88.0 
MOX 0.2 19.5 90.4 
EBC 0.2 26.0 89.3 
 
As with the original primer sets, the PCR products from the assays with the revised 
primers were referred for sequencing. The ClustalW alignments of the resulting 
sequences showed a good degree of sequence identity with the respective GenBank 
sequences (Table 3-10). The level of sequence identity for the new CIT and FOX 
primers was reduced slightly when compared to the original primers (94.1% and 
92.3%, respectively). 
Table 3-10: Degree of pairwise identity (%) for the amplification products obtained with the new 
primer pairs for the CIT, FOX, MOX and EBC plasmid gene groups, when compared with the 
reference plasmid gene sequences. 
GenBank accession numbers are given for each reference sequence. 
 
Control Strain GenBank 
Sequence 
Total Bases Consensus 
Bases 
% Identity 
CIT X78117 370 346 93.5 
FOX X77455 124 112 90.3 
MOX D13304 284 282 99.3 
EBC M37839 522 518 99.2 
 
3.3.6 Development of Multiplex Assays 
In order to simplify the analysis of large numbers of isolates, multiplex assays were 
devised for the six AmpC plasmid gene groups. Two assays were designed, each 
containing three of the plasmid gene groups. One multiplex assay included the CIT, 
ACC and DHA plasmid gene groups and the other assay included the FOX, MOX and 
EBC groups. A positive assay could be seen on the melting curve analysis as a 
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B 
distinct peak for each product (Figure 3-5). A similar approach was taken by Brolund 
et al. (2010), who also used SYBR Green real-time PCR. The CT and TM results of the 
CIT/ACC/DHA and FOX/MOX/EBC multiplex assays are shown in Table 3-11. 
 
 
Figure 3-5: Melting curve graphs for the two AmpC plasmid gene multiplex assays. 
Each of the AmpC bacterial control strains produced a characteristic peak at the expected melting 
temperature. The multiplex assays were split into two groups: A) for the CIT/ACC/DHA plasmid gene 
groups and B) for the FOX/MOX/EBC plasmid gene groups. 
 
 
 
 
 
 
 
 
 
CIT 
DHA 
ACC 
FOX 
EBC MOX 
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Table 3-11: Results of two multiplex assays for CIT, ACC, DHA and FOX, MOX, EBC using the 
combined primer solutions. 
The negative assays (Neg) were run using water as a blank DNA template. 
 
Assay (Combined Primers) Control CT Value TM Value (oC) 
CIT/ACC/DHA CIT 15.7 88.8 
ACC 13.6 86.6 
DHA 15.5 88.8 
Neg 27.0 80.8 
FOX/MOX/EBC FOX 17.5 88.8 
MOX 15.0 90.5 
EBC 13.2 89.2 
Neg 25.1 81.2 
 
It was noted that the level of non-specific amplification appeared to be higher with 
the use of the pooled primers. In order to establish whether this was the case, a 
blank run of both the multiplex primer solutions were tested, using water in place 
of DNA template. The presence of non-specific amplification could be seen on the 
dissociation curve (Figure 3-6), with melting temperatures in the region of 81oC. The 
level of non-specific amplification appeared to be lower in the presence of a 
“positive” amplification peak, due probably to competition for the master-mix 
components (Higuchi et al., 1993). 
 
Figure 3-6: Melting curves for a series of three blank multiplex assays using the CIT/ACC/DHA 
pooled primers. 
Evidence of non-specific amplification is present consistently at the 81
o
C point in the three assays. 
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3.4 Discussion 
3.4.1 Use of SYBR Green PCR and Melting Curve Analysis 
The results from the method development stage demonstrated that a quick and 
accurate assay could be implemented using SYBR Green real-time PCR for the 
detection of acquired blaAmpC genes. The assay protocol was easily amended to use 
different primers for different target DNA, such as blaCTX-M genes. The results here 
demonstrate robust assay performance for both the AmpC plasmid gene groups 
and the CTX-M ESBL genes, with a similar utility also for pre-sequencing 
amplification. The basic simplex assay protocol took approximately 43 minutes to 
complete, including the melting curve protocol. At the end of this period, the 
presence of the target gene could be easily determined from the melting curve 
analysis without the need for further handling.  
The development stage included the important components of creating a new PCR 
assay. The optimal primer concentrations were determined using a set of previously 
published primers (Perez-Perez & Hanson, 2002). This enabled a useful initial 
benchmark to be set for future evaluation. Although none of the assays included an 
internal amplification control, assays were run with a positive and negative control 
sample included where relevant (Public Health England, 2013). In the case of the 
negative control, this was always PCR-grade water. In the case of the positive 
controls, it was one of the bacterial control strains used for this purpose. The AmpC 
plasmid control strains were obtained from the national reference laboratory and 
were reported to be those used in their AmpC plasmid gene PCR assay (Woodford, 
2010 personal communication). Other control strains were obtained from the 
National Collection for Type Cultures (NCTC, Colindale). The specificity of each of 
the AmpC plasmid control strains was confirmed by the absence of cross-reactivity 
with other primers (Table 3-4). In the case of all the control strains, the PCR 
products were referred for sequencing to confirm that the correct target had been 
amplified by each assay. This also helped to confirm the suitability of the AmpC 
plasmid control strains as PCR controls, since they had not been purchased as 
recognised NCTC strains. 
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SYBR Green PCR technology and melting curve analysis have been reported to offer 
a robust solution for the detection of beta-lactamase genes. Brolund et al. (2010) 
have shown previously that the SYBR Green real-time PCR method could be used for 
the detection of AmpC plasmid-mediated genes, and can be used in the form of two 
triplex assays. Although some of the primers were updated in the Brolund paper to 
improve detection of the newer plasmid genes at the time, the assays were based 
largely on the original primers described by Perez-Perez and Hanson (2002). The 
decision to include the CIT, ACC and DHA primers together in the same multiplex in 
the current study was based on the prevalence reported in the UK for these 
plasmid-mediated enzymes (Woodford et al., 2007). Although not tested on clinical 
isolates of other species of Enterobacteriaceae in the current study, some of the 
AmpC plasmid control strains included Klebsiella pneumoniae, Citrobacter freundii 
and Enterobacter cloacae. The simplex and multiplex assays were also shown to 
detect the presence of the AmpC plasmid genes in these strains as well as the E. coli 
strains. The multiplex assays developed in the current study, therefore, would have 
a similar utility in detecting blaAmpC genes in these species isolated from clinical 
samples. The decision to group CIT, ACC and DHA together was taken so that a 
single PCR assay could be run as a screening assay to detect the most likely plasmid 
gene groups present in a wide range of clinical isolates. This would offer the 
important benefits to a diagnostic laboratory of increased speed and reduced cost. 
One of the authors on the original plasmid AmpC PCR paper (Hanson) has 
subsequently published other work on the use of real-time PCR and fluorescent 
probe-labelled dyes for the detection of plasmid genes. In the paper by Geyer et al. 
(2012), they used fluorescent FAM-labelled probes to detect the presence of the 
plasmid genes in multiplex reactions. Although the use of the FAM-labelled probe 
would help increase the specificity of the assay, a positive reaction would not 
actually indicate which plasmid gene was present in this case as all probes were 
labelled with a FAM dye. It was also interesting to note that the authors still 
reported the presence of non-specific amplification from the formation of primer-
dimers. Later, using SYBR Green PCR and melting curve analysis, Geyer and Hanson 
(2014) published a method for the detection and differentiation of AmpC plasmid 
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genes in a single multiplex assay, based on the melting temperature of the PCR 
product. They reported an assay performance of 100% sensitivity and 96% 
specificity for a range of plasmid genes and in a range of different 
Enterobacteriaceae species tested. 
Boot et al. (2013) developed a SYBR Green and melting curve protocol for the 
detection of ESBL genes carried on plasmids in E. coli. They observed a ten-fold 
increase in sensitivity of the real-time PCR assay compared to using gel 
electrophoresis as the detection method. The intensity of the bands on the 
electrophoresis gel was reported to correspond with the height of the melting curve 
peaks. Chandramohan and Revell (2012) also used SYBR Green PCR and melting 
curve analysis for the detection of ESBL genes in Enterobacteriaceae. 
The use of melting curve analysis in the current study facilitated the development of 
multiplex assays for the detection of AmpC plasmid genes. Each of the intended 
amplicons gave consistent melting temperatures for both simplex and multiplex 
assays. Although there was some overlap in the position of the peaks on the melting 
curve graphs, this did not present a problem as the multiplex assays were intended 
to be used as an initial screen, with subsequent confirmation using simplex PCR 
assays with individual primer sets. Furthermore, it was not expected that isolates 
would possess multiple plasmid genes; so only one peak would usually be present 
for each assay. 
3.4.2 Updated Primers for AmpC Plasmid Gene Groups 
In this study, the original primers for the six AmpC plasmid gene groups were 
reviewed for current suitability. It was not surprising to note that some of the 
primer pairs would no longer detect all the AmpC plasmid genes currently recorded. 
However, it could be argued that with the predominance of CMY-2 and DHA-1 as 
the most frequently encountered plasmid-mediated AmpC enzymes in the UK 
(Woodford et al., 2007), the need to fully encompass all current plasmid genes may 
not be necessary. However, the counter-argument that emerging plasmid genes 
would not be detected unless regular reviews of primer sequences are undertaken 
also holds true. Although commercial diagnostic assays are available for the 
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detection of AmpC plasmid genes, they are more expensive than the traditional 
culture-based methods. In the clinical setting, there is a balance to be struck 
between speed, accuracy and utility and the price of the assay. The benefit of using 
culture as a screening method for resistant strains is that new, emerging 
mechanisms should still be detected. 
Both the CMY-2 and DHA-1 plasmid genes would be detected using the primers 
published in the original paper (Perez-Perez & Hanson, 2002), representing the CIT 
and DHA plasmid gene groups, respectively. The review did highlight the speed at 
which additional plasmid genes are being detected and recorded. Any review of this 
nature will only have a limited lifespan if full coverage is a key objective. Indeed, it 
was not even possible to achieve full coverage for some of the plasmid gene groups. 
The CMY-13 gene had a large number of additional nucleotides present, making 
alignment with other members of the CIT group impossible. This sequence did not 
align with any of the other five plasmid gene groups either. In the case of the ACC 
group, it was not possible to identify new primers for the four plasmid genes 
recorded. The two additional ACC plasmid genes (ACC-3 and ACC-4) have not yet 
been reported to be present in the UK (Girlich et al., 2000; Papagiannitsis et al., 
2007). The other four AmpC plasmid gene groups were either covered by existing 
primers (DHA) or were able to have updated primers selected from aligned 
sequences (FOX, MOX, EBC). Although some other studies have also reported the 
use of updated primers for plasmid-mediated ampC genes (Dallenne et al., 2010; 
Voets et al., 2011), these were also found not to fully include all plasmid genes 
available at the time of this review (data not shown).  
3.4.3 Further Developments 
One obvious future development would be the use of probes labelled with different 
fluorescent dyes. This would enable the detection of the AmpC plasmid genes, with 
a simultaneous identification of the plasmid gene group present through the use of 
different coloured-dyes. One limitation of this approach would be the number of 
detection channels available on the real-time PCR instrument. In the case of the 
Smart Cycler instrument used in this study, there are four detection channels 
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available. This would limit the number of target probes to three plasmid gene 
groups if one channel was allocated for an internal control (Public Health England, 
2013). 
The assays developed in this stage of the study were subsequently used for the 
detection of blaAmpC and blaCTX-M genes present in local and regional isolates of E. 
coli. Although the AmpC plasmid primers were reviewed against the current list of 
known plasmid genes, the same process was not undertaken for the CTX-M genes. 
At the time of last checking, there were 172 CTX-M genes listed on the international 
website (www.lahey.org/studies/other, last accessed 15th July 2015). It is likely that 
many of these will have been discovered since the CTX-M primers used in this study 
were first developed. It would be useful as a future study to investigate whether the 
universal CTX-M primers and Group 1-specific CTX-M primers are still able to detect 
the clinically relevant CTX-M genes. Although many studies report CTX-M-15 as the 
most common type of ESBL present in E. coli, there is a danger that the use of 
primers that are now over ten years old will, in time, miss some of the newer genes 
as they arise. It is worth noting that CTX-M ESBL enzymes were only discovered 15 
years ago (Livermore, 2007). 
The underlying PCR protocols in the study were also used for the amplification of 
target genes prior to sequencing. The use of the melting curve analysis was helpful 
in identifying the successful amplification of a product before the sample was 
referred for sequencing. Although not investigated further, there was some 
anecdotal evidence that the height of the melting curve peak was related to the 
success of achieving a full sequence result. Therefore, a judgement could be made 
on whether to repeat an amplification step before sending the product for 
sequencing. 
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4 Pilot Study of AmpC-Mediated Resistance in Gloucestershire 
4.1 Introduction 
All E. coli strains carry the chromosomal ampC gene for enzyme production (Olsson 
et al., 1983). This gene is expressed weakly, but constitutively, and at a level low 
enough that clinical resistance to beta-lactam antibiotics is not seen. Mutations can, 
however, occur in the promoter region of the gene, affecting the expression and 
subsequent production of the AmpC enzyme. Strains with these mutations are said 
to hyper-produce the AmpC enzyme (Caroff et al., 2000). 
The common RNA promoter sequence for E. coli includes a -35 box (TTGACA), 
separated from a -10 box (TATAAT) by a distance of 17 base pairs (Hawley & 
McClure, 1983). The promoter sequence for the ampC gene, however, is different 
by a single base pair change in each of the boxes, and has an inter-box distance of 
16 base pairs. It is these small changes that reduce the power of the promoter and 
the level of enzyme expression (Corvec et al., 2002). 
There are reported mutations that can return the wild-type promoter sequence to 
one closer to the common promoter sequence for E. coli. The mutations create 
either a new -35 box in a different location, or change the existing -35 box. The 
most commonly reported mutation is a C to T transition at position -42 in the 
promoter region (Tracz et al., 2007). This mutation creates a displaced -35 box, 
increasing enzyme production by 20-fold when compared to the wild-type level. 
Other important mutations affecting enzyme expression include a T to A transition 
at position -32 and the insertion of one or two bases at position -13 (Tracz et al., 
2007). Mutations have also been reported throughout the rest of the promoter and 
attenuator regions, but have less of an impact on enzyme expression. Mulvey et al. 
(2005) found 91% of 183 cefoxitin-resistant E. coli isolates had one or more 
mutations at 29 different locations in the sequenced ampC promoter regions. 
E. coli strains can also acquire ampC genes on plasmids from other species. Plasmid 
ampC genes were first described in 1988, and are derived from species such as 
Enterobacter spp. and Citrobacter spp. (Philippon, Arlet & Jacoby, 2002). AmpC 
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plasmid genes have been classified into six groups, based on the species of origin: 
CIT, ACC, DHA, FOX, MOX and EBC (Perez-Perez & Hanson, 2002). The most 
common AmpC plasmid gene, also with the largest geographic spread, is the CMY-2 
gene (CIT-type) (Jacoby, 2009). 
In a UK study (Woodford et al., 2007) of cephalosporin-resistant E. coli, 49% had an 
AmpC plasmid-mediated gene present. The isolates were submitted to the national 
UK reference laboratory, and were selected for potential AmpC production based 
on the presence of cephalosporin-resistance without potentiation by clavulanic 
acid. The majority of isolates with plasmid genes carried the CIT-type, but ACC, FOX 
and DHA plasmid gene groups were also found.  
Even though E. coli is one of the most common pathogens in the UK, there is a lack 
of data for AmpC resistance in clinical isolates. This is particularly the case for the 
chromosomal mutations in the ampC promoter region. In a study by a national UK 
reference laboratory (Hopkins et al., 2006a), 12 isolates were found with mutations 
in the ampC promoter region. These isolates were from an archived library, were 
collected between 1995 and 2003, and are unlikely to be fully representative of 
current clinical strains. 
Epidemiological studies are only ever a snapshot of a particular time and place, so it 
is important to update and renew the data wherever possible. This helps to ensure 
that the rapid spread of new resistance genes or dominant clones are detected 
quickly. The CTX-M ESBL enzymes, for example, went from being first reported in 
2000 to the predominant cause of cephalosporin resistance in the UK in less than 5 
years (Livermore et al., 2007). 
This stage of the current study was considered to be a pilot study for the larger, 
regional study. Undertaken in 2011, with isolates collected from clinical urine 
samples in the Gloucester laboratory, the purpose of the pilot study was to 
establish the background data for prevalence of AmpC plasmid genes and ampC 
chromosomal promoter region mutations, and to evaluate the PCR assays and 
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protocols for sequencing products. This phase of the study has been published in 
the British Journal of Biomedical Science (Lewis et al., 2015). 
4.2 Methods 
Isolates were collected in the Gloucester laboratory during the period June 2011 
and November 2011, and were eligible for inclusion in the study if they had a 
phenotypic susceptibility pattern suggestive of AmpC enzyme production; resistant 
to cefpodoxime, but with a negative clavulanic acid synergy test (M’Zali et al., 
2000). Isolates were excluded if the same species had been isolated from the same 
patient in the previous 28 days. Isolates were allocated a unique study reference 
number, in order to anonymise patient-specific data. Isolates were collected from 
samples referred from both hospital and community settings. As samples from GP 
surgeries represent only a subset of actual UTI cases, this may have introduced an 
element of bias into the collection process (McNulty et al., 2006). 
Isolates were identified using chromogenic agar plate media and biochemical 
identification strips. Disc susceptibility testing was performed according to a 
national standard method (Andrews & Howe, 2011) to a range of cephalosporins, 
including cefpodoxime, cefuroxime, cefoxitin, cefotaxime and cefepime. Isolates 
were tested to determine the MIC of cefotaxime, using gradient antibiotic strips, 
and were also tested for the presence of ESBL enzymes using clavulanic acid synergy 
discs. 
DNA templates for PCR were prepared using a crude lysis method (Woodford, 
2010). The presence of ampC-carrying plasmids was determined using two 
multiplex real-time SYBR Green PCR assays. The primers used were a combination 
of those published previously (Perez-Perez & Hanson, 2002) and those developed in 
this study (Section 3.3.6). The multiplex assays were designed to detect CIT, ACC 
and DHA plasmid gene groups in one assay, and the FOX, MOX and EBC plasmid 
gene groups in the other. Multiplex AmpC plasmid gene PCR assays with a positive 
melting curve peak were confirmed using the same primers in three separate 
simplex reactions. 
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A 271bp region of the ampC gene was amplified and sequenced, using primers 
previously published by Caroff et al. (2000). The amplified sequence included the 
promoter region, attenuator region and the first part of the coding region. The PCR 
products were sent to an external laboratory (Eurofins Genomics, Germany) for 
sequencing. The reported sequence of each product was compared against the 
ampC sequence for the E. coli NCTC 12241 strain (GenBank Accession No. 
AY899338). 
4.3 Results 
4.3.1 Patient Demographics 
A total of 50 E. coli isolates were isolated from urine samples sent in for clinical 
diagnostic purposes. A total of 75% of isolates were from female patients and 25% 
were from male. The mean age of all patients was 58.3 years, with a range from 1 to 
94 years. No further demographic data were collected on the samples. 
4.3.2 Susceptibility Testing 
All isolates were tested against a range of five cephalosporins, with results analysed 
using the breakpoints set by the British Society of Antimicrobial Chemotherapy 
(BASC) (Andrews & Howe, 2011). The summary of results is given in Table 4-1. 
The majority of isolates (98%) were resistant to cefuroxime at the breakpoint of a 
19mm zone size. This is in contrast to the cefotaxime results, in which 28% of 
isolates were resistant at the 19mm breakpoint zone size. Further results included 
98% of isolates demonstrating resistance to cefoxitin and 44% with intermediate or 
resistant zone sizes for cefepime. 
Isolates were also tested for the minimum inhibitory concentration of cefotaxime 
using gradient antibiotic strips. The geometric mean MIC for cefotaxime was 
1.2mg/L for the whole group of 50 isolates, which is just above the recommended 
clinical breakpoint of 1.0mg/L (Andrews & Howe, 2011). 
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Table 4-1: Disc susceptibility testing results for the 50 pilot study isolates of E. coli to a range of 
five cephalosporins. 
The zone diameter breakpoints shown are for resistant isolates, or for resistant and intermediate 
isolates if a range is given. S = Resistant, I = Intermediate, R = Resistant. Percentage values are given 
in parenthesis. (Andrews & Howe, 2011). 
 Disc 
Content 
(μg) 
Zone 
Diameter 
Breakpoints 
(mm) 
S (%) I (%) R (%) 
Cefpodoxime 10 ≤19 0 (0) N/A 50 (100) 
Cefuroxime 30 ≤19 1 (2) N/A 49 (98) 
Cefotaxime 30 ≤23 to ≤29 14 (28) 22 (44) 14 (28) 
Cefoxitin 30 ≤22 1 (2) N/A 49 (98) 
Cefepime 30 ≤26 to ≤31 28 (56) 12 (24) 10 (20) 
 
 
4.3.3 Prevalence of ampC-Carrying Plasmids 
The 50 isolates were tested for the presence of AmpC plasmid genes using the two 
multiplex AmpC plasmid gene PCR assays (CIT/ACC/DHA and FOX/MOX/EBC) 
developed in Section 3.3.6. Ten of the 50 isolates gave an initial positive result in 
the CIT/ACC/DHA multiplex assay (Table 4-2). All of these were subsequently 
confirmed as being a CIT-type gene using the simplex version of the assay (Figure 
4-1). None of the other AmpC plasmid gene groups were detected (ACC, DHA, FOX, 
MOX, EBC). The isolates with the CIT-type genes were not investigated further to 
determine the specific plasmid gene present. 
Table 4-2: Melting temperatures (TM) from the multiplex AmpC plasmid gene assay for the 
detection of CIT/ACC/DHA plasmid genes in E. coli, with the corresponding repeat simplex assay 
for confirmation. 
Also shown are the cycle threshold (CT) values for the simplex PCR reactions using the CIT primers. 
Isolate Multiplex TM (oC) Simplex CT Simplex TM (oC) 
G-010 88.8 22.6 88.6 
G-012 88.9 19.5 88.6 
G-014 88.6 26.3 89.5 
G-017 88.6 16.9 88.8 
G-018 88.9 22.4 89.0 
G-026 88.5 23.1 88.7 
G-042 88.5 25.6 88.7 
G-050 88.8 22.9 89.0 
G-052 88.7 21.5 88.8 
G-054 88.7 26.3 88.2 
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Figure 4-1: Melting curve graphs of the ten isolates identified as carrying a CIT-type AmpC plasmid 
gene. 
The assays were simplex PCR reactions to confirm the presence of a positive peak in the screening 
multiplex assays. Each of the two sets of five simplex reactions was tested along with a bacterial 
control strain (CIT) and a negative PCR control (NEG) of water. Isolates were tested in two batches; A 
and B. 
 
4.3.4 ampC Promoter Region Mutations 
In the remaining 40 isolates (those without an AmpC-plasmid gene present), 
sequencing the 271bp region of the chromosomal ampC promoter revealed 
mutations at 16 different locations. The full list of mutations is provided in Table 
4-3. 
From the 16 mutations, a total of 18 different genotype patterns were recorded. All 
of the 40 isolates had at least one mutation in the amplified sequence, when 
compared to the sequence for the E. coli NCTC 12241 control strain (GenBank No: 
AY899338). Genotype numbers were allocated to each of the unique patterns, 
A 
B 
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based initially on the frequency of detection (e.g. G1 most common, G2 second 
most common, etc.). 
In general, the types of mutations detected fell into three principal groups: 
1. Mutations in the wild-type promoter region (Section 4.3.4.1) 
2. Creation of a displaced promoter (Section 4.3.4.2) 
3. Increases to the spacer region distance (Section 4.3.4.3) 
 
 
4.3.4.1 Mutations in the Wild-Type Promoter 
The most common mutation detected in the 40 isolates was a T to A substitution at 
position -32. This mutation was found in a total of 25 isolates (62.5%) overall, but 
was also commonly associated with other mutations at positions +58 and +63. This 
genotype pattern of -32, +58, +63 (designated G1) was found in a total of 11 
isolates, and represented the most common genotype pattern detected. The -32 
mutation alters the normal wild-type -35 box from TTGTCA to TTGACA, thus 
retaining its original position but now with a promoter sequence identical to that of 
the E. coli consensus promoter (TTGACA) (Hawley & McClure, 1983). 
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Table 4-3: Details of mutations observed at different positions in the amplified 271bp region of the promoter, attenuator and coding regions of the chromosomal ampC gene. 
Each genotype is shown, with the corresponding numbers of isolates allocated to that group. Genotype numbers were allocated within this study. Position numbers for locations 
on the ampC gene were those used by Jaurin et al. (1981). The control sequence is derived from the GenBank entry for E. coli NCTC 12241 (AY899338). ins = 1 or 2 bp insertions at 
position -13. 
Genotype No. of  Isolates -42 -32 -28 -18 -14 -13 -13ins -1 +6 +17 +23 +34 +37 +58 +63 +70 +81 
Control  C T G G T T - C C C G G G C T C A 
G1 11  A            T C   
G2 8  A                
G3 2  A              T G 
G4 2       T  T         
G5 2 T   A    T      T   G 
G6 2   A    AT           
G7 2   A  A  T   T        
G8 1    A    T      T   G 
G9 1   A               
G10 1   A    T           
G11 1      G TT           
G12 1  A A       T        
G13 1  A A               
G14 1  A  A    T   A   T   G 
G15 1  A           A   T G 
G16 1 T   A    T   A   T   G 
G17 1   A         A  T    
G18 1   A       T        
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The -32 mutation was also found with mutations at other positions in the amplified 
sequence. Two isolates had mutations at positions +70 and +81 in the coding 
region, in addition to the change at position -32 (Genotype G3). One isolate had 
mutations at positions -32 and -28 (Genotype G13), and one isolate had mutations 
at positions  -32, -28 and +17 (Genotype G12). Two further isolates had the -32 
mutation present with a number of various changes at other positions in the region 
(-18, -1, +23, +37, +70 and +81). The -32 mutation was also detected as the only 
nucleotide change present. This was observed in a total of 8 isolates (20%), and was 
allocated the genotype number G2, as the second most common genotype. 
4.3.4.2 Creation of a Displaced Promoter 
Mutations at positions -42 and -18 have been reported to create new -35 and -10 
boxes, respectively, at different locations in the promoter region (Olsson et al., 
1983). Of the 40 isolates tested, the -42 mutation (C to T) was found in only 3 
isolates (7.5%). In all three cases, this mutation was found together with a G to A 
transition at position -18 (Genotypes G5 and G16). 
The -18 mutation itself was found to be present in two isolates without the -42 
mutation. One of these isolates was found to have mutations at positions -18, -1, 
+58 and +81 (Genotype G8). In the other isolate, it was found to be present in 
conjunction with the -32 and other mutations (Genotype G14). 
4.3.4.3 Increase in Spacer Region 
The distance between the -35 and -10 boxes, either in the wild-type or the 
displaced locations, is known to have an influence on the level of enzyme 
production (Ayers et al., 1989). An increase in the spacer region can occur through 
the -42 and -18 mutations described above. The two mutations together create two 
new -35 and -10 boxes that are 17bp apart in the promoter region. The normal wild-
type distance for the two boxes is 16bp. 
However, increases in the spacer region were also observed in 8 of the 40 isolates 
(20%), with the insertion of one or two nucleotides at position -13. The additional 
bases were either adenine or thymine, and were found as single insertions in 5 
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isolates (Genotypes G4, G7, and G10) and double insertions in 3 isolates (Genotypes 
G6 and G11). In all 8 isolates, the insertions at position -13 were present along with 
mutations at other various positions, but not with either the -42 or -32 mutations.  
4.3.4.4 Mutations at Other Positions 
In addition to the mutations described above (-42, -32, -18 and -13ins), there were 
other mutations noted to be present in the 40 isolates. A mutation at position -28 
(G to A) was observed in 25% of the isolates. This was associated with the -32 
mutation (2 isolates) or with the -13 insertions (5 isolates), but not with the -42 
mutation. In one isolate, the -28 mutation was the only mutation detected 
throughout the amplified region. In two isolates, it was found only along with 
mutations in the attenuator region (positions +17 and +34). 
Mutations in the attenuator region (positions +17 to +37) are thought to destabilise 
the effect of the stem-loop and thereby allow for increased levels of enzyme 
transcription (Caroff et al., 2000). In the 40 isolates tested, mutations in the 
attenuator region were observed in a total of 8 isolates, but always along with one 
of the key mutations (-42, -32 and -13ins) described by Tracz et al. (2007). In two 
isolates, this was seen in conjunction with a single base pair insertion at position -
13. In three isolates, the attenuator mutations were observed along with the -32 
mutation, and with the -42 mutation in one further case. As mentioned above, 
there were two further isolates in which the attenuator mutations were found 
together with the mutation at position -28. 
Mutations were seen at three positions in the coding region (+63, +70 and +81). In 
total, 47.5% of isolates (n=19) had at least one of the mutations at these positions. 
They were seen in conjunction with both the -42 and the -32 mutations, but not the 
-13 insertions. 
Mutations were also observed at three positions outside the promoter, attenuator 
and coding regions. Positions -1, +6 and +58 are outside the three main regions, but 
were commonly seen as mutations in the 40 isolates tested. Two of the mutations    
(-1 and +58) were occasionally found together, as was the case in 5 of the 40 
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isolates. In total, there were 24 of the 40 isolates in the group with mutations in at 
least one of these three positions. 
4.3.5 Mutations Seen in the AmpC Plasmid Gene-Carrying Isolates 
The ten isolates carrying a CIT-type AmpC plasmid gene were also investigated for 
the presence of mutations in the chromosomal promoter region. None of the ten 
isolates had one of the -42, -32 or -13ins mutations present (Table 4-4). Eight of the 
isolates had mutations present at one of the three locations in the coding region 
(+63, +70 or +81). The mutations at positions -28, -18 and -1 were each present in 
two of the ten isolates. The mutation at position +58 was present in three isolates. 
Table 4-4: ampC chromosomal mutations present in the E. coli isolates carrying AmpC CIT-type 
plasmid genes. 
Study Ref AmpC Plasmid 
Gene 
ampC chromosomal mutation(s) 
G-010 CIT +81 
G-012 CIT -18, -1, +58, +81 
G-014 CIT +70, +81 
G-017 CIT -28,  
G-018 CIT +70, +81 
G-026 CIT +70, +81 
G-042 CIT -18, -1, +58, +81 
G-050 CIT +58, +63 
G-052 CIT +81 
G-054 CIT -28 
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4.4 Discussion 
4.4.1 Susceptibility Testing 
The use of cefoxitin resistance as a screening method is recommended in national 
standard methods for susceptibility testing (Andrews & Howe, 2011). All but one of 
the isolates (98%) were resistant to cefoxitin by disc susceptibility testing, thus 
confirming its use as a screening method. The specificity of the method, however, is 
reduced by the existence of other means in which E. coli strains can become 
resistant to cefoxitin (i.e. membrane permeability) (Chen & Livermore, 1993). 
Strains producing AmpC enzymes are normally considered to exhibit the 
antibiogram phenotype of cefoxitin resistance, but with cefepime susceptibility 
(Potz et al., 2006; Woodford et al., 2007). In this study, only 56% of the isolates met 
the criteria for both cefoxitin-resistant and cefepime-sensitive, as only 42% had a 
disc zone size larger than the 32mm breakpoint for cefepime susceptibility. This 
highlights the importance of using a method (phenotypic or molecular) to confirm 
initial antibiogram results. 
4.4.2 Prevalence of ampC-Carrying Plasmids 
The results from this pilot study of 50 isolates revealed chromosomal mutations and 
acquired genes associated with AmpC resistance. Ten of the isolates (20%) had a 
CIT-type plasmid gene present. Although not fully characterised in this study, the 
most common of the CIT-type plasmid-mediated genes is CMY-2; reported globally 
in clinical samples (Mammeri et al., 2008; Jorgensen et al., 2010; Bogaerts et al., 
2010; Mulvey et al., 2005). It has also been associated with poultry (Voets et al., 
2013; Dhanji et al., 2010), livestock and companion animals (Dierikx et al., 2012), 
water and beaches (Mataseje et al., 2009) and retail vegetables (van Hoek et al., 
2015b). The importance of monitoring AmpC plasmid genes in clinical samples is 
discussed further in Section 1.4, and was highlighted recently in a case report (Lin et 
al., 2015). A CMY-2 plasmid gene was reported to have transferred from an E. coli 
strain to a Klebsiella pneumoniae strain isolated from a liver abscess. Both strains 
had been isolated from the same patient. 
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The presence of ampC-carrying plasmids in 20% of the cephalosporin-resistant E. 
coli isolates in the current study appears to be in line with studies from other 
countries. Mammeri et al. (2008) investigated 2800 isolates of E. coli in France, 
finding 34 with an AmpC phenotype. Most of the isolates were isolated from urine 
samples or purulent exudate. Eight (23.5%) had an AmpC plasmid gene present, the 
majority of which were CMY-2. In Denmark, Jorgensen et al. (2010) found 24 of 
6356 E. coli isolates to have a phenotype suggestive of AmpC-mediated resistance. 
CIT-type plasmid genes were found in 4 of the 24 isolates (16.7%), all of which were 
confirmed by sequencing as CMY-2. 
Bogaerts et al. (2010) investigated 83 E. coli isolates in Belgium with a confirmed 
AmpC phenotype. The isolates had been isolated mainly from urine samples or 
screening rectal swabs. Of the 83 isolates, 13.3% (n=11) carried an AmpC plasmid 
gene; ten isolates with CMY-2 and one isolate with ACC-1. Finally, in a Canadian 
study, Mulvey et al. (2005) reported 13.5% of mainly uropathogenic E. coli isolates 
to be carrying an AmpC plasmid gene. All of these were confirmed to be CMY-2. 
4.4.3 ampC Promoter Region Mutations 
In the 40 isolates without an AmpC plasmid gene present, 70% (n=28) possessed 
either the -42 or -32 mutation (Figure 4-2); both of which are considered to be key 
factors for increased AmpC enzyme production. These two mutations are known to 
create a new -35 box, to one with a greater degree of sequence identity to the E. 
coli consensus RNA promoter sequence (Tracz et al., 2007). 
The -32 mutation (T to A) was the most common mutation found, present in 62.5% 
of isolates without an AmpC plasmid gene present. The mutation was present either 
alone or in combination with mutations at other positions. First described by 
Kobayashi et al. in 1990 (Kobayashi, Nagata & Ishihama, 1990), the -32 mutation is 
reported to cause an increase of enzyme over-expression by up to 46-fold when 
compared to the susceptible wild-type E. coli strains (Tracz et al., 2007). In the 
current study, the cefotaxime MIC tests gave a geometric mean of 0.6mg/l for the 
isolates with the -32 mutation present. This represented a 10-fold increase in the 
MIC when compared to the E. coli control strain (NCTC 12241) MIC of 0.06mg/l. 
Page 80 of 188 
 
 
Figure 4-2: Sequence of the E. coli ATCC 25922 (NCTC 12241) ampC promoter region. 
Reproduced with permission from Tracz et al. (2007). 
 
Caroff et al. (2000) cloned sections of the ampC promoter region into indicator 
genes. The sections of the promoter region investigated included the -42 and -32 
locations, tested both with and without mutations. Results indicated that enzyme 
concentrations increased by 70- to 120-fold in the presence of the mutations. Tracz 
et al. (2007) also found significant increases in promoter expression for the -42 
mutation and -13 spacer insertions, of 20-fold and 24- to 61-fold, respectively. 
In the current study, only three isolates (6%) possessed the -42 mutation. Other 
studies, however, have found a higher prevalence for this particular mutation. 
Mammeri et al. (2008) found 57.7% (n=15) of isolates in a French study with the -42 
mutation and 23.1% (n=6) of isolates with the -32 mutation. In a Danish study, 
Jorgensen et al. (2010) found 25% (n=5) of isolates each with the -42 mutation and 
the -32 mutation, equally. Bogaerts et al. (2010) found that 100% (n=72) of the 
isolates in Belgium with chromosomal mutations had the -42 mutation present. 
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Mulvey et al. (2005) found 23.5% of isolates in the large Canadian study to have the 
-42 mutation present and 18.0% of isolates to have the -32 mutation. To date, the 
current study (Lewis et al., 2015) appears to be the only published data in which the 
-32 mutation is more prevalent than the -42 mutation. 
It is thought that the -42 and -32 mutations are able to have a direct effect on the 
transcription process, due to the binding of the RNA polymerase (Olsson et al., 
1983). In the current study, the -32 mutation was seen as the only mutation present 
in 20% of isolates (n=8), thus confirming its importance as a controlling influence on 
enzyme production.  
Mutations were seen at positions -28 and -18 in ten isolates and five isolates, 
respectively. These were seen commonly in conjunction with the insertions at 
position -13, but were also observed together with the -32 mutations. Corvec et al. 
(2007) also noted that the -18 and -28 mutations were present in a number of the 
fully sensitive isolates they tested (13% and 29%, respectively), thus calling into 
doubt the role these two mutations actually play in influencing enzyme production. 
Tracz et al. (2007) demonstrated that the -18 mutation alone had a 1 to 4-fold 
increase in enzyme production and the -28 mutation a 1 to 3-fold increase, also 
confirming a minimal role in promoter control. 
Ayers et al. (1989) first described the impact of the spacer region between the -35 
and -10 boxes in 1989. Tracz et al. (2007) demonstrated that strains with a single 
base pair insertion at position -13 had a 24- to 61-fold increase in enzyme 
expression. This was similar to the effect seen with two nucleotides inserted at the 
same position. The insertion of one or two base pairs at position -13 was recorded 
in 20% of isolates tested in the current study. The inserted bases were either 
adenine or thymine, and increased the spacer region between the -35 and -10 
boxes from 16bp to 17 or 18bp. Mulvey et al. (2005) reported 10.4% of isolates with 
the insertions at position -13 (1 or 2bp).  
Mutations in the attenuator region (positions +17 to +37) were found in 17.5% of 
isolates (n=7). These mutations were thought to increase enzyme production 
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through the destabilisation of the stem-loop structure (Caroff et al., 2000), but have 
been demonstrated to have little actual effect on enzyme production (Tracz et al., 
2007). Mulvey et al. (2005) described a small number of isolates with single base 
pair deletions at a position in the attenuator region (positions +34 and +37), but 
these were not seen in the current study. Evidence for the impact of attenuator 
mutations is somewhat indirect in nature, and is currently limited to the functional 
assays described above. Introducing mutations into the attenuator region to obtain 
direct evidence is considered to be difficult due to the stem-loop structure (Caroff 
et al., 2000). Mutations in the coding region (positions +63 to +81) were seen in 
nearly half (47.5%) of all isolates. The contribution of these mutations in unknown 
(Mulvey et al., 2005). 
4.5 Summary 
The pilot stage of the project tested 50 isolates of uropathogenic cefpodoxime-
resistant, ESBL-negative E. coli. AmpC-mediated resistance was confirmed in 92% of 
isolates. Although some isolates did carry a plasmid-mediated ampC gene, the 
majority possessed one of the key ampC chromosomal promoter region mutations 
(-42, -32, -13ins) known to cause hyper-production of the enzyme (Tracz et al., 
2007). 
The -32 mutation, -42 mutation and -13 insertions accounted for 90% of the 
resistance in the 40 isolates without an AmpC plasmid gene present. These three 
key mutations were not found together in the same isolate, providing further 
evidence that they are the primary chromosomal mechanisms responsible for 
enzyme hyper-production. Indeed, the -32 mutation was seen as the only mutation 
present in a fifth of isolates. 
There is a general lack of published data for the prevalence of these key mutations 
within UK strains. Hopkins et al. (2006a) investigated a selection of isolates that had 
been referred to the Laboratory of Enteric Pathogens, London. Of the 37 archive 
isolates tested, 12 had chromosomal mutations potentially related to AmpC hyper-
production, but the -42 and -32 mutations were only found in half.  
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In the current study, the -32 mutation was the most prevalent, rather than the -42 
mutation reported as the most common elsewhere. It is unclear whether the two 
mutations would have significantly different impacts on actual clinical resistance. 
The studies by Tracz et al. (2007) indicated that the -32 mutation resulted in a 10 to 
45-fold increase in enzyme production, whereas the isolates with the -42 mutation 
had 22 to 280-fold increases. Whether this would actually translate to a difference 
in the MIC for the isolate is not clear. As it is unlikely that the two mutations have 
significantly different effects on the level of enzyme production, this probably does 
not represent a clinically important difference. However, the difference may be a 
reflection of the variation in dominant clones in the local strain population. The 
extension of the project to include regional isolates, and to use molecular typing 
methods, will help to confirm whether this pattern is observed in other areas. 
4.6 Future Work 
The typing of the isolates with different mutations could give an indication of 
whether a dominant clone exists within the local population. This may explain why 
the isolates with the -32 mutation were more prevalent in this study. Using a PCR-
based phylogenetic method (Clermont, Bonacorsi & Bingen, 2000), E. coli isolates 
can be allocated to one of four phylogenetic groups (A, B1, B2 and D), based on the 
presence of three PCR products (two genes chuA and yjaA and an anonymous 
fragment TSPE4). Pathogenic extra-intestinal strains are often reported to be in 
Groups B2 or D, whereas the environmental commensal strains are often in Groups 
A and B1. Typing methods were not used in the pilot stage of the study. However, 
an assay for phylogenetic typing the E. coli isolates would be a reasonably easy 
development using the SYBR Green PCR protocols.  
Corvec et al. (2007) found a range of ampC chromosomal mutations in fully-
sensitive isolates of E. coli. Of 100 isolates tested, 78 had mutations present at 
positions that included -88, -82, -73, -28, -18, -1, +17, +58, +63, +70 and +81. It is 
interesting to note that none of the three key mutations (-42, -32 and -13ins) 
described by Tracz et al. (2007) were found in the sensitive isolates. The current 
pilot study did not include the investigation of sensitive isolates or isolates with 
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other resistance phenotypes (e.g. ESBLs). However, this could be one useful area for 
investigation, to provide further evidence for the actual role of different mutations 
in the degree of phenotypic resistance observed.  
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5 Study of Cephalosporin-Resistance in E. coli in South West England 
5.1 Introduction 
A number of previous studies have investigated the prevalence of blaESBL genes in 
the UK. One principal study was by Potz et al. (2006), in which 16 laboratories in 
London and the South East of England submitted a range of cephalosporin-resistant 
Enterobacteriaceae isolates. Isolates were categorised as: ESBL-producing (CTX-M), 
ESBL-producing (Non-CTX-M), AmpC-producing and a fourth group for other 
mechanisms. Although the presence of blaCTX-M genes was determined using PCR, 
the categorisation of AmpC-producing isolates was done on the basis of interpretive 
reading from the MIC data and species identification. The investigation of 
chromosomal ampC promoter mutations was not undertaken. However, the study 
did highlight a variation in the proportion of CTX-M-producing isolates of 0.6% to 
4.3% between some of the laboratories and their catchment populations. 
In an earlier study, Woodford et al. (2004) investigated the presence of blaCTX-M 
genes in 291 E. coli isolates from 42 laboratories across the UK. Rather than a 
planned submission, these clinical isolates were referred to the testing laboratory to 
confirm unusual resistance phenotypes. Although they would have represented a 
wide geographic spread of locations, the collection of isolates was bias towards a 
more resistant phenotype. The Group 1-specific blaCTX-M genes were the most 
common, at 96% of the isolates investigated. 
Later, the same group (Woodford et al., 2007) reported on a study of 135 E. coli and 
38 Klebsiella sp. isolates that had been sent to the national reference laboratory for 
investigation of cephalosporin resistance (without evidence of ESBL production). 
Although again not a regional study as such, the study did include isolates from 86 
laboratories across UK and Ireland. Nearly half of all the E. coli isolates were shown 
to have an acquired ampC gene present, with a variety of types found. This study 
still represents the most comprehensive UK study of AmpC plasmid gene carriage in 
E. coli. 
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The first study of AmpC plasmid gene carriage in UK isolates had actually been 
published the previous year (Hopkins et al., 2006a). A total of 24.3% (n=25) of E. coli 
isolates had an AmpC plasmid gene present, all of which were of the CIT-type. The 
majority of these were subsequently confirmed as being CMY-7 (n=20). The isolates 
had been sent from 11 different laboratories in the UK. This study also investigated 
the presence of chromosomal ampC promoter mutations in 12 isolates that were 
cefoxitin-resistant but without an AmpC plasmid gene. The number of isolates 
tested was quite small, making interpretation of the significance difficult, but the -
42 mutation was seen to be present in higher numbers than the -32 mutation (4 vs 
2). 
Data published from studies conducted in other countries are often limited to 
isolates collected in just one location. This is the case for studies in France 
(Mammeri et al., 2008), Denmark (Jorgensen et al., 2010), Spain (Gude et al., 2013) 
China (Li et al., 2008) and the United States (Coudron, Moland & Thomson, 2000). 
The principal large-scale overseas study is one in Canada (Mulvey et al., 2005), in 
which 232 cefoxitin-resistant E. coli isolates were collected from 12 laboratories 
over a 1-year period in 2000. A total of 49 different ampC phylogroups were 
reported from mutations at 28 different locations in the promoter sequence. 
The regional stage of the current study followed on from the initial pilot phase 
conducted in 2011. The principal aim was to see whether the pilot findings (Chapter 
4) were mirrored elsewhere in the region, and to determine whether there were 
variations between laboratories for resistance rates and the types of genes present. 
This had been noted by Potz et al. (2006). In particular, one aim was to see whether 
the -32 mutation observed to be the most common in the pilot study was also the 
most common in isolates collected from other laboratories. 
5.2 Methods 
A full description of methods is provided in Chapter 2. Clinical isolates of 
cefpodoxime-resistant E. coli were collected from five laboratories in the South 
West region over a 3-month period. Isolates were excluded if the same species had 
been isolated from the same patient in the previous 28 days. Isolates were 
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identified using chromogenic agar plate media and biochemical identification strips, 
as described in Chapter 2.10. Isolates were allocated to an ESBL group or a Non-
ESBL group, based on the results of a clavulanic acid synergy test (M’Zali et al., 
2000). The methods used for detecting blaCTX-M, blaAmpC, chromosomal ampC 
mutations and multi-locus sequence typing is provided in Figure 5-1.  
5.3 Results 
5.3.1 Isolate Collection 
The regional phase of the current study was undertaken in 2013. Five laboratories 
were recruited to participate, from a total of 14 available in the South West region. 
Each laboratory was asked to submit the first 50 isolates isolated from the start of 
the collection period (April 2013). The Gloucester laboratory was asked to collect 
the first 100 isolates (in addition to the 50 isolates in the pilot study; Chapter 4). 
The five laboratories collected a total of 310 isolates over a 3-month period. On 
receipt in the testing laboratory (Gloucester), all isolates were tested for 
confirmation of E. coli identification and for resistance to cefpodoxime. As there is 
known variation in the performance of susceptibility testing between laboratories 
(Livermore et al., 2012), the mean zone sizes for cefpodoxime were checked for the 
isolates later confirmed to have ampC chromosomal mutations (Table 5-1). With 
the exception of Dorchester, all laboratories had mean zone sizes for cefpodoxime 
that were similar to the mean for the whole group. 
Table 5-1: Mean zone sizes for cefpodoxime (10µg disc) for the 53 E. coli isolates with confirmed 
ampC chromosomal mutations. 
Laboratory No. of Isolates Mean zone 
size (mm) 
SD P 
Dorchester 5 7.4 0.55 0.029 
Gloucester 23 10.0 1.87 1.000 
Swindon 10 10.3 3.09 0.743 
Taunton 8 10.1 2.75 0.919 
Truro 7 10.9 3.72 0.411 
Total 53 10.0 2.56  
SD; standard deviation 
P values were calculated using unpaired t-tests 
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Figure 5-1: Sequence of methods used for detecting various resistance genes, ampC promoter 
mutations and assigning MLST-derived sequence types. 
The relevant sections in Chapter 2 for the description of methods are provided in parentheses. 
(a) Isolates were allocated into an ESBL or Non-ESBL using a clavulanic acid synergy test 
(b) Isolates that were negative for the presence of CTX-M Group 1 genes were tested using the CTX-
M universal primers 
 
 
 
(a) 
(b) 
All isolates 
(n=276) 
 
ESBL Group 
(n=199) 
Non-ESBL Group 
(n=77) 
All isolates were investigated for the presence of 
ampC chromosomal mutations (Chapter 2.5) 
Isolates were tested for CIT and DHA type AmpC 
plasmid genes using simplex PCR assays (Chapter 
2.4) 
All isolates were tested for the presence of CTX-
M Group 1 specific genes by PCR (Chapter 2.6) 
CTX-M PCR using 
universal primers 
Isolates were tested 
for AmpC plasmid 
gene groups using 
two multiplex PCR 
assays: CIT/DHA/ACC 
and FOX/MOX/EBC 
(Chapter 2.4.2) 
All isolates were investigated for the MLST 
sequence type (Chapter 2.7)  
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From the initial screening tests, a total of 35 isolates were excluded from the study: 
10 isolates were susceptible to cefpodoxime; 20 isolates were species other than E. 
coli (see Appendices, Section 9.9); 4 isolates were removed as potential duplicates 
of other isolates; and one isolate was submitted without demographic data. 
There were 276 isolates finally eligible for inclusion in the study. Confirmation of 
ESBL enzyme production by synergy discs allowed the isolates to be allocated to 
either an ESBL-producing group or a Non-ESBL group (Table 5-2), based on the 
reversal of cefpodoxime resistance in the presence of clavulanic acid. For practical 
purposes, the Non-ESBL Group of isolates was considered to be the group of 
isolates most likely to have potential AmpC mechanisms present. This was 
supported by the fact that 92% of the isolates in the pilot study (all cefpodoxime-
resistant and ESBL-negative) were shown to have either an AmpC plasmid gene 
present or one of the key ampC chromosomal mutations (-42, -32 and -13ins) 
described by Tracz et al. (2007). 
Table 5-2: Details of the numbers of isolates submitted from each laboratory; together with the 
numbers of isolates excluded.  
Isolates were excluded on the basis of species identification, cefpodoxime susceptibility, potential 
duplicates and lack of demographic data. Isolates were allocated to either the ESBL or Non-ESBL 
group, based on the results of phenotypic cefpodoxime / clavulanic acid synergy tests. 
Laboratory No. Submitted No. Excluded ESBL Group Non-ESBL 
Group 
Dorchester 51 5 29 17 
Gloucester 108 17 63 28 
Swindon 50 0 36 14 
Taunton 51 7 31 13 
Truro 50 5 38 7 
Total 310 34 197 79 
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5.3.2 Demographic Data 
Of the 276 isolates, the majority were isolated from urine samples (97.1%). Other 
sample types included blood cultures (n=6) and wound swabs (n=2). Isolates from 
female patients were most common (74.6%), and isolates from GP surgeries made 
up the majority (76.1%) of source locations. The mean age of patients was 66.7 
years, with a range of 1 to 102 years. The breakdown of how the demographic data 
varied by laboratories is given in Table 5-3. It was interesting to note that the 
Swindon laboratory had a higher proportion of female patients (92%) compared to 
the average, but a lower proportion of GP samples. The proportion of female 
patients was statistically significant (p<0.0001) using the chi-square test. However, 
the proportion of GP patients was not found to be significant (p=0.06), when 
compared against the mean. 
Table 5-3: Distribution of patient demographic data between the five laboratories. 
The proportions of female patients and samples originating from GP patients are given as 
percentages. The mean age is calculated from the ages of patients (in whole years) at the time the 
sample was collected. 
Lab Female Patients 
(%) 
GP Samples 
(%) 
Mean Age 
(years) 
Dorchester 67.4 84.8 70.2 
Gloucester 70.3 73.6 65.0 
Swindon 92.0 68.0 65.3 
Taunton 61.4 75.0 68.9 
Truro 84.4 82.2 66.1 
 74.6 76.1 66.7 
 
5.3.3 Prevalence of ampC-Carrying Plasmids 
All 276 isolates were tested for the presence of CIT and DHA plasmid genes using 
two separate simplex PCR assays. The isolates allocated to the Non-ESBL group 
were further tested for the other four AmpC plasmid gene groups using the same 
two multiplex assays as in the pilot study (CIT/DHA/ACC and FOX/MOX/EBC). 
Overall, a total of 19 isolates had a PCR result compatible with the presence of an 
ampC-carrying plasmid. All of these isolates were in the non-ESBL group. Fifteen 
isolates had a plasmid gene from the CIT group and four isolates were carrying a 
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plasmid gene from the DHA group. None of the other four AmpC plasmid gene 
groups were detected in the multiplex screening assays. 
The 19 isolates with an ampC-carrying plasmid were investigated further to identify 
the specific plasmid gene involved. Each of the PCR products from the simplex 
reactions were referred to the external sequencing company, using the relevant 
forward amplification primer as the sequencing primer. Full sequences were 
obtained for 14 of the 15 isolates with a CIT-type plasmid gene. When aligned using 
ClustalW, the sequences showed 100% identity with each other and with a 
reference sequence for CMY-2 (GenBank Acc. No. AB212086) (Figure 5-2). 
The consensus sequence obtained from the alignment was analysed using the 
BLAST (Basic Local Alignment Search Tool) located at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi. Results indicated similarity with a number of 
hits, due to the relatively small portion of the gene sequenced. There were a total 
of 112 registered sequences that gave 100% identity with the query sequence 
across the 303bp (Figure 5-3). These included CMY-2 as a potential match, but also 
included some other AmpC plasmid genes too. The full hit table is given in the 
appendices (Section 9.10).  
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Figure 5-2: Alignment of sequences from 14 isolates with CIT-type plasmid gene. 
Alignment was done using the ClustalW plugin module in the Geneious software. The green bar at the top indicates 100% identity across the sequence. 
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Figure 5-3: Alignment view of the CMY-2 plasmid gene match from the BLAST query. 
The consensus sequence extracted from the alignment of the 14 isolates was submitted to the BLAST 
query software. 
 
The alignment of the four isolates with a DHA-type plasmid gene demonstrated 
100% identity with each other. The BLAST results indicated the highest level of 
similarity with 100 registered GenBank sequences, including those for the DHA-1 
gene. The full list is provided in the appendices (Section 9.11). The DHA consensus 
sequence also showed 100% identity with the GenBank sequences for DHA-1 in E. 
coli and K. pneumoniae (Accession Nos. KP683353 and AY635140, respectively) 
(Figure 5-4). 
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Figure 5-4: Alignment view of the DHA-1 plasmid gene match from the BLAST query. 
The consensus sequence extracted from the alignment of the 4 isolates was submitted to the BLAST 
query software. 
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5.3.4 Presence of Mutations in the ampC Promoter Region 
All 276 isolates were investigated for the presence of mutations in the 
chromosomal ampC promoter region. Amplification failed with primers for two of 
the isolates (DO-014 and G-375). Two further attempts were made, but without 
success. The species identification of these two isolates was repeated using an 
API20E strip. DO-014 was confirmed as being E. coli. G-375 was identified as a 
Citrobacter freundii and was excluded from further analysis. 
Analysis of the sequences in the remaining 274 isolates revealed mutations at 28 
different positions throughout the 271bp region (Table 5-4). Geneious software 
(Version 7.1.7) was used to align all the sequences to the reference sequence 
(GenBank Accession No: AY899338.1). This was done using the Geneious alignment 
tool. Mutations and insertions could be easily identified from the alignment output, 
using an annotated version of the reference sequence (Figure 5-5). 
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Table 5-4: Mutations present in the 271bp amplified region of the E. coli ampC promoter gene. 
The locations were numbered according to the system described by Jaurin et al. (1981). Position +1 
is the start position of the transcription process. 
Position Mutation No. of Isolates % of Isolates 
-82 A to G 26  9.5 
-76 G to A 11 4.0 
-73 C to T 192 69.8 
-42 C to T 9 3.3 
-32 T to A 36 13.1 
-28 G to A 148 53.8 
-20ins T insertion 2 0.8 
-18 G to A 26 9.5 
-13ins G or T insertion 7 2.8 
-11 C to T 1 0.4 
-1 C to T 26 9.5 
+6 C to T 1 0.4 
+17 C to T 9 3.3 
+21 C to A 1 0.4 
+22 C to T 11 4.0 
+24 C to A 1 0.4 
+26 T to G 11 4.0 
+27 A to T 11 4.0 
+30 G to A 1 0.4 
+31 C to G 1 0.4 
+32 G to A 13 4.7 
+33 G to A 1 0.4 
+34 G to A 5 1.8 
+37 G to A, G to T 3 1.1 
+58 C to T 60 21.8 
+63 T to C 21 7.6 
+70 C to T 38 13.8 
+81 A to G 82 29.8 
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Figure 5-5: Identification of mutations and insertions from the Geneious alignment output, using an annotated version of the reference sequence. 
The reference sequence (AY899338 is shown at the top of the alignment, with mutations annotated by blue squares. Differences in nucleotides at each position are highlighted 
using different colours. 
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The most common mutation observed was a C to T transition at position -73, which 
was often seen together with a range of other polymorphisms. This mutation was 
only seen on its own in 8 isolates (2.2%). The second most common mutation was 
the -28 transition of G to A, seen in over half of all isolates. This polymorphism was 
always seen together with mutations at other locations. 
The three key mutations seen in the pilot study (-42, -32 and -13ins), and described 
by Tracz et al. (2007), were again observed in the regional study isolates. Nine 
isolates (3.3%) had the -42 mutation, 13.1% isolates (n=36) had the -32 mutation 
present and 2.8% of isolates (n=7) had one or two bases inserted at position -13. 
None of the three key ampC promoter mutations were seen in the ESBL group of 
isolates. Together with the AmpC plasmid genes identified in 19 isolates, the 
presence of ampC chromosomal mutations and acquired ampC genes was 
confirmed in 90.9% of the 76 isolates tested in the Non-ESBL group. 
Phylogenetic analysis of the 76 ampC promoter sequences (Figure 5-6) 
demonstrates how the isolates with the -42 mutation and those carrying the CIT-
type plasmid genes are clustered into separate groups, clearly distinct from the 
main population of isolates with the -32 mutation. There are five isolates with 
AmpC plasmid genes that are clustered with the main group. It is possible that 
these are similar in nature to the main group, but that have acquired the plasmid 
genes. Studies have indicated that isolates with chromosomal mutations are more 
likely to be commensal strains (Corvec et al., 2007). 
5.3.5 Prevalence of ESBL Resistance Genes in E. coli 
A total of 151 isolates (54.9%) were positive for the Group 1-specific CTX-M assay. 
Of the remaining isolates, three subsequently gave PCR reactions indicative of the 
presence of another type of CTX-M ESBL gene. There were 44 isolates with a 
positive clavulanic acid synergy result that did not have PCR results indicating the 
presence of a CTX-M gene. These isolates are likely to have either a SHV or TEM 
ESBL gene present, but were not investigated further. 
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Figure 5-6: Phylogenetic tree of the 76 isolates of E. coli in the Non-ESBL group. 
Tree was created in the Geneious software package (Version 7.1.7), using the Jukes-Cantor model 
and Neighbor-Joining method. The labels indicate the primary ampC mutation present (-42, -32,         
-20ins or -13ins), presence of an AmpC plasmid gene (CIT or DHA) or the presence of CTX-M ESBL 
genes. n/a indicates an unknown mechanism. 
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There were 4 isolates that were negative with the clavulanic acid synergy test, but 
which later gave a positive result for a CTX-M Group 1 ESBL in the PCR assay. This 
highlights one of the limitations of the phenotypic method for detecting ESBL 
enzymes. In these four cases, the zone sizes for both cefpodoxime and cefpodoxime 
with clavulanic acid were 0mm, making interpretation impossible. The 
interpretation of the combination disc method relies on a ≥5mm difference in the 
two zone sizes to identify a positive result (M’Zali et al., 2000). 
5.3.6 Summary of Resistance Mechanisms 
Having completed the PCR assays for detecting the various resistance genes, 
isolates were allocated to one of six groups based on the evidence of the genotypic 
mechanism present (Table 5-5). 
Table 5-5: Criteria used for allocating the E. coli isolates to one of six groups for the identified 
resistance mechanism present. 
Group Criteria 
CTX-M Type ESBL Evidence of cephalosporin / clavulanic acid synergy with 
a positive PCR assay for the universal CTX-M primers 
(negative for Group 1). 
CTX-M-Group 1 ESBL  Evidence of cephalosporin / clavulanic acid synergy with 
a positive PCR assay for the Group 1 specific CTX-M 
primers 
Non-CTX-M ESBL Evidence of cephalosporin / clavulanic acid synergy, but 
with negative PCR assays for the universal and Group 1 
specific CTX-M primers 
AmpC BL 
(plasmid-mediated)  
No evidence of cephalosporin / clavulanic acid synergy, 
but with a positive AmpC plasmid gene PCR assay 
AmpC BL 
(chromosomal) 
No evidence of cephalosporin / clavulanic acid synergy, 
but with presence of key chromosomal promoter region 
mutations (-42, -32 and -13ins) 
Other  No evidence of cephalosporin / clavulanic acid synergy, 
and no evidence of AmpC mechanism present 
 
Although isolates could have been allocated to more than one group, all in fact 
were assigned to just one group each based on the results of the PCR and 
phenotypic tests. The proportion of isolates in each group for the laboratories is 
provided in Figure 5-7. 
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Figure 5-7: Proportions (%) of E. coli isolates in each of the resistance mechanism groups. 
Lab Key: Dorchester (DO), Gloucester (GL), Swindon (SW), Taunton (TA) and Truro (TR). 
Colour Key: CTX-M (Other) – Yellow; CTX-M Group 1 – Red; Non CTX-M – Green; AmpC Plasmid – 
Purple; AmpC Chromosomal – Blue; Other Mechanism – Orange. 
 
5.3.7 Designation of Phylogroups from ampC Promoter Region Mutations 
In total, 31 different phylogroups were allocated from the patterns of mutations in 
the 28 locations in the ampC promoter region (Table 5-6). There were 21 additional 
phylogroups recorded compared to the pilot study isolates, and there were 9 
phylogroups seen in the pilot study that were not recorded in the regional study 
(G3, G6, G7, G10, G11, G12, G14, G15 and G16). There were significant differences 
in the phylogroups observed between the ESBL and Non-ESBL groups of isolates 
(Figure 5-8). 
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Table 5-6: Details of the 31 AmpC phylogroups identified from sequencing E. coli isolates collected 
in the regional study. 
The bold underlined characters indicate the key mutations responsible for AmpC enzyme hyper-
production, as described by Tracz et al. (2007). 
*Phylogroups G1 to G18 were also detected in the pilot study stage. 
(Numbers G3, G6, G7, G10, G11, G12, G14, G15 and G16 were allocated in the pilot study, but were 
not observed in isolates from the regional study). 
WT indicates a wild type isolate, with no identified mutations. 
Type Mutations No. of Isolates % of Isolates 
WT none 1 0.4 
G0 +81 13 4.7 
G1* -73, -32, +58, +63 16 5.8 
G2* -32 11 4.0 
G4* -73, -13ins, +6 1 0.4 
G5* -82, -42, -18, -1, +58, +81 7 2.5 
G8* -82, -18, -1, +58, +81 17 6.2 
G9* -73, -28 119 43.3 
G13* -73, -32, -28 3 1.1 
G17* -73, -28, +34, +58 4 1.5 
G18* -73, -28, +17 5 1.8 
G19 +70, +81 31 11.3 
G20 -73, +58, +63 4 1.5 
G21 -73, -28, +58 7 2.5 
G22 -73, -28, -13ins 2 0.7 
G23 -73, -28, -13ins, +31, +58 1 0.4 
G24 -82, -42, -18, -1, +33, +58, +81 1 0.4 
G25 -73, +32, +58, +63 1 0.4 
G26 -73, -32, -28, -20ins 1 0.4 
G27 -73, -32, +28, +37 1 0.4 
G28 -73, -28, -13ins, +17 2 0.7 
G29 -73, -32, -28, +58 1 0.4 
G30 -73, -28, -13ins, +17 1 0.4 
G31 -73, -32, -28, -11 1 0.4 
G32 -73, -28, -20ins, +17, +34 1 0.4 
G33 -73, -32, +32, +37 1 0.4 
G34 -82, -42, -18, -1, +21, +58, +81 1 0.4 
G35 -73, -32, +37 1 0.4 
G36 -73 8 2.9 
G37 -76, +22, +26, +27, +32, +70, +81 6 2.2 
G38 -76, +22, +26, +27, +32, +81 5 1.8 
G39 +30, +70, +81 1 0.4 
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Figure 5-8: Number of E. coli isolates recorded in each of the AmpC phylogroups. 
Numbers are indicated on each graph for A) the ESBL Group comprising 199 isolates and 13 
phylogroups and B) the Non-ESBL group comprising 76 isolates and 27 phylogroups. 
WT indicates a wild type isolate, with no identified mutations. 
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The most common phylogroup overall was G9, which was observed in 43.3% of 
isolates (n=119). This phylogroup had mutations at positions -73 and -28 and was 
seen mainly in isolates in the ESBL group. G19 was the second most common 
phylogroup, seen in 11.3% (n=31) of all isolates. Although 20 of the G19 isolates 
were again from the ESBL group, there were 11 isolates from the Non-ESBL group; 
all of which were identified as carrying an AmpC plasmid gene. As was seen in the 
pilot study, the most common phylogroup in the Non-ESBL group was G1; 
represented by 21.1% of the 76 isolates and including the key chromosomal 
mutation at position -32. Overall therefore, >50% of all isolates were allocated to 
one of just two phylogroup patterns (G9 and G19). The variations in phylogroups 
detected in each of the different laboratories in shown in Table 5-7.  
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Table 5-7: Analysis of different phylogroup patterns for the five laboratories in the regional study. 
The number of each phylogroup observed in isolates collected from each laboratory is given. 
Phylogroup patterns are listed in order of frequency of detection. 
Lab Key: Dorchester (DO), Gloucester (GL), Swindon (SW), Taunton (TA) and Truro (TR). 
Genotype DO GL SW TA TR Total 
G9 13 29 23 22 29 119 
G19 12 12 4 3 
 
31 
G8 2 6 3 3 3 17 
G1 1 10 2 2 1 16 
G0 3 6 3 
 
1 13 
G2 
 
5 2 2 2 11 
G36 2 1 
 
4 1 8 
G5 1 4 
 
1 1 7 
G21 2 4 
  
1 7 
G37 2 2 1 
 
1 6 
G18 1 2 
 
1 1 5 
G38 1 2 1 1 
 
5 
G17 1 3 
   
4 
G20 1 
 
3 
  
4 
G13 
 
2 1 
  
3 
G22 2 
    
2 
G28 
  
1 
 
1 2 
G30 
   
1 
 
1 
G27 
  
1 
  
1 
G39 
   
1 
 
1 
G31 
   
1 
 
1 
G29 
  
1 
  
1 
G32 
    
1 1 
G26 
  
1 
  
1 
G33 
    
1 1 
G4  
 
1 
   
1 
G34 
 
1 
   
1 
G23 1 
    
1 
G35 
   
1 
 
1 
WT 
    
1 1 
G24 
  
1 
  
1 
G25 
  
1 
  
1 
Total 45 91 50 44 45 275 
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5.4 Discussion 
5.4.1 Patient Demographics 
In this regional study, 74.6% of samples received were from female patients and the 
mean age was 66.7 years (range of 1 to 102 years). This compares with the smaller 
pilot study of the 50 isolates collected at the Gloucester laboratory (Lewis et al., 
2015), in which 75% of samples were from females and the mean age was 58.3 
years. 
Only six of the isolates in the current study originated from blood culture samples. 
Although laboratories were asked to submit isolates from all sample types, the 
population of isolates was heavily biased towards the urine samples. It was not 
possible, therefore, to investigate whether there were differences between blood 
and urine samples as two groups. It is more likely for isolates to have been collected 
from urine and blood culture samples, due to the routine identification of E. coli to 
species level in these sample types. Isolates of E. coli from other sample types are 
commonly reported in clinical laboratories as a generic “coliform” identification. 
Although the current study collected more isolates from urine samples than any 
other sample type, this still represents an important population. Not only is there a 
considerable amount of morbidity associated with urinary tract infections, but 
these infections are known to act as a primary source for more serious infections 
such as bacteraemia (Horner et al., 2013). Davies et al. (2012) reported that 45% of 
bacteraemia cases caused by E. coli had a urinary tract infection as the primary 
source. 
5.4.2 Epidemiology of ESBL-Mediated Resistance 
The presence of blaESBL genes was not investigated as part of the pilot study, as the 
focus was mainly on ampC genes. In the regional study, however, there was 
phenotypic evidence of ESBL-mediated resistance in 71.4% of the isolates collected 
(Table 5-2). All the isolates in this part of the study were included on the basis of 
identification as E. coli and having resistance to cefpodoxime. 
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Using the PCR assays developed in Chapter 3, the presence of CTX-M Group 1 ESBL 
genes was confirmed in 54.9% of the isolates overall, and in 76.6% of the isolates 
with an ESBL phenotype. This confirms the importance of these genes as a cause of 
cephalosporin resistance in E. coli. Although the identification of the actual CTX-M 
gene present was not completed, it is likely that the majority of these were CTX-M-
15.  
Woodford et al. (2004) tested 287 E. coli isolates with a CTX-M phenotype (defined 
as having a cefotaxime MIC of ≥8-fold higher than ceftazidime, both reduced in the 
presence of clavulanic acid). A total of 96% of the isolates were PCR positive for 
CTX-M Group 1 genes (includes CTX-M-15). Hopkins et al. (2006a) found 31 isolates 
with a CTX-M gene present in an early collection of isolates submitted to the UK 
national reference laboratory. Of these, 29 isolates were confirmed as having CTX-
M-15 (Group 1) genes. Enoch et al. (2012) investigated 67 isolates in the UK and 
found that 58% were positive for CTX-M-Group 1 genes, 18% had CTX-M-Group 9 
genes, one isolate had both and 22% had neither present. Horner et al. (2013) 
found 68% of 63 ESBL-positive E. coli isolates were identified as CTX-M Group 1. 
Only a small number of isolates (n=3) were positive for the universal CTX-M 
primers, but negative for the Group 1-specific primers. This was somewhat 
surprising, as a higher number of other blaCTX-M genes had been expected to be 
present. This is particularly the case for CTX-M genes in Group 9, such as CTX-M-9 
and CTX-M-14. Courpon-Claudinon et al. (2010) investigated 1081 bacteraemia E. 
coli isolates in France, finding 18 with CTX-M genes; identified as CTX-M-15 (n=9), 
CTX-M-14 (n=6), CTX-M-1 (n=2) and CTX-M-9 (n=1). Wickramasinghe et al. (2012) 
investigated the carriage of ESBL-producing strains in faecal samples submitted for 
routine microbiological analysis. Of the 80 ESBL-producing E. coli isolates found, 
72.5% were CTX-M-15 and 16.3% were CTX-M-9, with one isolate having both genes 
present.  
The presence of other ESBL genes (SHV and TEM) was not investigated as part of 
this study. However, it is likely that the remaining 43 isolates with an ESBL 
phenotype were producing one of these types of ESBL enzymes. Voets et al. (2012) 
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found that 14.4% of 479 E. coli isolates had one of either a SHV or TEM type ESBL 
present. Izdebski et al. (2013) reported proportions of blaSHV and blaTEM genes of 
13.5% and 1.1% in 376 E. coli isolates, respectively. 
5.4.3 Association of ESBL Type with Location 
In the regional study in London and the South East, Potz et al. (2006) found the 
prevalence of CTX-M producing isolates varied between 12 laboratories, from 0.6% 
to 4.3%. There was a similar variation observed when all ESBL types were included. 
These are comparable with the data from an informal audit conducted in 2013 
(Lewis, 2013), in which the prevalence of ESBL-producing isolates found in urine 
samples varied between 1.3% and 6.2% for five laboratories in the South West 
region (data provided in the Appendices, Section 9.12). 
In the current study, the denominator data for laboratory isolation rates were not 
collected; so overall prevalence rates are not available. However, the proportions of 
cephalosporin-resistant E. coli isolates with confirmed ESBL resistance (genotypic 
and phenotypic) did vary significantly between laboratories. The Dorchester and 
Truro laboratories had the biggest differences in rates of ESBL genes present, at 
65.2% for Dorchester and 86.7% for Truro (p=0.02, Fisher’s Exact test). This 
compared to 30.4% and 13.3%, respectively for the confirmed AmpC-producing 
isolates (not quite significant at p=0.08). Variations in resistance rates could be 
indirectly explained by differences in antibiotic prescribing rates. Nearly 80% of all 
antibiotic prescribing happens in the primary care setting, of which over half is for 
respiratory tract infections. National data from the NHS Atlas of Variation (Public 
Health England, 2015a) suggests a four-fold variation in the prescribing rates for key 
antibiotics (includes cephalosporins) for the different clinical commissioning groups 
(CCG) in England. Hawker et al. (2014) demonstrated that prescribing rates in 
English GP surgeries for coughs and colds varied between one-third of all presenting 
patients to two-thirds. Although this does not relate directly to prescribing for 
urinary tract infections, it is possible that a similar level of variation would exist. 
Not all studies, however, have demonstrated evidence of a variation in resistance 
rates. Horner et al. (2013) found no significant variation in the distribution of ESBL 
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genes between the laboratories in their study of bacteraemia isolates from 14 
laboratories in the Yorkshire region. 
5.4.4 Epidemiology of AmpC-Mediated Resistance 
A total of 19 of the 276 isolates (6.9%) carried an AmpC plasmid gene; 15 with a CIT-
type and 4 with a DHA-type. These isolates were all in the Non-ESBL group. 
Sequencing the PCR products with the forward amplification primer provided mixed 
results in trying to identify the actual plasmid gene present. Other studies have 
used different primer sets to ensure a larger portion of the plasmid gene is 
amplified. In the original AmpC plasmid paper, for example, the authors used 
different primers to sequence the whole region flanking the CMY-2 gene (Perez-
Perez & Hanson, 2002). 
Although likely to be CMY-2 plasmid genes, the CIT type products detected by PCR 
in this study may actually be caused by other plasmid-mediated genes. Based on 
evidence from other studies, one cannot rule out the possibility of a different or 
novel plasmid gene being present. Hopkins et al. (2006b) discovered a new CIT-type 
plasmid gene (CMY-21) which shared 99% identity with the known CMY-2 gene. 
In the current study, results of the sequencing of the chromosomal ampC promoter 
region were available for 274 of the isolates (Table 5-4). The sequencing analysis 
revealed mutations at 28 different positions in the amplified region, compared to 
just the 16 positions found in the pilot study. There were a total of 31 different 
phylogroups detected, compared to the 18 allocated in the pilot study.  
Within the ESBL group, there were 12 different phylogroups present. The most 
commonly observed mutations in this group were at position -73 (70.1%) and 
position -28 (64.5%). The most common phylogroup in the ESBL group was G9, 
which included both the -73 and -28 mutations. The -28 mutation was always seen 
together with the -73, but not vice versa. There were also mutations in the coding 
region at positions +70 and +81 in 13.2% and 29.4% of isolates, respectively. The -18 
mutation was seen in 15 of the isolates in the ESBL group. Observed in the pilot 
study together with the -32 and -13ins mutations, the -18 and -28 mutations are 
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thought to have a minimal impact on the level of enzyme production (Tracz et al., 
2007). Corvec et al. (2007) also demonstrated that the -18 and -28 mutations are 
present in E. coli isolates that are fully sensitive.  
Within the AmpC group, the three key mutations identified in the pilot study (-42,    
-32 and -13ins) were observed in a total of 51 isolates (66.2%). Again, the most 
common of these mutations was the T to A transition at position -32, seen in a total 
of 36 isolates. The -42 and -13ins mutations were seen in 9 isolates and 6 isolates, 
respectively. 
A similar range of mutation patterns were seen, when compared with the results of 
the pilot study. Mutations in the wild-type promoter were observed primarily at 
position -32. The creation of a displaced promoter was seen with mutations at 
positions -42 and -18 and six of the isolates had an increased spacer region from 
insertions at position -13. 
There were two isolates with insertions at position -20 (SW-007 and TR-032) (Figure 
5-9). Not seen in the pilot study or the large Canadian study (Mulvey et al., 2005), 
this may be the first report of insertions at this location in the UK. In both cases, the 
insertion was a thymine base, and was always seen in association with -73 and -28 
mutations. One isolate had a -32 mutation as well. Both isolates originated from 
different laboratories (Swindon and Truro), suggesting that this type of mutation 
may be reasonably widespread throughout the region. Jorgensen et al. (2010) also 
reported one isolate with a thymine base insertion at this position. A recent study in 
Spain identified two isolates with a mutation at position -20, and confirmed a 
corresponding increase in enzyme production of 20-fold (Alonso et al., 2016). 
Within the whole group of isolates, there were a total of 15 of the 32 phylogroups 
that were seen only in one of the laboratories (Table 5-7). There were only three 
phylogroups (G1, G8 and G9) that were seen in all the five laboratories. These three 
phylogroups were associated primarily with the Non-ESBL group for phylogroup G1 
and the ESBL group for phylogroups G8 and G9. This suggests a wide diversity of 
strains within the region, and in particular for the isolates in the Non-ESBL group. Of 
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the 17 phylogroups with one of the key ampC mutations present (-42, -32, -13ins), 
15 were seen in only one or two laboratories. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-9: Presence of thymine nucleotide insertion at position -20 in two isolates of E. coli, 
increasing the ampC promoter spacer region by one base pair. 
The two isolates (SW-007 and TR-032) were isolated at different laboratories (Swindon & Truro) in 
the region. 
 
5.4.5 Association of AmpC Type with Location 
The variation in AmpC plasmid gene carriage rates was considerable between the 
five laboratories (Table 5-7), with a range from 0% to 19.6% as a proportion of all 
isolates. This was found to be a significant difference between the Truro and 
Dorchester laboratories (p<0.005, Fisher’s Exact test). To date, no other study has 
detected such a significant variation between different laboratories. 
When looking at the group of isolates most comparable with the pilot study 
(Gloucester isolates of cefpodoxime-resistant, ESBL-negative E. coli), the 27 isolates 
had ampC chromosomal mutations at a total of 15 locations in the amplified 
sequence. Compared to the 16 locations seen in the pilot study, this suggests that 
the number and nature of the ampC mutations also vary by laboratory location, as 
the additional mutations seen in the regional study must have come from other 
locations. This is further supported by observations that the allocated phylogroups 
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had some variation between laboratories, with a total of 46.9% of the phylogroups 
being individually unique to their respective locations. 
The question of whether the -32 mutation was restricted to, or had a higher 
prevalence in Gloucester compared to the other laboratories was investigated. The 
proportion of -32 mutations as a total of potential AmpC isolates (i.e. the Non-ESBL 
group) showed significant variation between the five laboratories. The lowest 
prevalence was seen in the Dorchester laboratory at 5.9% (1 of 17 isolates) and the 
highest was in Gloucester at 63.0% (17 of 27 isolates). However, the -32 mutation 
was also the most common mutation at the other three laboratories as well: 61.5% 
in Swindon, 57.2% in Truro and 46.2% in Taunton. This confirms that the higher 
prevalence of this mutation in AmpC-producing isolates is not unique to the 
Gloucester laboratory, and is certainly a picture seen throughout most of the South 
West region. There are, as yet, no other studies published for UK data to confirm 
whether this holds true for the rest of the country. 
5.5 Summary 
The data presented in this chapter represent a unique snapshot picture of the 
cefpodoxime-resistant E. coli population in the South West region in 2013. There 
are relatively few published reports of ESBL and AmpC-mediated resistance in UK 
strains of E. coli, and fewer still that examine patterns over a regional distance. To 
date, there have been no studies published related to the investigation of strains 
isolated in laboratories in the South West region. 
The isolates were collected over a relatively short period (3 months), so may have 
been influenced by some collection bias. The differences in AmpC plasmid gene 
rates between the laboratories may have been due to a short-term increase in 
prevalence of a particular mechanism. As the collection numbers were limited to 50 
isolates for most laboratories, a higher rate of ESBL isolates would reduce the 
numbers of potential AmpC isolates, and vice versa. A further collection of isolates 
after a 1-2 year period would have helped to confirm unusual observations, and 
would also have highlighted trends in resistance or isolation rates.  
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This study represents the first regional investigation of chromosomal ampC 
mutations in the UK. Similar types and locations of mutations were seen here as 
have been reported in publications elsewhere. The -32 mutation was the most 
common of the key mutations (-42, -32 and -13ins) in the pilot study, and this 
observation was confirmed in the regional study for four of the five laboratories. 
This has not been the case in any other published study. However, the full 
implications of a different picture for the UK are uncertain. 
This study is also the first in the UK to report the insertion of a single nucleotide at 
position -20. This mutation was seen in two isolates isolated from different 
laboratories, so is not restricted to one particular location. The -20 insertion would 
result in an increased spacer region, similar to the -13 insertion. Tracz et al. (2007) 
reported a 24- to 61-fold increase in enzyme production resulting from a single base 
pair insertion at position -13. It is not clear at this stage though, whether a similar 
effect on enzyme production would be observed for the -20 insertion. Further 
investigations on a larger number of isolates are required. 
5.6 Future Work 
The majority of isolates collected in this study were from urine samples. Although 
this represents an important population, a higher number of isolates from blood 
culture samples would have enabled useful comparisons with other studies. A 
further study of either local or regional bacteraemia E. coli isolates would provide 
more detailed data on the proportions and types of resistance mechanisms present. 
A decision was made at the start of the study to collect all cefpodoxime-resistant 
isolates for the regional study. Although the pilot study had focussed only on those 
isolates likely to be producing AmpC enzymes, there was a potential risk that 
isolates with new or multiple genes present could be missed if the same selection 
criteria were used for the regional study. The disadvantage of this approach, 
however, is that a significantly smaller number of AmpC-producing isolates were 
included in the study. Further collection of cefpodoxime-resistant, ESBL-negative 
isolates only would help to confirm the significance of the -20 mutation found in 
this study. 
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6 Clonal Structure of Regional E. coli Isolates 
6.1 Introduction 
Multi-locus sequence typing (MLST) is a method designed to study the genetic 
relatedness of a collection of isolates. Its principle was first described in 1998 by 
Maiden et al. (1998), when the DNA sequences of six housekeeping genes were 
used to type isolates of Neisseria meningitidis. The main advantage of the method 
described at the time was that data would be comparable between laboratories, 
and would thus enable the creation of global databases to facilitate wider 
surveillance of strains. Strains are grouped into clonal complexes, based on sharing 
the same allele sequences at a number of the different loci. Clonal complexes are 
usually comprised of a single dominant sequence type, with a number of less 
common close relatives. The emergence of clonal complexes within a population 
occurs as a particular sequence type (ST) increases in frequency, and as a result of 
genetic changes over time becomes the dominant founder of the complex (Feil et 
al., 2004).  
Tartof et al. (2005) published one of the initial papers on the use of MLST to 
investigate uropathogenic E. coli strains in the United States. A total of 45 E. coli 
isolates from a variety of sources and sample types were tested, giving 17 different 
sequence types. The majority of the isolates were allocated to the STC69 clonal 
complex, with ST69 the most common sequence type overall.  
In terms of early UK studies, Lau et al. (2008) used MLST to investigate 
cephalosporin-resistant E. coli isolates. A total of 88 isolates isolated in North West 
England from urine samples (68 isolates) and blood cultures (20 isolates) gave 22 
different sequence types in 10 clonal complexes. The most common sequence type 
was the ST131 clone, accounting for 59% of all isolates. The isolates included in the 
study were described as cephalosporin-resistant, but were not characterised further 
to determine the actual mechanisms of resistance. Later, in another UK study, 
Gibreel et al. (2012) investigated 300 E. coli isolates from urine samples. A total of 
102 sequence types were found; the most common being ST73 (17%), ST131 (13%) 
and ST69 (9%). Half of the isolates were included in just six sequence types. 
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In one of the few studies to use MLST to investigate potential AmpC-producing E. 
coli isolates, Corvec et al. (2010) tested 41 isolates from a range of different clinical 
samples in France. All the isolates were potential AmpC producers; selected as 
cefoxitin-resistant and ESBL-negative. Of the 41 isolates, 18 had ampC chromosomal 
mutations (all with the -42 mutation) and 23 carried a CIT-type plasmid gene. The 
23 isolates with a CIT-type plasmid gene present were typed using MLST, and the 
most common sequence types were ST156 (34.8%), followed by ST46 (21.7%), 
ST354 (8%) and then 8 other individual STs. The authors did not report whether the 
typing was extended to include the 18 isolates with ampC chromosomal mutations.  
One of only two sets of published MLST data for isolates with identified ampC 
chromosomal mutations was reported in 2009 (Guillouzouic et al., 2009). The 
number of isolates included in the French study was quite small. Only 12 clinical 
samples were included, which were compared against 12 animal isolates and 10 
fully sensitive human isolates. The majority of the 12 resistant human isolates had 
the     -42 mutation (n=8), with two having the -32 mutation and two having a -11 
mutation. Interestingly, all of the AmpC-producing isolates were allocated to a 
single complex STC23 (ST88, n=8 and ST23, n=4).  
In the current study, MLST was used to type all the isolates collected from the 
regional laboratories. The Achtman scheme was chosen for this project, as it has a 
larger number of sequence types and registered isolates in the database; 5216 STs 
compared to the 687 STs in the Pasteur database (last checked 27th August 2015). 
Although the Pasteur scheme (Jaureguy et al., 2008) uses 8 genes, it  has less 
sequence types recorded.  
The aim of the study was to establish whether dominant clones of E. coli were 
circulating within the population of the South West region. A further aim was to 
establish whether particular clones were associated with different mechanisms of 
ESBL and AmpC-mediated resistance. 
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6.2 Methods 
The full details of the MLST methods used are provided in Section 2.7. Using the 
method described by Wirth et al. (2006), fragments of seven housekeeping genes 
were amplified and sequenced. DNA was extracted from each of the isolates using 
the mechanical lysis method described in Section 2.3.1. Each of the seven genes 
was amplified using the respective primers, using the standard SYBR Green PCR 
method used throughout the project. The primers used were those published on 
the central database website: 
http://mlst.warwick.ac.uk/mlst/dbs/Ecoli/documents/primersColi. 
The PCR products were sent to an external company (Eurofins Genomics, Germany) 
for purification and sequencing. The forward amplification primer was used 
primarily as the sequencing primer. The reported sequence of each allele was 
entered onto an online database (http://pubmlst.org/) to obtain the allele profile 
number (Jolley & Maiden, 2010). Once the full set of seven alleles had been 
identified, the final sequence type was obtained from entering the profile number 
into the same database. 
The web-based eBURST software (http://eburst.mlst.net/v3/) was used to cluster 
the MLST types into related clonal groups (Feil et al., 2004). Clonal complexes were 
identified from groups of sequence types that have MLST genes that are identical at 
six loci. The diversity of a population was calculated from the sequence type data 
using the Simpson’s Index of Diversity formulae (Hunter & Gaston, 1988), with 
calculated 95% confidence intervals (Grundmann, Hori & Tanner, 2001). 
6.3 Results 
6.3.1 Prevalence of Sequence Types 
A total of 275 isolates (97.5%) gave complete allele profiles for all seven genes 
sequenced, resulting in the generation of a sequence type. There were 74 different 
sequence types assigned from the 275 isolates. ST131 was the most common type, 
with 120 (43.6%) of the isolates; followed by ST73 (6.2%), ST12 (4.7%) and ST38 
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(4%). Overall, 68.4% of all isolates were included in just 10 sequence types (Table 
6-1). 
The distribution of sequence types between locations is also provided in Table 6-1. 
ST131 was found in all five locations, but the proportion of isolates varied between 
the five laboratories, ranging from 30.4% for Dorchester to 64.4% for Truro (Table 
6-2). The proportion of ST131 isolates for the Gloucester and Truro laboratories was 
found to be significantly different from the average of the whole population 
(p<0.05, χ2 test). 
The second-most common type (ST73) was found in all laboratories, with the 
exception of Dorchester. The third-most common type (ST12) was found in just 
three of the five locations (Gloucester, Swindon and Taunton). 
Table 6-1: Distribution of E. coli sequence types (ST) by location for the five laboratories in the 
regional study. 
There were an additional 59 types that were present in only one location. Lab Key: Dorchester (DO), 
Gloucester (GL), Swindon (SW), Taunton (TA) and Truro (TR). 
ST DO GL SW TA TR Total 
131 14 30 24 23 29 120 
73 0 7 3 4 3 17 
12 0 9 2 2 0 13 
38 4 4 2 1 0 11 
69 4 3 2 0 0 9 
648 2 4 1 0 1 8 
405 2 2 1 1 1 7 
88 1 2 0 1 1 5 
778 2 2 0 0 0 4 
10 0 1 1 0 0 2 
23 0 1 0 0 1 2 
40 0 1 0 0 1 2 
58 0 2 0 0 0 2 
95 0 0 0 1 1 2 
117 1 0 0 1 0 2 
127 0 0 1 0 1 2 
141 0 0 2 0 0 2 
357 0 0 1 1 0 2 
393 1 1 0 0 0 2 
617 0 2 0 0 0 2 
636 1 0 0 1 0 2 
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Table 6-2: Comparison of ST131 isolation rates for each laboratory in the regional study. 
The comparison of the proportion of ST131 isolates for each laboratory when compared to the 
average rate for the whole population is indicated by the p-value, as determined by chi-square tests. 
Location Total Isolates 
Tested 
% of ST131 
Isolates 
P-value 
Dorchester 46 30.4 0.072 
Gloucester 90 33.3 0.049 
Swindon 50 48.0 0.530 
Taunton 44 52.3 0.246 
Truro 45 64.4 0.005 
Total 275 43.6  
 
6.3.2 Association of Sequence Type with Genotypic Mechanism Present 
The association of resistance mechanism with sequence type is provided in Table 
6-3. The most common sequence type (ST131) was predominantly associated with 
the CTX-M and ESBL isolates. A total of 94.2% of the isolates with an ST131 profile 
were either confirmed as having blaCTX-M genes by PCR, or were in the phenotypic 
ESBL group. There was one ST131 isolate (TA-024) with an AmpC plasmid gene 
present (CIT-type), and 6 isolates that had a chromosomal ampC mutation (3 with 
the -32 mutation and 3 with insertions at position -13). 
The second-most common sequence type (ST73) was predominantly associated 
with the chromosomal ampC genotype. A total of 88.2% of these isolates had one of 
the key ampC mutations, nearly all of which were the -32 mutation. The ST12 
sequence type was the third most common, and was again associated primarily 
with the chromosomal ampC genotype. A total of 92.3% of these isolates had the     
-32 mutation present, with the one other ST12 isolate carrying an AmpC plasmid 
gene. 
In general, the sequence types were associated with either ESBL or AmpC 
mechanisms, or in some cases with ESBL mechanisms and AmpC plasmid genes. 
Sequence types ST38 and ST69 were predominantly associated with ESBL-producing 
isolates, but did have two isolates with AmpC plasmid genes present. ST648 had 3 
isolates with CTX-M genes present and 3 isolates with an AmpC plasmid gene 
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present. ST778 was exclusively associated with isolates carrying AmpC plasmid 
genes, all of which were carrying the CIT-type. 
Table 6-3: Distribution of E. coli sequence types (ST) by different resistance mechanisms. 
There were an additional 59 types that were present only in one mechanism group. CTX-M isolates 
were identified using the universal or Group 1 specific PCR assay. ESBL isolates were non-CTX-M 
isolates with phenotypic evidence of ESBL production. AmpC plasmid isolates were confirmed by PCR 
to be carrying either a CIT- or DHA-type plasmid gene. The AmpC chromosomal isolates were 
identified as having one of the key mutations present in the ampC promoter region (-42, -32, -13ins). 
ST CTX-M ESBL AmpC 
plasmid 
AmpC 
chrom 
Other Total 
131 99 14 1 6 0 120 
73 1 1 0 15 0 17 
12 0 0 1 12 0 13 
38 1 8 2 0 0 11 
69 3 4 2 0 0 9 
648 3 0 3 1 1 8 
405 5 1 0 0 1 7 
88 3 0 0 2 0 5 
778 0 0 4 0 0 4 
10 1 0 1 0 0 2 
23 1 1 0 0 0 2 
40 0 0 0 2 0 2 
58 0 2 0 0 0 2 
95 1 0 1 0 0 2 
127 0 0 1 1 0 2 
141 2 0 0 0 0 2 
357 0 0 0 2 0 2 
393 2 0 0 0 0 2 
617 2 0 0 0 0 2 
636 1 1 0 0 0 2 
 
6.3.3 Association of Sequence Type with AmpC Genotype 
The 19 isolates carrying an AmpC plasmid genes were allocated to 14 different 
sequence types. Eleven of the sequence types were seen as individuals, one of 
which (ST5023) was novel to this study. ST778 was designated for 4 of the isolates, 
ST38 for 2 isolates and ST69 for 2 isolates. 
The most common ampC chromosomal mutation was the -32 mutation, seen in a 
total of 36 isolates. These isolates were allocated to 9 different sequence types. The 
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majority were designated as ST73 (38.9%), ST12 (33.3%), ST131 (8.3%) and ST357 
(5.6%). The remaining five isolates were allocated to individual sequence types. 
The association of sequence type with the allocated AmpC phylogroups from 
Chapter 5 is provided in Table 6-4. The most common sequence type (ST131) was 
seen in 120 isolates. Within this group, there were five different AmpC phylogroups 
recorded (G9, G13, G22, G26 and G32). Of these, G9 was the predominant 
phylogroup present, representing 113 isolates (94.2%). This suggests that 42% of all 
the 275 isolates tested for both MLST profiles and AmpC chromosomal genotypes 
had identical sequences across a combined length of over 3600 nucleotides (nearly 
0.1% of the whole genome for E. coli). The seven isolates with one of the other four 
phylogroups in the ST131 group were all in the Non-ESBL group, and all of which 
had one of the three key ampC chromosomal mutations present (-42, -32 or -13ins). 
6.3.4 Detection of Novel Sequence Types 
Five isolates (DO-015, G-394, G-430, G-447 and TA-034) gave sequences for one 
locus each that did not have a recognised allele number. Full sequence type profiles 
were therefore not available for these five isolates. The raw sequence data files for 
the five alleles were submitted to the database curator for allocation of new allele 
numbers. Following the acceptance of the data files and the allocation of new allele 
numbers, these five isolates were registered as sequence types ST5025 to ST5029. 
A further five isolates (DO-013, G-355, G-364, TA-040, TR-050) had valid allele 
numbers at the seven loci, but combinations of which had not previously been 
registered on the database. These were registered on the online database, with 
new sequence types generated as ST5015, ST5016, ST5017, ST5023 and ST5024, 
respectively. Overall, therefore, this study discovered ten new sequence types, all 
of which were registered on the central curated database 
(www.mlst.warwick.ac.uk/mlst/dbs/Ecoli). 
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Table 6-4: Distribution of E. coli sequence types (ST) by different AmpC phylogroup. 
Only the most common 12 sequence types are shown, with the relevant AmpC phylogroups. The AmpC phylogroups were allocated in Chapter 5.
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6.3.5 Comparison of Diversity Indices 
The Simpson’s Index of Diversity (Hunter & Gaston, 1988) is an indication of the 
diversity of a particular population. It represents the probability that two isolates 
selected at random from the same population are truly different. A population in 
which every isolate is different would have a diversity index of 1.0. The Diversity 
Index (DI) for the whole population was 0.789, suggesting that 78.9% of the isolates 
were different. Confidence intervals (95%) of 0.737 to 0.841 where calculated using 
the method of Grundmann et al. (2001). 
In the two main groups of isolates (ESBL and Non-ESBL), there were clear 
differences in the ST patterns. The Non-ESBL group, comprising mainly of AmpC-
producing isolates, had 73 with a total of 29 different sequence types. The most 
common sequence type was ST73 (20.5%), with ST12 the next common (19.2%). In 
this group, the ST131 isolates represented only 9.6% of the isolates (n=7). The Non-
ESBL group had a DI of 0.91 (95% CI: 0.87-0.95), indicating a population with a high 
degree of diversity. 
The larger ESBL group, comprising 196 isolates, had a total of 52 different sequence 
types. The most common sequence type by far was ST131, with 114 isolates 
(58.2%). The next common sequence type was ST405, with only seven (3.6%) 
isolates. The presence of the dominant ST131 clone, meant the overall DI for this 
group was 0.66 (95%CI: 0.58-0.74), representing a significantly less diverse 
population than the Non-ESBL group. 
The overall populations for the five laboratories showed some variation in the 
diversity indices (Figure 6-1). Although not significantly different from the mean for 
the whole group, the diversity index for the Truro laboratory was significantly 
different to the indices for both Dorchester and Gloucester, at the 95% confidence 
interval. 
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Figure 6-1: Comparison of Diversity Indices (DI), with 95% confidence intervals, for the five 
laboratories in the regional study. 
The five laboratories are shown in blue. The overall DI for the whole population is shown in red. Lab 
Key: Dorchester (DO), Gloucester (GL), Swindon (SW), Taunton (TA) and Truro (TR). 
 
6.3.6 Phylogenetic Analysis of Sequence Types 
At the time of checking (27th August 2015), there were 5216 ST profiles for E. coli 
and 7749 isolates registered in the principal database. Registered isolates were 
from a range of sources, including human, animal, food and environmental. The ten 
isolates from this study with novel sequence types are included in these totals. 
The 275 isolates from the current study were analysed with the eBURST software. 
There were 74 different sequence types allocated into 16 groups with 33 isolates 
appearing as singletons (Figure 6-2). The largest group included 18 isolates and 5 
sequence types. ST38 was designated as the group founder by the eBURST 
software. The other four STs (ST315, ST778, ST963 and ST1177) in the group were 
all single-locus variants (SLV). 
  
0
0.2
0.4
0.6
0.8
1
Total DO GL SW TA TR
D
iv
e
rs
it
y 
In
d
e
x 
Laboratory 
Page 124 of 188 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2: eBURST diagram for the 275 E. coli isolates in the regional study with a complete sequence type profile. 
The size of each circle is proportionate to the number of isolates in that ST. The blue circles represent the two main founder STs, as determined by the eBURST software (Feil et al., 
2004). 
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Other groups with designated founders included Group ST88, with 9 isolates and 4 
sequence types. Group ST648 comprised of 10 isolates and 3 sequence types. Group 
ST69 had 11 isolates and three sequence types. Group ST95 had 4 isolates and three 
sequence types. Group ST73 was the last designated group with ≥ 3 STs, with 19 
isolates and three sequence types. 
The other ten groups all comprised of two sequence types with no founder 
identified. The most common sequence type (ST131) was shown to be represented 
largely by a single clone. The sequence type did have one isolate acting as a SLV; 
ST5015 was novel to this study and differed only at the recA locus. 
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6.4 Discussion 
6.4.1 Common MLST Sequence Types 
A total of 74 different sequence types were identified in the 275 isolates tested. The 
most common sequence type was ST131, which accounted for 43.6% of all isolates. 
The next most common sequence types were ST73 (6.2%), ST12 (4.7%), ST38 (4.0%) 
and ST69 (3.3%). Overall, 68% of isolates were allocated to one of just 10 sequence 
types. These findings are similar to those of others, with ST131, ST73, ST38 and 
ST69 commonly reported in other studies. 
In a UK study (Nottingham), Croxall et al. (2011) found 52 sequence types in 121 E. 
coli isolates isolated from urine samples from an elderly patient population. The 
most common types were ST131, ST73 and ST69. In another UK study (Yorkshire), 
Horner et al. (2013) investigated 770 E. coli isolates from bacteraemia cases over a 
2-year period. A total of 96 different sequence types were found, with just four STs 
accounting for 55% of the isolates. The most common types were ST73, ST131 and 
ST69. Adams-Sapper et al. (2013) investigated a series of Gram-negative 
bacteraemia isolates in the US. The study found that nearly two-thirds of the 249 E. 
coli isolates were allocated to just five sequence types: ST131 (23%), ST95 (18%), 
ST73 (8%) and ST69 (9%). 
In terms of data from sensitive isolates, a European study (Bengtsson et al., 2012) of 
80 E. coli isolates from four countries (Greece, Portugal, Sweden and the UK) 
investigated uropathogenic isolates without any detectable antibiotic resistance. 
The 80 isolates were allocated to 36 different sequence types, eleven of which were 
new to the study. The most common STs in the sensitive isolates were ST73, ST95 
and ST420. 
The eBURST diagram (Figure 6-2) for the regional isolates demonstrate clearly the 
dominance of the ST131 clone, and how it sits as a separate clone within the overall 
population. Other than ST131, there were a number of significant sequence types 
by volume, including ST73, ST12, ST38, ST69 and ST648. These are broadly similar 
findings to those observed in other UK studies of uropathogenic isolates. Gibreel et 
al. (2012) found that ST73 was the most common, with ST69 the third most 
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common after ST131, in uropathogenic UK isolates with a range of antibiotic 
susceptibilities. Lau et al. (2008) found ST131 as the most common sequence type 
in 68 uropathogenic UK isolates with cephalosporin resistance, followed by ST73 
and ST95. In these studies of UK uropathogenic isolates, ST12 was either not 
present, or was seen only in small numbers. In the current study, it was seen as the 
third most common sequence type (4.7%). 
In the current study, there were two main groups of sequence types, designated as 
clonal complexes as they differed at just one allele. ST38 was the founder of a 
complex that included ST778, ST1177, ST315 and ST963. This complex included 7 
isolates with an AmpC plasmid gene and 11 isolates with ESBL resistance (mainly 
non-CTX-M). Secondly, ST88 was the founder of a complex that included ST23, 
ST1279 and ST410. This group comprised mainly of isolates with confirmed CTX-M 
genes, with two isolates having ampC chromosomal mutations (-42 mutation). 
6.4.2 Association of Sequence Type with Location  
The distribution of ST131 varied significantly between the five locations. The 
Gloucester and Truro laboratories had proportions of ST131 that differed 
significantly from the average rate for the whole population. There was also a level 
of variation seen in some of the other common sequence types, and some types 
that were not seen at all in one or more locations. There were also significant 
differences seen in the diversity indices for some of the laboratories. This is 
probably a reflection of the dominance of the ST131 clone in the whole population. 
The laboratory with the lowest proportion of ST131 isolates (Dorchester) was also 
the one with the highest diversity index. The reverse was true for the Truro 
laboratory, with the highest proportion of ST131 isolates and the lowest diversity 
index. Again, this confirms the significance of this particular clone, and the impact it 
has on the diversity of a particular population. The impact of the ST131 clone 
dominance may have been reduced if a larger number of isolates from each 
laboratory had been tested. 
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6.4.3 Association of Sequence Type with AmpC Plasmid Genes 
The 19 isolates identified as carrying AmpC plasmid genes were allocated to 14 
different sequence types, with 11 seen as individuals. This confirms the findings of 
others, in which isolates with AmpC plasmid genes had a high degree of diversity. In 
one of the few studies using MLST on AmpC-producing isolates, Naseer et al. (2010) 
investigated 402 potential AmpC-producing E. coli isolates in Norway, collected 
from 21 laboratories. A total of 38 of the E. coli isolates were confirmed as carrying 
an AmpC plasmid gene (35/38 were CMY-2), and were allocated to 25 different 
sequence types.  
In a Spanish study, Gude et al. (2013) investigated 72 E. coli isolates known to be 
carrying AmpC plasmid genes (mainly CMY-2). Although the study used PFGE for 
typing purposes, the data showed 59 different clones amongst the isolates. The 
authors suggested that there is likely to be a wide heterogeneity of clones and that 
the AmpC plasmid-mediated mechanism is not due to the dissemination of a clonal 
strain. 
Although in the current study there were 14 different STs identified in the 19 
isolates with AmpC plasmid genes, the ST778 isolates were exclusively linked with 
the carriage of an AmpC plasmid gene (CIT-type). The numbers were small, 
however, with only four isolates, and were only isolated in the Dorchester and 
Gloucester laboratories. It is not clear, without testing a larger number of isolates, 
whether these would be seen elsewhere in the region. 
6.4.4 Association of Sequence Type with ampC Chromosomal Mutations 
Published studies using MLST to investigate isolates with ampC chromosomal 
mutations are rare. In addition to the paper by Guillouzouic et al. (2009), a more 
recent study from the Netherlands investigated the carriage of ESBL and AmpC 
genes in rectal swabs (van Hoek et al., 2015a). The 8 isolates with ampC 
chromosomal mutations were designated as sequence types ST131 (n=2), ST453 
(n=2), ST88, ST95, ST345 and ST500. These findings are substantially different to 
those in the current study, in terms of the sequence types found. The Guillouzuic 
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paper tested a small number of human and animal isolates, which were probably 
not fully representative of uropathogenic E. coli isolates. Similarly, van Hoek et al. 
tested isolates that had been isolated from faecal screening samples. It is possible 
that these would have been different in terms of virulence and pathogenicity, and 
represent a totally different population. 
The comparison of MLST data with ampC chromosomal mutations has not 
previously been published for UK strains, or performed on the scale seen in the 
current study. The -32 mutation was seen in isolates assigned mainly to ST73 (n=14) 
and ST12 (n=12). These two sequence types were the most common overall, after 
the ST131 isolates. It is possible that these represent the presence of a dominant 
clone with chromosomal ampC mutations. However, one of these sequence types 
(ST73) is commonly found in sensitive strains, so may simply reflect normal strains 
with spontaneous mutations. Bengtsson et al. (2012) investigated 80 uropathogenic 
isolates from four countries (Greece, Portugal, Sweden and the UK). All isolates 
were selected on the basis of having no detectable antibiotic resistance. The three 
most common sequence types included ST73. There were only three isolates of 
ST12, all of which were isolated in Greece. The ST12 isolates from the current study 
may represent a potentially sub-dominant clone of E. coli, which is genotypically 
characterised by the  -32 ampC promoter mutation. 
6.4.5 Comparison of Diversity Indices 
It was clear in the current study that there were significantly different diversity 
indices for the two main groups of isolates (ESBL and Non-ESBL), at 66% versus 91%. 
This is almost certainly a reflection of the dominance of the ST131 clone in the ESBL 
population.  
In a study of rectal screening swabs, Izdebski et al. (2013) investigated 376 E. coli 
isolates collected in five centres in four countries (France, Italy, Spain and Israel). A 
total of 76 STs were identified from the 240 isolates that were investigated by 
MLST. The diversity index of the whole group was 81.9% (95% CI of 77.9 to 85.8), 
but ranged from 73.8% to 91.3% between centres. The authors commented that 
approximately half of the sequence types observed in a centre were usually not 
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observed in the others. A similar level of variance in the diversity indices for the five 
laboratories in the current study was also observed, ranging from 58.7% (Truro) to 
88.3% (Dorchester).  This variation in diversity is partly due to the dominance of the 
ST131 clone, but may also be due to natural variations in the local populations.  
Adams-Sapper et al. (2013) found that the overall diversity index for a population of 
249 bacteraemia E. coli isolates was 89%. Although there was some difference in 
the diversity indices for sensitive and resistant isolates (87% and 81%, respectively), 
this was not found to be statistically significant. Lau et al. (2008) established that 
there were differences in the diversities of different types of populations. For 
example, E. coli isolates from urine samples were more diverse than blood culture 
samples, and isolates from the community were more diverse than those isolated 
from hospital patients. The authors suggest that ST131 could be more likely to be 
exposed to antibiotics, resulting in the development of virulence and antibiotic 
resistance over time. Woodford et al. (2011) concur, suggesting that those clones 
that are circulating widely are more likely to acquire the resistance-associated 
plasmids that are present locally. 
In the current study, CTX-M genes were found in 56 isolates assigned to 39 different 
sequence types. Eight of these 39 sequence types were novel to this study. This 
confirms that CTX-M genes are not exclusively limited to the ST131 isolates, and 
suggests that a range of uropathogenic strains can acquire the CTX-M genes via 
plasmids. 
6.5 Summary 
The current study provides data that confirms the dominance of the ST131 clone as 
a major cause of cephalosporin resistance in the South West region. This is clear 
from the fact that 43.6% of all isolates were of this particular sequence type, and 
that 82.5% of the ST131 isolates were confirmed as having blaCTX-M genes. There 
was also evidence that the proportions of this dominant clone vary between the 
five laboratories. Although this may have been due to the study design, and the 
restricted number of isolates collected from each laboratory, it may also be due to 
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differences in other local factors (such as antibiotic prescribing polices producing a 
selective pressure on strains). 
The ST131 isolates were predominantly found to have ESBL genes present, although 
this was not exclusive. The next most common sequence types found (ST73 and 
ST12) had a strong association with the presence of ampC chromosomal mutations. 
This suggests that there may be a sub-dominant population of E. coli strains with 
ampC mutations in the South West. Previous studies have reported a low 
prevalence of ST12 in uropathogenic isolates. The presence of a sub-dominant ST12 
clone with the -32 ampC mutation would also explain the higher prevalence of this 
mutation in the study compared to the findings of others. Overall, however, the 
diversity of the group of isolates with AmpC mechanisms (chromosomal mutations 
or plasmid genes) was significantly greater than that ESBL group, suggesting that a 
dominant clone is less likely. 
It was interesting to note that the 19 isolates with AmpC plasmid genes present 
were assigned to 14 different sequence types. This suggests that the plasmid-
carrying isolates are not the result of the spread of a dominant clone, rather the 
genuine acquisition of plasmids. The potential importance of the four ST778 isolates 
with a CIT-type plasmid gene present will need to be investigated further. It also 
seemed that the isolates with AmpC plasmid genes were more closely related to 
isolates with blaESBL genes, than those with ampC mutations.  
The current study identified ten new sequence types from the 275 isolates tested. 
The five new allele sequences identified were all single base pair mutations. This 
confirms the utility of the method as a broad typing method, as small changes in the 
housekeeping genes can be detected and used to differentiate strains and changes 
in populations over time. The current study has made a modest, but important, 
contribution to the development and utility of MLST as an international typing 
method. 
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6.6 Future Work 
The majority of the isolates included in the current study originated from urine 
samples. Whilst this has provided a robust group to investigate, it has excluded a 
significant source of pathogenic E. coli isolates. Some of the E. coli MLST data 
published have identified differences between the diversity indices between 
populations of uropathogenic isolates and bacteraemia isolates, even though the 
underlying lineages should be similar (Lau et al., 2008). It would be useful to expand 
the current study to include a larger group of bacteraemia isolates. National data 
indicate that there are approximately 260 strains of E. coli isolated from blood 
cultures in the South West every month (Public Health England, 2015b). This would 
also help to confirm the significance of the four ST778 isolates observed exclusively 
with an AmpC plasmid gene. 
The second and third most common sequence types were ST73 and ST12, both of 
which were associated with the -32 chromosomal ampC mutation. Although there is 
some evidence to suggest that sequence type ST73 is common in uropathogenic 
isolates, this has not been confirmed in the local populations. Investigating a 
selection of cephalosporin-susceptible isolates from each of the five laboratories 
would confirm both the presence of chromosomal ampC mutations in sensitive 
isolates and the importance of the ST73 and ST12 clones. 
The use of MLST in this study has provided a good overall picture of the 
cephalosporin-resistant E. coli population in five locations in the South West of 
England. The main benefit of using this method is that results are directly 
comparable with the work of others. However, the resolution is not sufficient to 
confirm the presence of cross-infection and direct transfer of strains between 
patients. There were 12 isolates of sequence type ST12, all of which had the same 
ampC chromosomal mutation pattern. Further investigation with a more 
discriminatory typing method, such as single nucleotide polymorphism (SNP) 
analysis (Sherry et al., 2013) or ribosomal MLST (Jolley et al., 2012), would offer a 
greater insight of how strains transfer between patients. 
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7 Conclusion 
7.1 Genotypic Characteristics of AmpC-Producing E. coli 
This study presents a unique picture of AmpC-mediated resistance in E. coli isolates 
in the South West of England. It also represents a significant contribution to the 
overall understanding of chromosomal ampC mutations in UK isolates. There are no 
other published studies of ampC chromosomal mutations in UK E. coli isolates on 
this scale, or that investigate differences between populations. In the 276 isolates 
collected in the regional study, 25.8% were confirmed as having a genotype 
associated with AmpC resistance. This is significantly higher than the proportion 
(7.1%) found by Potz et al. (2006) (p<0.05, Fisher’s Exact Test). However, the AmpC 
mechanisms in their isolates were not fully investigated, with 26% being allocated 
to the “other” category. It is likely that many of these would have had ampC 
chromosomal mutations. 
There were 19 isolates in the regional study found to be carrying an AmpC plasmid 
gene. The AmpC plasmid genes in the CIT group were likely to be CMY-2, but this 
was not fully confirmed. If true, this would confirm the importance of this particular 
mechanism for AmpC enzyme production. In this study, only the CIT and DHA types 
of AmpC plasmid genes were found. It is possible that small numbers of other 
plasmid gene types would be found in the South West if further isolates or 
laboratory locations were tested. However, the potential additional impact of these 
strains would be minimal. 
The analysis of ampC chromosomal mutations is complicated by the numbers of 
different mutations present. In the regional study, there were mutations in 28 
different positions in the amplified region, giving 31 different phylogroups (Table 
5-6). A similarly complex picture was seen by Mulvey et al. (2005). Not all of the 
phylogroups were associated with AmpC resistance. Half of the phylogroups 
contained one of the key mutations (-42, -32, -13ins) described by Tracz et al. 
(2007). The other half were associated mainly with ESBL resistance. Although not 
investigated in this study, other studies have found some ampC chromosomal 
mutations in E. coli isolates without detectable resistance (Corvec et al., 2007). 
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Overall the three key ampC mutations (-42, -32 and -13ins) were found in 18.6% of 
the cefpodoxime-resistant isolates collected in the five laboratories. So although a 
smaller proportion compared to the dominance of the ESBL isolates, chromosomal 
ampC resistance is still accounting for nearly a fifth of cephalosporin resistance in E. 
coli. 
There were two key findings from the regional stage of the project. Firstly, that the  
-32 (T to A) mutation was more common than the -42 and -13ins mutations. 
Although this was also seen in the pilot study, it was in direct contrast to all other 
studies of ampC chromosomal mutations in E. coli. The second interesting finding 
was the presence of a mutation (thymine base insertion) at position -20 (Figure 
5-9). This was only found in two isolates, but has not been previously reported in 
the UK. As this mutation would increase the inter-box distance by 1bp to the 
optimum distance of 17bp, it is likely to have a similar impact as the -13ins mutation 
on AmpC enzyme production. It should, therefore, be considered as a fourth key 
chromosomal ampC mutation. 
7.2 Existence of a Dominant AmpC-Producing E. coli Clone 
The impact of ST131 as a dominant clone was clearly evident in this study. Of all the 
isolates tested, 43.6% were of this sequence type (Table 6-1). The evidence for a 
second dominant clone was less convincing. In the 19 isolates with AmpC plasmid 
genes, 11 were of different sequence types; suggesting a reasonable amount of 
diversity within this group. There were four isolates of sequence type ST778 that 
were all found to be carrying an AmpC plasmid gene (CIT type). It is not clear 
whether these were all the same clone, or simply strains of the same sequence type 
that had acquired the AmpC plasmid genes independently. Cross-infection of the 
same strain between patients may have been a consideration if all had been 
collected in the same laboratory. Similarly, a failure of the de-duplication stage of 
the collection process to detect the same strain from the same patient in multiple 
samples could also explain a cluster of identical isolates in one laboratory. Even if 
these four isolates do represent a single clone spreading across the region, the 
current impact on the overall population is small. 
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In terms of strains with chromosomal ampC mutations, there were 12 isolates of 
sequence type ST12 that all had the same mutation at position -32 (Table 6-4). 
These isolates were isolated from three different laboratories, suggesting again that 
a cross-infection or outbreak event was not the cause. If these were all a single 
clone that had spread across part of the region, it would still represent a fairly small 
impact compared to that of the ST131 clone (4.4% versus 43.6%). The presence of a 
dominant clone, however, would explain why the -32 mutation was more prevalent 
in this study compared to others. This was the finding in both the pilot study and 
the regional study, which were conducted two years apart. 
7.3 Utility of SYBR Green Real-Time PCR 
This study used SYBR Green chemistry as the method for detecting a PCR product. 
Although the real-time PCR process could have been developed further to include 
the use of fluorescent probes, this would have added a further layer of method 
optimisation and cost. The results of this study demonstrate that a robust method 
for detecting the presence of PCR products can be implemented on equipment 
commonly found in clinical laboratories. 
Since the conclusion of this study, the same underlying method and equipment 
have been used in the Gloucester laboratory to detect a number of other genes, 
using primers published by others. These have included fosfomycin (fosA) resistance 
genes in Enterobacteriaceae (Gray et al., 2001), MLST genes for typing Clostridium 
difficile (Griffiths et al., 2010), spa typing genes in Staphylococcus aureus (Harmsen 
et al., 2003) and the 16S ribosomal genes used in bacterial identification (Harris & 
Hartley, 2003). All of these have been successfully implemented in the laboratory, 
using the same protocols and regents as in the current study. This confirms the 
potential usefulness of the method as a research and diagnostic tool for clinical 
laboratories. 
7.4 Differences in Laboratory Populations 
In terms of differences between laboratories, there were significant variations in 
the numbers of isolates with AmpC plasmid genes collected from laboratories 
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(Figure 5-7). This ranged from 0% in Truro to nearly 20% in Dorchester. There were 
variations also in the proportion of isolates with a -32 chromosomal mutations, 
ranging from 2.2% in Dorchester to 19% in Gloucester. The underlying reasons for 
these variations were not investigated further. One reason could be due to 
differences in antibiotic prescribing policies. Although no direct evidence exists for 
this in relation to urinary tract infections, there is some general evidence that 
prescribing rates do differ amongst primary care providers (Public Health England, 
2014). 
The differences seen in prevalence rates of AmpC plasmid-carrying isolates may, 
however, just be a factor of study design. Laboratories were asked to collect up to 
50 isolates over a period of 3 months. It may be that the data are unusual for these 
laboratories, and would not be replicated if re-investigated. The laboratory 
(Dorchester) with a high AmpC plasmid gene prevalence rate had a low rate for CTX-
M-carrying ST131 isolates. This was also the reverse picture for the Truro 
laboratory. It is possible that the presence of the dominant ST131 clone is exerting a 
selective pressure, limiting the isolation of other resistance mechanisms. 
7.5 Study Limitations 
There are a number of limitations relating to the range of laboratories participating 
in the study. Although the five laboratories represented a good geographic 
coverage of the South West region, some of the larger laboratories were not able to 
participate. A particularly notable absence is Bristol, which would have provided a 
selection of isolates from a more urban area, when compared to laboratories such 
as Truro and Taunton. This limitation is due to the availability of resources in clinical 
laboratories to participate in research studies. Although laboratories were offered 
financial support of £3 per isolate submitted, this would only have covered basic 
time and materials costs. 
To meet timeframes and to help secure laboratory support, a relatively short 
collection period was used, and laboratories were asked to collect only the first 50 
isolates. This may have limited the number of different types of resistance 
mechanisms seen, and would have increased the impact of any outbreak or cross-
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infection event occurring at the time of collection. The significant differences 
between the Truro and Dorchester isolates may just have been a temporary shift in 
strain incidence, or may actually represent a difference in selective pressure from 
local prescribing policies. This can only be confirmed with the collection of further 
isolates, preferably over multiple time points.  
The limited collection period also meant that few isolates from bacteraemia cases 
were collected. These are the strains that have the highest impact on morbidity and 
mortality in patients. However, the study did collect 97% of the isolates in the 
regional stage from urine samples. This provides a robust population of isolates 
from similar types of infection, and also enables isolates to be compared with other 
studies and with the results of the pilot study. It is known that 45% of E. coli sepsis 
cases have the urinary tract as a suspected origin source (Davies et al., 2012), so 
investigating a population of >250 uropathogenic isolates still remains valid. These 
are also the strains most likely to circulating within populations as pathogenic 
strains. 
Focusing on pathogenic isolates, however, brings its own problems. Spratt and 
Maiden (1999) suggest that there is an inherent bias of any study of this nature, in 
which the focus is on disease-causing strains. In these cases, selecting the more 
virulent pathogenic strains may be neglecting the less pathogenic commensal or 
environmental strains, which often comprise a higher proportion of the overall 
population. The authors also suggest that restricting analysis to pathogenic isolates 
will underestimate the diversity of a population and overestimate the clonality. 
Designing a study to investigate commensal E. coli strains is possible, but often 
relies on the success of screening faeces sample or rectal swabs from healthy 
volunteers. This type of study has inherent difficulties with ethics approval and 
securing decent participating rates. It is difficult to use other types of samples 
routinely submitted to clinical laboratories, as even clinical faeces samples would be 
submitted from patients for the investigation of gastro-intestinal problems. 
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7.6 Contributions to New Knowledge 
The contributions to new knowledge are four-fold. Firstly, the study confirmed that 
SYBR Green Real-Time PCR can be used, and easily adapted, for detecting antibiotic 
resistance genes and typing genes in E. coli. Although this would be limited to 
research use only, it nonetheless offers most clinical laboratories an easy way of 
introducing PCR and sequencing methods into research projects. The use of melting 
curve analysis means that the PCR product can be detected and partly characterised 
without the need for a separate gel electrophoresis stage. 
Secondly, the study made a direct contribution to the continuing development of 
the E. coli MLST scheme, by registering five new alleles and ten new sequence 
types. The detection of novel sequence types in the current study confirms the 
usefulness of this method in analysing bacterial populations, as small changes to 
alleles would be expected to occur naturally over time. 
Thirdly, the study confirmed the findings of others that E. coli strains with AmpC 
plasmid genes are a diverse group. There was no significant evidence that a 
dominant clone of AmpC plasmid-carrying E. coli exists within the South West 
region. This suggests that isolates with AmpC plasmid genes are pathogenic strains 
that have acquired the plasmids on an ad-hoc or opportunistic basis, and provides 
some reassurance against the concerns of these clones spreading like ST131. 
Finally, the study identified some potential evidence of spread of an E. coli clone 
with a mutation in the ampC promoter region. In contrast to other studies, the 
current study identified a higher number of isolates with the -32 mutation present 
in both the pilot study phase and regional study phase. On investigation with MLST, 
there were 12 isolates of ST12 which all had the same AmpC genotype. Whether 
this is truly a dominant clone of E. coli can only be determined with further 
investigation of additional isolates. 
7.7 Recommendations for Future Work 
This study set out to achieve four key objectives. In doing so, it has generated a 
comprehensive picture of cephalosporin-resistance in the South West of England. 
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This picture is by no means complete, however. There are a number of natural 
avenues of further work and new questions that need answering. 
One obvious recommendation would be to repeat the study at a different time 
point. This would confirm the key findings of this study, and help collect more of the 
unusual strains (e.g. ST778 with AmpC plasmid genes and ST12 with -32 mutations).  
Restricting a future study to only collecting bacteraemia isolates would provide an 
important dataset of isolates that have progressed to causing sepsis. This could be 
developed further to include clinical and risk factor data collection. 
The evidence for clonal spread of AmpC resistance should be investigated further. 
The four isolates of ST778 with AmpC plasmid genes and the twelve isolates of ST12 
with the same ampC chromosomal mutation could be investigated using whole 
genome data. Ribosomal MLST (Jolley et al., 2012) would, in the first instance, be 
able to differentiate isolates were possible. To confirm whether isolates were truly 
identical clones, however, one would need to use a more details analysis of the 
genome such as SNP analysis (Sherry et al., 2013). 
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9 Appendices 
9.1 Quantification of DNA from extraction process 
Table 9-1: Quantification of DNA from extraction process 
DNA quantification in crude lysates was done using a Qubit fluorometer, testing a sample volume of 
10µl. Figures are given in ng/μl. 
 Test 1 Test 2 Test 3 Average 
Sample 1 
 
1.73 1.67 1.66 1.69 
Sample 2 
 
8.44 8.38 8.32 8.38 
Sample 3 
 
2.72 2.70 2.68 2.70 
Sample 4 
 
0.76 0.74 0.73 0.74 
Sample 5 
 
1.18 1.18 1.17 1.18 
Sample 6 
 
2.60 2.60 2.58 2.59 
Sample 7 
 
0.50 0.49 0.48 0.49 
Sample 8 
 
3.06 3.06 3.04 3.05 
Sample 9 
 
1.00 0.97 0.97 0.98 
Sample 10 
 
2.40 2.38 2.36 2.38 
 
  
Page 156 of 188 
 
9.2 Full list of AmpC plasmid genes 
Full list of AmpC plasmid genes available on the website (www.lahey.org/studies/) 
at the time of last checking (2nd February 2015). 
Enzyme Nucleotide  Enzyme Nucleotide 
CMY-1 X92508  CMY-117 KM087844 
CMY-2 X91840  CMY-118 KM087838 
CMY-3    CMY-119 KM087845 
CMY-4 Y15130  CMY-120 Assigned 
CMY-5 Y17716  CMY-121 Assigned 
CMY-6 AJ011293  CMY-122 Assigned 
CMY-7 AJ011291  CMY-123 Assigned 
CMY-8 AF167990  CMY-124 Assigned 
CMY-9 AB061794  CMY-125 Assigned 
CMY-10 AF357597  CMY-126 Assigned 
CMY-11 AF357599  CMY-127 Assigned 
CMY-12 Y16785  CMY-128 Assigned 
CMY-13 AY339625  CMY-129 Assigned 
CMY-14 AJ555825  CMY-130 Assigned 
CMY-15 AJ555823  CMY-131 KP281294 
CMY-16 AJ781421  CMY-132 KP862820 
CMY-17 AY513266  CMY-133 KP862819 
CMY-18 AY743434  CMY-134 Assigned 
CMY-19 AB194410  CMY-135 KP981366 
CMY-20 AY960293  CMY-136 Assigned 
CMY-21 DQ139328  ACC-1 AJ133121 
CMY-22 DQ256079  ACC-2 AF180952 
CMY-23 DQ463751  ACC-3 AF180958 
CMY-24 EF415650  ACC-4 EF504260 
CMY-25 EU515249  ACC-5 HE819401 
CMY-26 AB300358  ACT-1 U58495 
CMY-27 EU515250  ACT-2 AM076977 
CMY-28 EF561644  ACT-3 EF125013 
CMY-29 EF685371  ACT-4 EU427302 
CMY-30 EF685372  ACT-5 FJ237369 
CMY-31 EF622224  ACT-6 FJ237366 
CMY-32 EU496815  ACT-7 FJ237368 
CMY-33 EU496816  ACT-8 Assigned 
CMY-34 EF394370  ACT-9 HQ693810 
CMY-35 EF394371  ACT-10 JN848330 
CMY-36 EU331426  ACT-11 Assigned 
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Enzyme Nucleotide  Enzyme Nucleotide 
CMY-37 AB280919  ACT-12 JX440355 
CMY-38 AM931008  ACT-13 HE819402 
CMY-39 AB372224  ACT-14 JX440354 
CMY-40 EU515251  ACT-15 JX440356 
CMY-41 AB429270  ACT-16 AB737978 
CMY-42 HM146927  ACT-17 KF992026 
CMY-43 FJ360626  ACT-18 KF992028 
CMY-44 FJ437066  ACT-19 KF992029 
CMY-45 FN546177  ACT-20 KF526117 
CMY-46 FN556186  ACT-21 KF526118 
CMY-47 HM046998  ACT-22 KF992027 
CMY-48 HM569226  ACT-23 KF515536 
CMY-49 GQ402541  ACT-24 KJ207207 
CMY-50 FN645444  ACT-25 KJ207208 
CMY-51 JQ733571  ACT-26 Withdrawn 
CMY-52 Assigned  ACT-27 KJ207209 
CMY-53 HQ336940  ACT-28 KJ207206 
CMY-54 HM544039  ACT-29 KM087832 
CMY-55 HM544040  ACT-30 KM087833 
CMY-56 HQ322613  ACT-31 KM087843 
CMY-57 HQ285243  ACT-32 KM087835 
CMY-58 HQ185697  ACT-33 KM987834 
CMY-59 AB587082  ACT-34 Assigned 
CMY-60 JF460794  ACT-35 LC004922 
CMY-61 JF460795  ACT-36 KM926621 
CMY-62 JF460796  ACT-37 KM926622 
CMY-63 HQ650104  ACT-38 KP836350 
CMY-64 HQ832678  CFE-1 AB107899 
CMY-65 JF780936  DHA-1 Y16410 
CMY-66 JN714478  DHA-2 AF259520 
CMY-67 JQ711185  DHA-3 AY494945 
CMY-68 JN714480  DHA-4 Assigned 
CMY-69 JX049132  DHA-5 JF273491 
CMY-70 JX440350  DHA-6 HQ322612 
CMY-71 JQ711184  DHA-7 HQ456945 
CMY-72 JX440352  DHA-8 Assigned 
CMY-73 GQ351345  DHA-9 KJ207201 
CMY-74 JX440349  DHA-10 KP050490 
CMY-75 JQ733572  DHA-11 Assigned 
CMY-76 JQ733573  DHA-12 HG798963 
CMY-77 JX440353  DHA-13 KM087855 
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Enzyme Nucleotide  Enzyme Nucleotide 
CMY-78 JQ733575  DHA-14 KM087854 
CMY-79 JQ733576  DHA-15 KM087853 
CMY-80 JQ733577  DHA-16 KM087852 
CMY-81 JQ733578  DHA-17 KM087850 
CMY-82 KJ207203  DHA-18 KM087841 
CMY-83 JX440351  DHA-19 KM087849 
CMY-84 JQ733579  DHA-20 KM087848 
CMY-85 KJ207202  DHA-21 KM087847 
CMY-86 KJ207204  DHA-22 KM087856 
CMY-87 AB699171  DHA-23 Assigned 
CMY-88 Assigned  FOX-1 X77455 
CMY-89 Assigned  FOX-2 Y10282 
CMY-90 HE819404  FOX-3 Y11068 
CMY-91 Assigned  FOX-4 AJ277535 
CMY-92 Assigned  FOX-5 AY007369 
CMY-93 KF992025  FOX-6 AY034848 
CMY-94 JX514368  FOX-7 AJ703795 
CMY-95 JX514369  FOX-8 HM565917 
CMY-96 Assigned  FOX-9 JF896803 
CMY-97 Assigned  FOX-10 JX049131 
CMY-98 KC603538  FOX-11 Assigned 
CMY-99 KF305673  FOX-12 Assigned 
CMY-100 KF526113  LAT-1 X78117 
CMY-101 KF526114  MIR-1 M37839 
CMY-102 KF526115  MIR-2 AY227752 
CMY-103 KF526116  MIR-3 AY743435 
CMY-104 KF150216  MIR-4 EF417572 
CMY-105 KJ207205  MIR-5 FJ237367 
CMY-106 KM983294  MIR-6 JQ664733 
CMY-107 Assigned  MIR-7 KJ207200 
CMY-108 KF564648  MIR-8 KP050484 
CMY-109 Assigned  MIR-9 KM087860 
CMY-110 AB872957  MIR-10 KM087858 
CMY-111 KJ155695  MIR-11 KM087859 
CMY-112 KM087837  MIR-12 KM087863 
CMY-113 KM087836  MIR-13 KM087862 
CMY-114 KM087846  MIR-14 KM087864 
CMY-115 KM087839  MIR-15 KM087851 
CMY-116 KM087840  MIR-16 KM087861 
MIR-17 LN515535  MOX-4 FJ262599 
MIR-18 Assigned  MOX-5 GQ152600 
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Enzyme Nucleotide  Enzyme Nucleotide 
MOX-1 D13304  MOX-6 GQ152601 
MOX-2 AJ276453  MOX-7 GQ152602 
MOX-3 EU515248  MOX-8 JX173956 
 
  
Page 160 of 188 
 
9.3 Laboratory information sheet and submission instructions 
AmpC Study 
Background 
The main objective of the study is to establish the regional incidence of 
AmpC beta-lactamase production in clinical E. coli isolates. The study will 
use real-time PCR to identify the types of AmpC enzymes present and the 
phylogenetic types of positive isolates. The study will also use MLST (multi 
locus sequence typing) to determine the types of strains circulating in the 
region. 
The first collection period is due to run from 2nd April 2013. 
Anonymised Isolates 
In order to meet the requirements of the ethics panel, all isolates need to be 
anonymised before inclusion in the study. This ensures that each isolate is 
no longer linked to a patient. The study will use unique study numbers to 
identify isolates instead of lab numbers. 
De-duplication 
Before inclusion in the study, isolates should be checked to see whether a 
duplicate has been reported on the same patient in the previous 30 days. 
Duplicate isolates should not be included in the study. 
Inclusion Process 
Isolates are eligible for inclusion in the study if they: 
 Have been identified as E. coli (chromogenic plate or API) 
 Are cefpodoxime resistant 
 Have not been previously isolated in the last 30 days 
 
Isolates eligible for inclusion should be sub-cultured onto a nutrient agar 
slope. The slope should be labelled with a unique study number. No other 
information (e.g. surname or lab number) should be written on the slope. The 
corresponding sample data should be entered onto the record sheet. 
 
Slopes should be incubated overnight, and then stored until returning to the 
Gloucester laboratory. 
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9.4 Laboratory isolate record sheet 
AmpC Study 
Eligibility Criteria 
The study is open to all isolates of E. coli that are cefpodoxime-resistant. 
De-duplication 
Please check whether the isolate has been previously reported on the same 
patient in the previous 30 days. 
Subculture 
Please subculture the organism to a NA slope labelled only with a study 
label. Enter the relevant details onto the table below. 
Study No 
Specimen 
Type 
Specimen 
Date 
DOB Gender Inpatient / GP 
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9.5 Sequences of AmpC plasmid gene products 
9.5.1 DHA Plasmid Gene 
CT-03-DHA_DHA-F               ------------AAAATACCAGCCGGAGCTGGCTCTGCCGCAGTGGAAGG 38 
CT-04-DHA_DHA-F               TGATCCGGCGGCAAAATACCAGCCGGAGCTGGCTCTGCCGCAGTGGAAGG 55 
gi|2853120|emb|Y16410.1|      TGATCCGGCGGCAAAATACCAGCCGGAGCTGGCTCTGCCGCAGTGGAAGG 1350 
                                          ************************************** 
 
CT-03-DHA_DHA-F               GGATCACATTGCTGGATCTGGCTACCTATACCGCAGGCGGACTGCCGTTA 88 
CT-04-DHA_DHA-F               GGATCACATTGCTGGATCTGGCTACCTATACCGCAGGCGGACTGCCGTTA 105 
gi|2853120|emb|Y16410.1|      GGATCACATTGCTGGATCTGGCTACCTATACCGCAGGCGGACTGCCGTTA 1400 
                              ************************************************** 
 
CT-03-DHA_DHA-F               CAGGTGCCGGATGCGGTAAAAAGCCGTGCGGATCTGCTGAATTTCTATCA 138 
CT-04-DHA_DHA-F               CAGGTGCCGGATGCGGTAAAAAGCCGTGCGGATCTGCTGAATTTCTATCA 155 
gi|2853120|emb|Y16410.1|      CAGGTGCCGGATGCGGTAAAAAGCCGTGCGGATCTGCTGAATTTCTATCA 1450 
                              ************************************************** 
 
CT-03-DHA_DHA-F               GCAGTGGCAGCCGTCCCGGAAACCGGGCGATATGCGTCTGTATGCAAACA 188 
CT-04-DHA_DHA-F               GCAGTGGCAGCCGTCCCGGAAACCGGGCGATATGCGTCTGTATGCAAACA 205 
gi|2853120|emb|Y16410.1|      GCAGTGGCAGCCGTCCCGGAAACCGGGCGATATGCGTCTGTATGCAAACA 1500 
                              ************************************************** 
 
CT-03-DHA_DHA-F               GCAGTATCGGCCTGTTTGGTGCTCTGACCGCAAACGCGGCGGGGATGCCG 238 
CT-04-DHA_DHA-F               GCAGTATCGGCCTGTTTGGTGCTCTGACCGCAAACGCGGCGGGGATGCCG 255 
gi|2853120|emb|Y16410.1|      GCAGTATCGGCCTGTTTGGTGCTCTGACCGCAAACGCGGCGGGGATGCCG 1550 
                              ************************************************** 
 
CT-03-DHA_DHA-F               TATGAGCAGTTGCTGACTGCACGGATCCTGGCACCGCTGGGGTTATCTCA 288 
CT-04-DHA_DHA-F               TATGAGCAGTTGCTGACTGCACGGATCCTGGCACCGCTGGGGTTATCTCA 305 
gi|2853120|emb|Y16410.1|      TATGAGCAGTTGCTGACTGCACGGATCCTGGCACCGCTGGGGTTATCTCA 1600 
                              ************************************************** 
 
CT-03-DHA_DHA-F               CACCTTTATTACTGTGCCGGAAAGTGCGCAAAGCCAGTATGCGTACGG-- 336 
CT-04-DHA_DHA-F               CACCTTTATTACTGTGCCGGAAAGTGCGCAAAGCCAGTATGCGTACGG-- 353 
gi|2853120|emb|Y16410.1|      CACCTTTATTACTGTGCCGGAAAGTGCGCAAAGCCAGTATGCGTACGGTT 1650 
************************************************ 
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9.5.2 ACC Plasmid Gene 
CT-01-ACC_ACC-F                 AGTGGGTTCGCTGAGTAAA-CGTTTGCTGCCACCTTGGCGTCCTATGCGC 51 
CT-02-ACC_ACC-F                 -GTGGGTTCGCTGAGTAAA-CGTTTGCTGCCACCTTGGCGTCCTATGCGC 48 
gi|5419924|emb|AJ133121.1|      AGTGGGTTCGCTGAGTAAAACGTTTGCTGCCACCTTGGCGTCCTATGCGC 950 
                                 ****************** ****************************** 
 
CT-01-ACC_ACC-F                 AGGTGAGCGGTAAGCTGTCCTTGGATCAAAGCGTTAGCCATTACGTTCCA 101 
CT-02-ACC_ACC-F                 AGGTGAGCGGTAAGCTGTCCTTGGATCAAAGCGTTAGCCATTACGTTCCA 98 
gi|5419924|emb|AJ133121.1|      AGGTGAGCGGTAAGCTGTCTTTGGATCAAAGCGTTAGCCATTACGTTCCA 1000 
                                ******************* ****************************** 
 
CT-01-ACC_ACC-F                 GAGTTGCGTGGCAGCAGCTTTGACCACGTTAGCGTACTCAATGTGGGCAC 151 
CT-02-ACC_ACC-F                 GAGTTGCGTGGCAGCAGCTTTGACCACGTTAGCGTACTCAATGTGGGCAC 148 
gi|5419924|emb|AJ133121.1|      GAGTTGCGTGGCAGCAGCTTTGACCACGTTAGCGTACTCAATGTGGGCAC 1050 
                                ************************************************** 
 
CT-01-ACC_ACC-F                 GCATACCTCAGGCCTACAGCTATTTATGCCGGAAGATATTAAAAATACCA 201 
CT-02-ACC_ACC-F                 GCATACCTCAGGCCTACAGCTATTTATGCCGGAAGATATTAAAAATACCA 198 
gi|5419924|emb|AJ133121.1|      GCATACCTCAGGCCTACAGCTATTTATGCCGGAAGATATTAAAAATACCA 1100 
                                ************************************************** 
 
CT-01-ACC_ACC-F                 CACAGCTGATGGCTTATCTAAAAACATGGAAACCTGCCGATGCGGCTGGA 251 
CT-02-ACC_ACC-F                 CACAGCTGATGGCTTATCTAAAAACATGGAAACCTGCCGATGCGGCTGGA 248 
gi|5419924|emb|AJ133121.1|      CACAGCTGATGGCTTATCTAAAAGCATGGAAACCTGCCGATGCGGCTGGA 1150 
                                *********************** ************************** 
 
CT-01-ACC_ACC-F                 ACCCATCGCGTTTATTCCAATATCGGTACTGGTTTGCTAGGGATGATTG- 300 
CT-02-ACC_ACC-F                 ACCCATCGCGTTTATTCCAATATCGGTACTGGTTTGCTAGGGATGATTGG 298 
gi|5419924|emb|AJ133121.1|      ACCCATCGCGTTTATTCCAATATCGGTACTGGTTTGCTAGGGATGATTG- 1199 
                                *************************************************  
 
CT-01-ACC_ACC-F                 CGGCGAAAACTC-------------------------------AACTC-- 317 
CT-02-ACC_ACC-F                 CGGCGAAA------------------------------------------ 306 
gi|5419924|emb|AJ133121.1|      CGGCGAAAAGTCTGGGTGTGAGCTATGAAGATGCGATTGAGAAAACCCTC 1249 
                                ********         
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9.5.3 FOX Plasmid Gene 
FOX-1_FOX-F                  --------CGCG-ATCGCGCTGACCCACACCGGTTTCTACTCGGTGGGAG 41 
FOX-2_FOX-F                  --------------------TGACCCACACCGGTTTCTACTCGGTGGGAG 30 
gi|453214|emb|X77455.1|      GCTAAAAACGCGGATCGCGCTGACCCATACCGGTTTCTACTCGGTGGGAG 1550 
                                                 ******* ********************** 
 
FOX-1_FOX-F                  ACATGACCCAGGGACTGGGCTGGGAGAGTTACGCCTATCCGGTGACCGAG 91 
FOX-2_FOX-F                  ACATGACCCAGGGACTGGGCTGGGAGAGTTACGCCTATCCGGTGACCGAG 80 
gi|453214|emb|X77455.1|      ACATGACTCAGGGGCTGGGTTGGGAGAGCTACGCCTATCCGTTGACCGAG 1600 
                             ******* ***** ***** ******** ************ ******** 
 
FOX-1_FOX-F                  CAGACATTGCTGGCGGGTAACGCACCGGCGGTGAGCTTCCAGGCCAATCC 141 
FOX-2_FOX-F                  CAGACATTGCTGGCGGGTAACGCACCGGCGGTGAGCTTCCAGGCCAATCC 130 
gi|453214|emb|X77455.1|      CAGGCGCTGCTGGCGGGCAACTCCCCGGCGGTGAGCTTCCAGGCCAATCC 1650 
                             *** *  ********** *** * ************************** 
 
FOX-1_FOX-F                  GGTTACGCGCTTTG-ATTGTGC---------------------------- 162 
FOX-2_FOX-F                  GGTTACGCGCTTTA-AG--------------------------------- 146 
gi|453214|emb|X77455.1|      GGTTACGCGCTTTGCGGTGCCCAAAGCGATGGGCGAGCAGCGGCTCTATA 1700 
                             ************* 
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9.5.4 MOX Plasmid Gene 
MOX-1_MOX-F                  CTCA-GGATGGCAAGGCCCACTATTTCAATTACGGGGTGGCCAACCGGGA 51 
MOX-2_MOX-F                  CTCA-GGATGGCA-GGCCCACTATTTCAATTACGGGGTGGCCAACCGGGA 50 
gi|11761377|dbj|D13304.2|    CTCAAGGATGGCAAGGCCCACTATTTCAATTACGGGGTGGCCAACCGGGA 450 
                             **** ******** ************************************ 
 
MOX-1_MOX-F                  GAGCGGGGCCAGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGA 101 
MOX-2_MOX-F                  GAGCGGGGCCAGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGA 100 
gi|11761377|dbj|D13304.2|    GAGCGGGGCCAGCGTCAGCGAGCAGACCCTGTTCGAGATAGGATCCGTGA 500 
                             ************************************************** 
 
MOX-1_MOX-F                  GCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCG 151 
MOX-2_MOX-F                  GCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCG 150 
gi|11761377|dbj|D13304.2|    GCAAGACCCTGACTGCGACCCTGGGGGCCTATGCGGTGGTCAAGGGAGCG 550 
                             ************************************************** 
 
MOX-1_MOX-F                  ATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATC 201 
MOX-2_MOX-F                  ATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATC 200 
gi|11761377|dbj|D13304.2|    ATGCAGCTGGATGACAAGGCGAGCCGGCACGCGCCCTGGCTCAAGGGATC 600 
                             ************************************************** 
 
MOX-1_MOX-F                  CGTCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAG 251 
MOX-2_MOX-F                  CGTCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAG 250 
gi|11761377|dbj|D13304.2|    CGTCTTTGACAGCATCACCATGGGGGAGCTTGCCACCTACAGCGCCGGAG 650 
                             ************************************************** 
 
MOX-1_MOX-F                  GCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGC 301 
MOX-2_MOX-F                  GCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGC 300 
gi|11761377|dbj|D13304.2|    GCCTGCCACTGCAATTCCCCGAGGAGGTGGATTCATCCGAGAAGATGCGC 700 
                             ************************************************** 
 
MOX-1_MOX-F                  GCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCA 351 
MOX-2_MOX-F                  GCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCA 350 
gi|11761377|dbj|D13304.2|    GCCTACTACCGCCAGTGGGCCCCTGTCTATTCGCCGGGCTCCCATCGCCA 750 
                             ************************************************** 
 
MOX-1_MOX-F                  GTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCC 401 
MOX-2_MOX-F                  GTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCC 400 
gi|11761377|dbj|D13304.2|    GTACTCCAACCCCAGCATAGGGCTGTTCGGCCACCTGGCGGCGAGCAGCC 800 
                             ************************************************** 
 
MOX-1_MOX-F                  TGAAGCAGCCATTTGCCCAGTTGATGGAGCAGACCCTGCTGCCCGGGCTC 451 
MOX-2_MOX-F                  TGAAGCAGCCATTTGCCCAGTTGATGGAGCAGACCCTGCTGCCCGGGCTC 450 
gi|11761377|dbj|D13304.2|    TGAAGCAGCCATTTGCCCAGTTGATGGAGCAGACCCTGCTGCCCGGGCTC 850 
                             ************************************************** 
 
MOX-1_MOX-F                  GGCATGCACCACACCT-TGTT----------------------------- 471 
MOX-2_MOX-F                  GGCATGCACCACACCT-TGTCA---------------------------- 471 
gi|11761377|dbj|D13304.2|    GGCATGCACCACACCTATGTCAATGTGCCGAAGCAGGCCATGGCGAGTTA 900 
                             **************** ***  
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9.5.5 EBC Plasmid Gene 
EBC-1_EBC-F                  ----GCAA-CCCTGTTTGAGCTGGGCTCTATAAGTAAAACCTTCACCGGC 45 
EBC-2_EBC-F                  ---CGCAA-CCCTGTTTGAGCTGGGCTCTATAAGTAAAACCTTCACCGGC 46 
gi|4558518|gb|M37839.2|      CCCCGCAAACCCTGTTTGAGCTGGGCTCTATAAGTAAAACCTTCACCGGC 1200 
                                 **** ***************************************** 
 
EBC-1_EBC-F                  GTACTGGGCGGCGATGCCATTGCCCGGGGTGAAGTAGCGCTGGGCGATCC 95 
EBC-2_EBC-F                  GTACTGGGCGGCGATGCCATTGCCCGGGGTGAAGTAGCGCTGGGCGATCC 96 
gi|4558518|gb|M37839.2|      GTACTGGGCGGCGATGCCATTGCCCGGGGTGAAATAGCGCTGGGCGATCC 1250 
                             ********************************* **************** 
 
EBC-1_EBC-F                  GGTAGCAAAATACTGGCCTGAGCTCACGGGCAAGCAGTGGCAGGGCATTC 145 
EBC-2_EBC-F                  GGTAGCAAAATACTGGCCTGAGCTCACGGGCAAGCAGTGGCAGGGCATTC 146 
gi|4558518|gb|M37839.2|      GGTAGCAAAATACTGGCCTGAGCTCACGGGCAAGCAGTGGCAGGGCATTC 1300 
                             ************************************************** 
 
EBC-1_EBC-F                  GCATGCTGGATCTGGCAACCTATACCGCAGGCGGTCTGCCGTTACAGGTG 195 
EBC-2_EBC-F                  GCATGCTGGATCTGGCAACCTATACCGCAGGCGGTCTGCCGTTACAGGTG 196 
gi|4558518|gb|M37839.2|      GCATGCTGGATCTGGCAACCTATACCGCAGGCGGTCTGCCGTTACAGGTG 1350 
                             ************************************************** 
 
EBC-1_EBC-F                  CCGGATGAGGTCACGGATACCGCTTCTCTGCTGCGCTTTTATCAAAACTG 245 
EBC-2_EBC-F                  CCGGATGAGGTCACGGATACCGCTTCTCTGCTGCGCTTTTATCAAAACTG 246 
gi|4558518|gb|M37839.2|      CCGGATGAGGTCACGGATACCGCCTCTCTGCTGCGCTTTTATCAAAACTG 1400 
                             *********************** ************************** 
 
EBC-1_EBC-F                  GCAGCCGCAGTGGAAG---------------------------------A 262 
EBC-2_EBC-F                  GCAGCCGCAGTGGAAG---------------------------------A 263 
gi|4558518|gb|M37839.2|      GCAGCCGCAGTGGAAGCCGGGCACCACGCGTCTTTACGCTAACGCCAGCA 1450 
                             ****************                                 * 
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9.6 ClustalW Analysis for the CTX-M Group 1 PCR Product 
gi|39545937|gb|AY463958.1      ACTGCGCCAGTTCACGCTGATGGCGACGGCAACCGTCACGCTGTTGTTAG 250 
EC-13441_ctxm1-f               ------------CACGC---------------------CGCTGTTGTTAG 17 
                                           *****                     ************ 
 
gi|39545937|gb|AY463958.1      GAAGTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCC 300 
EC-13441_ctxm1-f               GA-GTGTGCCGCTGTATGCGCAAACGGCGGACGTACAGCAAAAACTTGCC 66 
                               ** *********************************************** 
 
gi|39545937|gb|AY463958.1      GAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACAC 350 
EC-13441_ctxm1-f               GAATTAGAGCGGCAGTCGGGAGGCAGACTGGGTGTGGCATTGATTAACAC 116 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      AGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGT 400 
EC-13441_ctxm1-f               AGCAGATAATTCGCAAATACTTTATCGTGCTGATGAGCGCTTTGCGATGT 166 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      GCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAA 450 
EC-13441_ctxm1-f               GCAGCACCAGTAAAGTGATGGCCGCGGCCGCGGTGCTGAAGAAAAGTGAA 216 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      AGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCT 500 
EC-13441_ctxm1-f               AGCGAACCGAATCTGTTAAATCAGCGAGTTGAGATCAAAAAATCTGACCT 266 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      TGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCAC 550 
EC-13441_ctxm1-f               TGTTAACTATAATCCGATTGCGGAAAAGCACGTCAATGGGACGATGTCAC 316 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      TGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATG 600 
EC-13441_ctxm1-f               TGGCTGAGCTTAGCGCGGCCGCGCTACAGTACAGCGATAACGTGGCGATG 366 
                               ************************************************** 
 
gi|39545937|gb|AY463958.1      AATAAGCTGATTGCTCACGTTGGCGGCCCGGCTAGCGTCACCGCGTTCGC 650 
EC-13441_ctxm1-f               AATAAGCT------------------------------------------ 374 
                               ********   
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9.7 ClustalW analysis following review of CIT primers 
9.7.1 CIT Forward Primer 
LAT-1           ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAAAAGTGGCAGGGTATCCGCCTGC 520 
CMY-2           ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 2302 
CMY-3_4_        ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-4           ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-5           ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 2752 
CMY-6           ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-7           ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-12          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-14          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-15          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-16          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-17          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 543 
CMY-18          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 425 
CMY-20          ATCCGGTCACGAAATACTGGCCCGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGC 376 
CMY-21          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 539 
CMY-22          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-23          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 454 
CMY-24          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-25          ATCCGGTCACGAAATACTGGCCAGAACTGACTGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-26          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGATATCAGCCTGC 379 
CMY-27          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-28          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-29          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-30          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-31          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-32          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-33          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-34          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGC 379 
CMY-35          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-36          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 2753 
CMY-37          ATCCGGTCACGAAATACTGGTCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGC 379 
CMY-38          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-39          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGC 379 
CMY-40          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGTCTGC 379 
CMY-41          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGC 393 
CMY-43          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-44          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-45          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-47          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGAGGTATCAGCCTGC 1418 
CMY-48          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCGGGGTATCAGCCTGC 1418 
CMY-49          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGC 379 
CMY-54          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-55          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-56          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-57          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 379 
CMY-58          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 1646 
CMY-59          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCCGCCTGC 421 
CMY-64          ATCCGGTCACGAAATACTGGCCAGAACTGACAGGCAAACAGTGGCAGGGTATCAGCCTGC 379 
CMY-73          ATCCGGTCACGAAATACTTGCCAGAACTGACAGGCAAGCAGTGGCAGGGTATCAGCCTGC 379 
CFE-1           ATCCGGTCACGCAATACTGGCCTGAGCTGACGGGTAAGCAGTGGCAGGGTATCAGCCTGC 1386 
                *********** ****** * * ** ***** ** **  ******  * **** * **** 
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9.7.2 CIT Reverse Primer 
LAT-1           CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 934 
CMY-2           CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 2716 
CMY-3_4_        CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-4           CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-5           CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 3166 
CMY-6           CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-7           CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-12          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-14          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-15          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-16          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-17          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 957 
CMY-18          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 839 
CMY-20          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 790 
CMY-21          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 953 
CMY-22          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-23          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 868 
CMY-24          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-25          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-26          CCAACGTTACCGATATGGCACGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGG 793 
CMY-27          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-28          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-29          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-30          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-31          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-32          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-33          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-34          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-35          CCAGTGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGG 793 
CMY-36          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 3167 
CMY-37          CCAGCGTTATTGATATGGCACGCTGGGTTCAGGCCAACATGGATGCCAGCCGCGTTCAGG 793 
CMY-38          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-39          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAGG 793 
CMY-40          CCAGCGTTATCGATATGGCCCACTGGGTACAGGCCAACATGGACGCCAGCCACGTTCAGG 793 
CMY-41          CCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGG 807 
CMY-43          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-44          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-45          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-47          CCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGG 1832 
CMY-48          CCAGCGTTATCGATATGGCCCGCTGGGTTCAGGCCAACATGGACGCCAGCCACGTTCAGG 1832 
CMY-49          CCAACGTTACCGATATGGCCCGTTGGATTCAGGTCAACATGGACGCCAGCCGCGTTCAGG 793 
CMY-54          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 799 
CMY-55          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-56          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-57          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 793 
CMY-58          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 2060 
CMY-59          CCAGCGTTATTGATATGGCCCGCTGGGTTCAGGCCAACATGGATGCCAGCCACGTTCAGG 835 
CMY-64          CCAGTGTTATTGATATGGCCCGCTGGGTTCAGGTCAACATGGACGCCAGCCGCGTTCAAG 793 
CMY-73          CCAACGTTACCGATATGGCCCGTTGGATTCAGGTCAACATGGACGCCAGCCGCGTTCAGG 793 
CFE-1           CAAGCGTTGTCGATATGACCCGCTGGGTCCAGGCCAACATGGATGCCAGCCAGGTTCAGG 1800 
                * *  ***   ****** * *  *** * **** ********* *******  ***** * 
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9.8 ClustalW analysis for the review of ACC plasmid gene sequences 
ACC-1           --CGATTAAAAGGTCACTTATTCATGCGTAAAA--AAATGCAGAA----CACAT--TGAA 666 
ACC-2           --CGATTAAAAGGTCACTTATTCATGCGTAAAA--AAATGCAGAA----CACCT--TGAA 1593 
ACC-3           -----------------------ATGCGTAAAA--AAATGCAGAA----CACCT--TGAA 29 
ACC-4           CACGATTGAA--GCCACCGATCTGTTCCTTGAAGCAGGTGTATTATTTGCGCCTGGTAAA 1698 
                                        * * *  **  *  ** *  *    * * *  * ** 
 
ACC-1           GCTGTTATCCGTGAT--TACC----TGTCTGG--CAGCAACTGTCCAAGGTGC------T 712 
ACC-2           GCTGTTATCCGTGAT--TACC----TGTCTGG--CAGCAACTGCCCAAGGTGC------T 1639 
ACC-3           GATGTTATCCGTGAT--TACC----TGTCTGG--CTTTAACGGCTCAGGGTGC------C 75 
ACC-4           GCAGCGAACGCTGGTGGTGTCGCAACATCGGGGCTAGAAATGGCGCAGAACGCCGCTCGT 1758 
                *  *  * *  ** *  *  *      ** **      **  *  **    **        
 
ACC-1           CTGG-CTGCTAATATCGATGAGAGCAAAATTAAAG--ACACCG--------TTGATGACC 761 
ACC-2           ATGG-CTGCCAATATCGATGAGAGCAAAATTAAAG--ACACCG--------TCGATGGCC 1688 
ACC-3           ATGG-CGTCAGAAATGGATCAGGCCAAAATTAAAG--ACACCG--------TTGATAGCC 124 
ACC-4           ATGGGCTG-GAAAGCCGA-GAAAGTGGATTTACGCCTACACCACATCATGCTGGATATCC 1816 
                 *** *     *    **  *      * ***     *****         * ***  ** 
 
ACC-1           TGATCCAGCC-GC--------TGATGCAGAAGAATAATATTCCCGGTATGTCGGTCGCAG 812 
ACC-2           TAATCCAGCC-GC--------TGATGCAGAAGAATAATATTCCCGGTATGTCGGTCGCAG 1739 
ACC-3           TGATCCAGCC-GC--------TGATGCAGAAGAATAATATTCCGGGCATGTCGGTGGCAG 175 
ACC-4           --ACCAAGCCTGCGTGGAATATGGCGGAGAAGATAAGCAAACCCACTACGT---TCGCGG 1871 
                  * * **** **        **  * ******  *  *  **    * **   * ** * 
 
ACC-1           TG--ACCGTCAACGG------TAAAA--ACT-ACATT-TATAACTATGGGTTA-GCGGCA 859 
ACC-2           TG--ACCATCAGAGG------TAGGA--ACT-ATATT-TATAACTACGGGTTA-GCGGCA 1786 
ACC-3           TT--ACGCTGAACGG------TAAAA--ATT-ATATT-TATAACTATGGCTTA-GCCTCC 222 
ACC-4           TGCAAACATCGCTGGATTTGTTAAAGTCGCTGATGCCATGCTGGCACAGGGCGTGCTGTA 1931 
                *   *   *    **      **       * *     *      *  *     **     
 
ACC-1           AAACAGCCTCAGCAGCCGGTTACGGAAAATA-CGTTATTTGAAGTGGG------------ 906 
ACC-2           AAACAGCCTCAGCAGCCGGTGACGGAAAATA-CGTTATTTGAAGTGGG------------ 1833 
ACC-3           AAACAGCCCCAGCAGCCCGTAACGGACAACA-CGCTATTTGAAGTTGG------------ 269 
ACC-4           ATACC-CCTGAGAAATCGGTGACTCAACATATCGCCTCTCCAAACGAGAGGCGATATCTA 1990 
                * **  **  ** *  * ** **  *  * * **    *  **    *             
 
ACC-1           -----------------TTCGCTGAGT--AAAACGTT---TGCTGCCACC--TTGGCGTC 942 
ACC-2           -----------------TTCGCTGAGT--AAAACGTT---TGCTGCCATC--TTGGCGTC 1869 
ACC-3           -----------------CTCGCTGAGC--AAAACCTT---TGCAGCGACG--CTGGCGTC 305 
ACC-4           TTTTCTACTTATTCCCTTCCAATGAGCTCAGGATTTTATACGCCACCGTCACTCGCTGAT 2050 
                                   *  ****   *  *  **    **  *        *  *   
 
ACC-1           CTAT-GCGCAG---------GTGAGCGGTAAG----CTGTCTTT------GGATCAAA-G 981 
ACC-2           CTAT-GCGCAG---------GCGAGCGGTAAG----CTGTCTTT------GGAGCAAA-G 1908 
ACC-3           TTAT-GCACAG---------GTCAGCGGCAAG----TTATCGCT------GGATAAAA-G 344 
ACC-4           CGATTGAGTAGTTTTTGTTAGCCAGCATCACGATCCCCATCTTCTTAGCAGGAACAAACG 2110 
                  ** *   **         *  ***   * *       **         ***  *** * 
 
ACC-1           CGTTA-----------GCCATTA--CGTTCCAGAGTTGCGTGGCAGCAGCTTT------- 1021 
ACC-2           CGTTA-----------GCCACTA--TGTTCCAGAACTACGTGGCAGCAGCTTT------- 1948 
ACC-3           CATTA-----------GCCATTA--TGTTCCAGAACTGCGCGGCAGCAGCTTC------- 384 
ACC-4           CAATATAGGCACCGAAGCCGTTAGTTGATCCGGTCTTATTAATCCACACATTTTCCTGTG 2170 
                *  **           ***  **   * *** *   *      *  **  **         
 
ACC-1           --GACCACGTTAGCGTACTCAATGTGGGCACGCATACC-TCA--GGCCTACAGCTATTTA 1076 
ACC-2           --GACCACGTTAGCGTACTCAATGTGGGTACGCATACC-TCA--GGTCTACAGCTGTTTA 2003 
ACC-3           --GATCACATTAGCGTGCTGAATGCGGGAACGCATACC-ACA--GGTTTAGCGCTGTTCA 439 
ACC-4           GCGGTAACGGCGGAACAATCGGCGTAGCCACGCTTTTCGTCATCGCCATATCGTTACCGG 2230 
                  *   **    *     *    *  *  **** *  *  **  *   **  * *      
 
ACC-1           TG-------CCGG--AAGATATTAAAAATA----------CCACA-CAG---CTGA-TGG 1112 
ACC-2           TG-------CCGG--AAGATATCAAGAACA----------CCACA-CAG---CTGA-TGA 2039 
ACC-3           TG-------CCTG--AAGAAGTGAAAAACA----------CCGAT-CAG---CTGA-TGG 475 
ACC-4           TGAGCAAATTCGGCAGAGAAACCGGATATGGCAGCTGCTCCCACATCAGATCCTGAGTAA 2290 
                **        * *   ***        *            **    ***   **** *   
 
ACC-1           CTT------ATCTAAAA------GCATGGAAACCTG-------CCGATGCGGCT-GGAAC 1152 
ACC-2           CTT------ATCTAAAA------GCATGGAAACCTG-------CTGATGCGGCT-GGAAC 2079 
ACC-3           CTT------ATCTGAAA------GCGTGGAAACCCG-------CCGATCCTGCG-GGGAC 515 
ACC-4           TCTCACCCGATTTGAAATAGCCGGTGTGGGTGGCTGTCAGAGCCTGTTGCATCTTGGCAT 2350 
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9.9 Excluded Isolates from the Regional Study 
Table 9-2: Details of the 20 isolates excluded from the study on the basis of an incorrect species 
identification. 
Study No. Laboratory Identification 
DO-018 Dorchester Morganella morganii 
DO-043 Dorchester Enterobacter cloacae 
DO-049 Dorchester Serratia marcescens 
G-338 Gloucester Klebsiella pneumoniae 
G-343 Gloucester Stenotrophomonas maltophilia 
G-348 Gloucester Serratia fonticola 
G-349 Gloucester Serratia fonticola 
G-365 Gloucester Proteus mirabilis 
G-370 Gloucester Roultella ornitholytica 
G-372 Gloucester Enterobacter cloacae 
G-390 Gloucester Pseudomonas sp. 
G-391 Gloucester Klebsiella pneumoniae 
G-397 Gloucester Pseudomonas sp. 
G-401 Gloucester Citrobacter braakii 
G-409 Gloucester Morganella morganii 
G-411 Gloucester Morganella morganii 
G-420 Gloucester Citrobacter freundii 
G-442 Gloucester Citrobacter freundii 
TA-030 Taunton Enterobacter aerogenes 
TR-042 Truro Citrobacter freundii 
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9.10 BLAST hit table for CMY-2 plasmid  gene sequences 
 
BLASTN 2.2.32+ 
Reference: Zheng Zhang, Scott Schwartz, Lukas Wagner, and 
Webb Miller (2000), "A greedy algorithm for aligning DNA 
sequences", J Comput Biol 2000; 7(1-2):203-14. 
 
Reference for database indexing: Aleksandr Morgulis, George 
Coulouris, Yan Raytselis, Thomas L. Madden, Richa Agarwala, 
Alejandro A. Schaffer (2008), "Database Indexing for 
Production MegaBLAST Searches", Bioinformatics 24:1757-1764. 
 
RID: V7FXPJU501R 
 
Database: Nucleotide collection (nt) 
31,279,139 sequences; 100,739,227,704 total letters 
Query= Length=303 
 
                                                                  Score     E 
Sequences producing significant alignments:                       (Bits)   Value 
 
gb|AB212086.1|  Escherichia coli bla CMY-2 gene for beta-lacta...  560     5e-156 
gb|KP037097.1|  Escherichia coli strain NP2 CMY-2 beta-lactama...  560     5e-156 
db|LC019731.1|  Escherichia coli plasmid pCMY2 DNA, complete  ...  560     5e-156 
gb|KP340125.1|  Salmonella enterica subsp. enterica SH6 CMY-2 ...  560     5e-156 
gb|KP207590.1|  Escherichia coli strain S62 plasmid pS62t stbE...  560     5e-156 
gb|KP207588.1|  Escherichia coli strain FS7E9S insertion seque...  560     5e-156 
gb|KP207589.1|  Escherichia coli strain S166 class C beta-lact...  560     5e-156 
gb|KR494248.1|  Escherichia coli strain M63 plasmid pESCR, com...  560     5e-156 
db|AB672503.1|  Salmonella enterica subsp. enterica serovar I...   560     5e-156 
gb|KP789019.1|  Escherichia coli strain WCHEC13-8 plasmid pCMY...  560     5e-156 
emb|LN831184.1|  Vibrio cholerae genome assembly V. cholerae 1...  560     5e-156 
gb|KP742988.1|  Salmonella enterica subsp. enterica serovar Se...  560     5e-156 
gb|CP011429.1|  Salmonella enterica subsp. enterica strain YU3...  560     5e-156 
gb|KP281294.1|  Escherichia coli strain 1152602 class C beta-l...  560     5e-156 
gb|KJ802405.1|  Providencia stuartii isolate GN576 plasmid pND...  560     5e-156 
gb|KJ802404.1|  Escherichia coli isolate GN568 plasmid pNDM-Ec...  560     5e-156 
gb|CP009413.2|  Salmonella enterica strain CFSAN007427 plasmid...  560     5e-156 
gb|CP009412.2|  Salmonella enterica strain CFSAN007426 plasmid...  560     5e-156 
gb|CP009411.2|  Salmonella enterica strain CFSAN007425 plasmid...  560     5e-156 
gb|CP009410.2|  Salmonella enterica strain CFSAN007405 plasmid...  560     5e-156 
gb|CP009409.2|  Salmonella enterica subsp. enterica serovar He...  560     5e-156 
gb|KP205272.1|  Escherichia coli strain EL-231 plasmid pQEL231...  560     5e-156 
dbj|AB906452.1|  Salmonella enterica subsp. enterica serovar I...  560     5e-156 
dbj|AB750370.1|  Salmonella enterica subsp. enterica serovar I...  560     5e-156 
gb|KJ588779.1|  Klebsiella pneumoniae strain ATCC BAA-2146 pla...  560     5e-156 
gb|KM507172.1|  Escherichia coli strain CNR581 CMY-121 beta-la...  560     5e-156 
gb|KP017243.1|  Klebsiella pneumoniae strain Kp2735 plasmid p2...  560     5e-156 
gb|KP056256.1|  Escherichia coli strain YDC637 plasmid pYDC637...  560     5e-156 
gb|CP009564.1|  Salmonella enterica subsp. enterica serovar Ne...  560     5e-156 
gb|CP009562.1|  Salmonella enterica subsp. enterica serovar Ne...  560     5e-156 
gb|CP009560.1|  Salmonella enterica subsp. enterica serovar Ne...  560     5e-156 
gb|CP009570.1|  Salmonella enterica subsp. enterica serovar Ne...  560     5e-156 
gb|CP009567.1|  Salmonella enterica subsp. enterica serovar Ne...  560     5e-156 
gb|CP009566.1|  Salmonella enterica subsp. enterica serovar Ne...  560     5e-156 
gb|CP007636.1|  Vibrio cholerae strain 2012EL-2176 plasmid, co...  560     5e-156 
gb|KJ909290.1|  Aeromonas salmonicida subsp. salmonicida strai...  560     5e-156 
gb|KC585021.1|  Escherichia coli strain E34OD insertion sequen...  560     5e-156 
emb|HG970648.1|  Escherichia coli plasmid pJIE512b, complete s...  560     5e-156 
dbj|AP014565.1|  Salmonella enterica subsp. enterica serovar T...  560     5e-156 
emb|HG941718.1|  Escherichia coli ST131 strain EC958 chromosom...  560     5e-156 
dbj|AB933352.1|  Klebsiella pneumoniae DNA, insertion sequence...  560     5e-156 
dbj|AB933351.1|  Klebsiella pneumoniae DNA, insertion sequence...  560     5e-156 
dbj|AB933350.1|  Klebsiella pneumoniae DNA, insertion sequence...  560     5e-156 
gb|KJ496347.1|  Escherichia coli strain C1310573 beta-lactamas...  560     5e-156 
gb|KJ155695.1|  Serratia marcescens strain A4Y201 class C beta...  560     5e-156 
gb|KJ488945.1|  Escherichia coli strain C1050854 CMY-2 beta-la...  560     5e-156 
gb|KJ135996.1|  Escherichia coli strain 4-462 class C beta-lac...  560     5e-156 
gb|KJ135995.1|  Escherichia coli strain 4-67 class C beta-lact...  560     5e-156 
gb|KJ135971.1|  Escherichia coli strain 1-46 class C beta-lact...  560     5e-156 
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9.11 BLAST hit table for DHA-1 plasmid gene sequences 
BLASTN 2.2.32+ 
Reference: Zheng Zhang, Scott Schwartz, Lukas Wagner, and 
Webb Miller (2000), "A greedy algorithm for aligning DNA 
sequences", J Comput Biol 2000; 7(1-2):203-14. 
 
Reference for database indexing: Aleksandr Morgulis, George 
Coulouris, Yan Raytselis, Thomas L. Madden, Richa Agarwala, 
Alejandro A. Schaffer (2008), "Database Indexing for 
Production MegaBLAST Searches", Bioinformatics 24:1757-1764. 
 
RID: V7HW61ET01R 
 
Database: Nucleotide collection (nt) 
31,279,139 sequences; 100,739,227,704 total letters 
Query= Length=359 
 
                                                                   Score     E 
Sequences producing significant alignments:                       (Bits)  Value 
 
gb|KP683353.1|  Escherichia coli strain DHA-1 AmpC (ampC) gene...  664     0.0   
gb|AY635140.1|  Klebsiella pneumoniae beta-lactamase DHA-1 gen...  664     0.0   
emb|LN831185.1|  Vibrio cholerae genome assembly V. cholerae 1...  654     0.0   
dbj|LC055503.1|  Klebsiella pneumoniae plasmid pHM881QN DNA, c...  654     0.0   
gb|KJ187752.1|  Klebsiella pneumoniae strain 7433 plasmid pTR2...  654     0.0   
gb|KF856624.1|  Proteus mirabilis strain PEL ThdF (thdF) gene,...  654     0.0   
gb|KM087850.1|  Morganella morganii class C beta-lactamase (bl...  654     0.0   
gb|KM111265.1|  Escherichia coli strain NF27595(CI13) insertio...  654     0.0   
emb|HG918041.1|  Klebsiella pneumoniae Kp15 plasmid pENVA comp...  654     0.0   
gb|KJ504228.1|  Klebsiella pneumoniae strain KUN-8056 plasmid ...  654     0.0   
gb|KJ135992.1|  Acinetobacter baumannii strain 4-495 class C b...  654     0.0   
gb|KJ135991.1|  Klebsiella pneumoniae strain 4-448 class C bet...  654     0.0   
gb|KJ135990.1|  Klebsiella pneumoniae strain 4-12 class C beta...  654     0.0   
gb|KJ135977.1|  Klebsiella pneumoniae strain 2-66 class C beta...  654     0.0   
gb|KJ135976.1|  Klebsiella pneumoniae strain 2-50 class C beta...  654     0.0   
gb|KJ135975.1|  Klebsiella pneumoniae strain 2-34 class C beta...  654     0.0   
gb|KJ135973.1|  Klebsiella pneumoniae strain 2-12 class C beta...  654     0.0   
gb|KJ135972.1|  Enterobacter cloacae strain 2-8 class C beta-l...  654     0.0   
gb|KJ135967.1|  Klebsiella pneumoniae strain 1-47 class C beta...  654     0.0   
gb|KJ135966.1|  Klebsiella pneumoniae strain 1-39 class C beta...  654     0.0   
gb|KJ135965.1|  Klebsiella pneumoniae strain 1-28 class C beta...  654     0.0   
gb|KJ127282.1|  Klebsiella pneumoniae strain T9 plasmid class ...  654     0.0   
gb|KJ127281.1|  Klebsiella pneumoniae strain F63 plasmid class...  654     0.0   
gb|KJ127279.1|  Klebsiella pneumoniae strain F58 plasmid class...  654     0.0   
gb|KJ127276.1|  Klebsiella pneumoniae strain F52 plasmid class...  654     0.0   
gb|KJ127275.1|  Klebsiella pneumoniae strain F50 plasmid class...  654     0.0   
gb|KJ127274.1|  Klebsiella pneumoniae strain F48 plasmid class...  654     0.0   
gb|KJ127273.1|  Klebsiella pneumoniae strain F44 plasmid class...  654     0.0   
gb|KJ127272.1|  Klebsiella pneumoniae strain F42 plasmid class...  654     0.0   
gb|KJ127271.1|  Klebsiella pneumoniae strain F33 plasmid class...  654     0.0   
gb|KJ127270.1|  Klebsiella pneumoniae strain F31 plasmid class...  654     0.0   
gb|KJ127261.1|  Klebsiella pneumoniae strain K40 plasmid class...  654     0.0   
gb|KJ127260.1|  Klebsiella pneumoniae strain K39 plasmid class...  654     0.0   
gb|KJ127251.1|  Klebsiella pneumoniae strain F26 plasmid class...  654     0.0   
gb|KJ127250.1|  Klebsiella pneumoniae strain F19 plasmid class...  654     0.0   
gb|KJ127249.1|  Klebsiella pneumoniae strain F16 plasmid class...  654     0.0   
gb|KJ127248.1|  Klebsiella pneumoniae strain F9 plasmid class ...  654     0.0   
gb|KF793937.1|  Klebsiella pneumoniae plasmid pKPS30, complete...  654     0.0   
gb|KF646592.1|  Enterobacter hormaechei subsp. oharae strain C...  654     0.0   
gb|KF250428.1|  Klebsiella pneumoniae strain CRE114 plasmid pI...  654     0.0   
ref|NG_041672.1|  Klebsiella pneumoniae plasmid pRI 1 QnrB38 (...  654     0.0   
gb|KC999035.1|  Escherichia coli plasmid pEC2-NDM-3, partial s...  654     0.0   
gb|KC848778.1|  Escherichia coli strain DEC216 plasmid pDEC216...  654     0.0   
dbj|AB759690.1|  Klebsiella pneumoniae plasmid pNDM-1saitama01...  654     0.0   
gb|CP004345.1|  Morganella morganii subsp. morganii KT, comple...  654     0.0   
gb|JQ356870.1|  Citrobacter freundii strain Iona 6 plasmid pCF...  654     0.0   
gb|JN215524.1|  Citrobacter freundii strain Iona 4 plasmid pCF...  654     0.0   
gb|JN215523.1|  Citrobacter freundii strain Iona 2 plasmid pCF...  654     0.0   
gb|JX988621.1|  Klebsiella pneumoniae strain 601 plasmid pNDM-...  654     0.0   
gb|JX495964.1|  Escherichia coli strain 11-905 beta-lactamase ...  654     0.0   
gb|JX268774.1|  Klebsiella pneumoniae strain AKH11/C53 beta-la...  654     0.0   
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9.12 Informal Audit of ESBL Reporting Rates, 2013. 
In 2013, as part of the South West Regional Biomedical Group (a quarterly forum of 
microbiology scientific staff), a small audit was undertaken of basic ESBL reporting 
rates in laboratories in the South West. Five laboratories were able to provide data 
for 2012 for urine samples and seven laboratories provided data for blood culture 
samples. The purpose of this informal audit was to identify whether there were 
variations in the ESBL-positivity rates between laboratories. Reported ESBL 
positivity rates varied from 1.3% to 6.2% for urine isolates and from 0.4% to 14.8% 
for blood culture isolates (Figure 9-1). The laboratories tested a total of 64,017 
blood culture samples and 320,775 urine samples during 2012. From these samples, 
46,260 isolates of E. coli were isolated, most of which were from urine samples 
(97%). A positive ESBL confirmation result was reported in a total of 1968, giving an 
overall prevalence rate of 4.3% for the presence of ESBL enzymes. The rate was 
significantly higher in the blood culture samples at 5.8%, compared to 4.2% for 
urine samples (p=0.003, χ2). Although only an informal audit, the study did provide 
some evidence of variation in ESBL prevalence rates between laboratories in the 
South West region. The results of this audit were presented to the SWRB Group on 
4th June 2013 by the author of the current study (Lewis, 2013). 
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Figure 9-1: ESBL positivity rates between laboratories for urine samples (blue) and blood cultures 
(green); identified as part of an informal audit of five laboratories in the South West region. 
Data were obtained from a regional audit undertaken in 2013 (Lewis, 2013). The presence of ESBL 
enzymes was determined using the phenotypic methods utilised by the various laboratories. 
Lab Key: Gloucester (GL), Truro (TR), Swindon (SW), Weston-Super-Mare (WE), North Devon (ND), 
Poole (PO) and Bournemouth (BM). 
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9.13 Copy of Published Material – Lewis et al. (2015) 
This is the authors’ accepted manuscript of an article published as the version of 
record in the British Journal of Biomedical Science (January 2015), available at: 
http://www.tandfonline.com/doi/abs/10.1080/09674845.2015.11666789 
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Abstract 
AmpC beta-lactamase is an enzyme commonly produced by E. coli that causes 
resistance to cephalosporins and penicillins. Enzyme production is controlled by the 
strength of the promoter encoded by the chromosomal ampC gene, with the level 
of production affected by the presence of certain mutations in this region. This 
study set out to determine the prevalence of ampC promoter mutations present in 
a group of uropathogenic E. coli strains. 
A total of 50 clinical strains of E. coli were collected from urine samples between 
June 2011 and November 2011. Strains were investigated for the presence of 
mutations in the chromosomal ampC promoter region by amplification and 
sequencing of a 271bp product. The presence of ampC-carrying plasmids derived 
from other species was also determined, to exclude these from further analysis. 
ampC-carrying plasmids were found in 10 of the 50 strains, all of which were of the 
CIT-type. Analysis of the chromosomal ampC promoter region in the 40 remaining 
strains showed mutations at 16 different positions, with 18 different genotype 
patterns detected overall. The most common ampC chromosomal mutation, 
present in 25 of 40 strains, was a T→A transition at position -32. This mutation has 
been shown by others to increase enzyme production by up to 46-fold. 
Altogether, three separate mutations (-32, -42 and -13ins) were present in 90% of 
the 40 non-plasmid strains, indicating a strong association with the resistance 
observed. It appears, therefore, that the majority of AmpC-mediated resistance in 
E. coli can be accounted for by just three point mutations in the chromosome. 
 
Keywords 
Antibiotic resistance 
Cephalosporin 
Escherichia coli 
AmpC beta-lactamase 
 
Introduction 
AmpC beta-lactamase is an enzyme commonly produced by Escherichia coli that 
causes resistance to cephalosporins and penicillins.1 All strains of E. coli carry the 
chromosomal ampC gene for enzyme production, which is normally weakly 
expressed and under tight control by regulatory mechanisms.2 Production of the 
chromosomally-encoded enzyme is constitutive, but at such a low level that clinical 
failure of beta-lactam antibiotics is not usually seen. Certain mutations can occur in 
the promoter region, affecting the level of enzyme production. Strains with 
chromosomal ampC mutations can produce enzymes in higher amounts and are 
said to hyper-produce the AmpC enzyme, leading to clinical resistance and 
treatment failures.3  
The common DNA sequence seen in numerous E. coli promoters is a -35 box 
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(TTGACA) separated from a -10 box (TATAAT) by 17bp.2 The normal ampC promoter 
sequence, however, includes single nucleotide difference in each of these 
hexameric boxes, together with a spacer difference of 16bp (Figure 1). These small 
differences are sufficient to affect the function of the promoter and decrease the 
normal AmpC enzyme production to its constitutive low level.4 
Mutations in the ampC promoter region can arise, and include transitions and 
insertions in the -35 or -10 boxes, which create a region more closely related to the 
standard E. coli promoter sequence, and thus a stronger promoter.2 The most 
frequently reported promoter mutation (C→T at position -42) is one that creates a 
displaced -35 box in the promoter sequence, and is associated with a 20-fold 
increase in enzyme production.5 Other reported key mutations include substitutions 
that change the sequence of the wild-type -35 box itself, and insertions in the 
spacer region between the -35 and -10 boxes. Mutations have also been reported 
throughout other locations in the promoter, attenuator and coding regions, but 
these are considered to have a lesser impact on the level of enzyme production.5 
In addition to chromosomal ampC mutations, E. coli can also acquire the genes for 
AmpC enzyme production from other species. First described in 1988, plasmid 
ampC genes are derived from species such as Enterobacter spp. and Citrobacter 
spp..6 Although there are >200 different plasmids reported to carry ampC genes, for 
convenience they are usually classified into six groups based on the species of 
origin; CIT, ACC, DHA, FOX, MOX, and EBC.7 The CMY-2 plasmid (within the CIT 
group) is the most common AmpC plasmid encountered to date, and also has the 
largest geographic spread.1 Woodford et al. (2007)8 tested 135 strains of E. coli 
referred from UK laboratories for the investigation of unusual resistance patterns, 
detecting an ampC-carrying plasmid in 49%. The majority were determined to be of 
the CIT-group, but ACC, FOX and DHA groups were also detected. Strains with 
plasmids carrying ampC genes were found to be more resistant to third-generation 
cephalosporins than those with ampC chromosomal promoter mutations. 
This study set out to characterise the chromosomal ampC mutations present in a 
group of uropathogenic E. coli strains. Although E. coli is one of the most common 
pathogens isolated in clinical laboratories, there is a lack of data for the UK 
describing the prevalence and nature of AmpC resistance in clinical isolates. This is 
particularly the case for the chromosomal mutations responsible for AmpC enzyme 
hyper-production. Whilst the ampC-carrying plasmids can give rise to a higher level 
of resistance, the chromosomal ampC mutations seen in E. coli represent a larger 
overall group of resistant strains. 
Materials & Methods 
Strain Collection 
Clinical strains of E. coli isolated from urine samples in the Gloucestershire 
laboratory between June 2011 and November 2011 were included if disc 
susceptibility testing indicated cefpodoxime resistance with a subsequent negative 
result for clavulanic acid synergy; thus excluding the presence of ESBL-mediated 
resistance.9 Strains were identified to species level using a chromogenic urine media 
plate (257481, Becton Dickinson, Oxford, UK) and API20E identification strips 
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(20100, Biomerieux, Basingstoke, UK). Isolates were excluded if the same species 
had previously been isolated from the patient within a 28-day period. Strains were 
anonymised before inclusion in the study, and only basic patient demographic data 
(e.g. age and gender) were collected for each sample. During the collection period, 
a total of 50 clinical urine strains were included. 
Susceptibility Testing 
Strains were tested for susceptibility to a range of cephalosporins, including the 
antibiotics cefpodoxime (10µg), cefuroxime (30µg), cefoxitin (30µg), cefotaxime 
(30µg) and cefepime (30µg), using a standardised disc susceptibility method.10 A 0.5 
MacFarland suspension was prepared and diluted to a 1:100 concentration. The 
final suspension was inoculated onto an Isosensitest agar plate (PO0779A, Oxoid, 
Basingstoke, UK) using a cotton-tipped swab. Antibiotic discs (various, Oxoid, 
Basingstoke, UK) were applied to the surface of the agar and the plate was 
incubated for 18-24 hours at 37oC in air. Following incubation, the zone size for 
each antibiotic disc was recorded. 
Strains were also tested to determine the minimum inhibitory concentration (MIC) 
of cefotaxime. MICE gradient strips (MA0111F, Oxoid, Basingstoke, UK) were used 
to test the cefotaxime MIC within the range 0.002 to 32mg/L. A 0.5 MacFarland 
suspension was prepared and inoculated directly onto an Isosensitest agar plate 
using a cotton-tipped swab. The MICE strip was applied to the surface of the agar 
and the plate was incubated for 18-24 hours at 37oC in air. Following incubation, the 
point of intersection of the zone to the strip was recorded as the MIC for the strain. 
Detection of ampC Plasmids 
DNA templates for PCR amplification were prepared using a crude-lysis method.11 
Strains were incubated overnight on Columbia Horse Blood agar plates (PB0122A, 
Oxoid, Basingstoke, UK). A heavy bacterial suspension, equivalent to MacFarland 
standard 4.0, was prepared in 100µl water. Tubes were vortex-mixed for 2 minutes 
and then centrifuged for 5 minutes at 8,000g. The resulting supernatants were used 
as the DNA template. 
PCR assays were run on the SmartCycler II instrument (Cepheid, Sunnyvale, US), 
using the DX software (Version 3.0). Assay parameters were those recommended 
for use with the Quantifast SYBR Green master-mix (204054, Qiagen, Manchester, 
UK): 95oC for 5 minutes, followed by 35 cycles of 95oC for 10 seconds and 60oC for 
30 seconds. Fluorescence was read after each cycle at the instrument settings for 
FAM dye. A melting curve protocol was run at the end of amplification, with the 
temperature increasing from 60oC to 95oC at a rate of 0.5oC / sec. The resulting 
dissociation curve was used to visualise the presence of an amplified product. 
The presence of AmpC plasmid groups was determined using two multiplex real-
time SYBR Green PCR assays (CIT/ACC/DHA and FOX/MOX/EBC). Primers for five of 
the plasmid groups were as previously described.7 The CIT primers were updated to 
include more recently reported plasmids: CIT-F (5’-TGA TGC AGG AGC AGG CTA TTC-
3’) and CIT-R (5’-ACA GAC CAA TGC TGG AGT TAG-3’). Primers (Invitrogen, Paisley, 
UK) were used at a 0.2µM final concentration. Multiplex AmpC plasmid assays with 
positive dissociation curves were confirmed using the same primers in three 
separate simplex reactions, to identify the individual plasmid present. 
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Sequencing the ampC Promoter Region 
A 271bp region of the ampC gene, including the promoter region, attenuator region 
and part of the coding region, was amplified for each isolate using previously 
published primers at 0.1µM concentration.3 PCR protocol parameters were: 95oC 
for 5 minutes, followed by 35 cycles of 95oC for 10 seconds and 60oC for 30 seconds. 
A melting curve protocol was run to confirm the presence of an amplified product 
prior to sequencing. PCR products were sent to an external company (Eurofins 
Genomics, Ebersberg, Germany) for purification and sequencing, using the forward 
amplification primer. The reported sequence of each product was compared against 
the GenBank entry for E. coli NCTC 12241 (GenBank Accession AY899338), a 
laboratory control strain. Sequences were aligned using the ClustalW online 
software (www.ebi.ac.uk/tools/msa/clustalw2). The nature and position of each 
mutation was noted, and recorded according to the numbering system of Jaurin et 
al. (1981).12 
Results 
The 50 collected strains comprised 75% from female patients, and 25% from male. 
The mean age of patients was 58.3 years, with a range from 1 to 94 years. The 
results for disc susceptibility testing are shown in Table 1. The majority (98%) of 
isolates were resistant to cefuroxime when zone sizes were compared against 
breakpoints set by the British Society of Antimicrobial Chemotherapy (BSAC).10 In 
contrast, only 28% of strains demonstrated resistance to cefotaxime. Results also 
showed 98% of strains were resistant to cefoxitin, and there were 22 strains (44%) 
with resistant or intermediate zone sizes to the fourth-generation cephalosporin 
cefepime.  
Ten strains demonstrated an amplification product typical of the CIT group of 
plasmids. None of the other plasmid groups (ACC, DHA, FOX, MOX, EBC) were 
detected. As the genes carried on AmpC plasmids can account for enzyme 
production alone, these strains were excluded from further analysis. 
From the remaining 40 strains, sequencing the 271bp region covering the 
chromosomal ampC promoter showed mutations at 16 different positions 
throughout the amplified region (See Table 2). Overall, 18 different genotype 
patterns were detected from the 40 strains investigated, with all strains containing 
at least one polymorphism when compared to the sequence for the E. coli control 
strain. The most common chromosomal ampC genotype (n=11) included a T→A 
substitution at position -32, together with substitutions at positions +58 and +63. 
The -32 mutation alters the wild-type -35 box from TTGTCA to TTGACA, one that is 
closer to the E. coli standard promoter sequence.5 The altered -35 box retains its 
original position in the promoter region. Mutations related to a displaced promoter 
region were found in three strains, at positions -42 and -18. The -42 (C→T) 
substitution creates a new -35 box, whereas the G→A mutation at -18 gives rise to a 
new -10 box region. These mutations are often reported together,13 and result in 
two new regions 17bp apart at different locations. The increased distance between 
the two regions has been reported to affect promoter strength.5 The -18 mutation 
was also observed in two strains without the -42 mutation present. 
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Insertions in the spacer region (position -13) were detected in eight strains, 
increasing the distance between the -35 and -10 boxes from 16bp through the 
insertion of 1 or 2 base pairs. Seven strains had mutations in the attenuator region 
(positions +17, +23 and +37), often present along with promoter mutations. A total 
of 19 strains were found to have mutations in the coding region. The three 
mutations at positions +63, +70 and +81 have been reported to alter the amino acid 
coded for at each of the three respective codons. However, it is not clear whether 
this has a significant impact on enzyme function.13 
The geometric mean MIC for cefotaxime was 1.2mg/L for all strains, just above the 
recommended breakpoint of 1.0mg/L.10 Those strains with the -32 mutation 
present had a lower cefotaxime MIC of 0.6mg/L, compared to 1.2mg/L for strains 
with other mutations. In contrast, the ten strains with a CIT plasmid present had a 
geometric mean cefotaxime MIC of 7.3mg/L. 
Discussion 
CIT-type plasmids were found in 20% of the 50 strains collected. Although not fully 
characterised in this study, these are usually reported to be the CMY-2 plasmid. The 
presence of CMY-2 plasmids has been reported globally in clinical samples, and has 
also been associated with foodstuffs and animals.14–16 Phylogenetic studies have 
shown that E. coli strains carrying AmpC plasmids are more likely to be virulent, 
pathogenic types, whereas the strains with chromosomal promoter mutations are 
more likely to be commensal or environmental strains.17 
A total of 28 (70%) of the remaining 40 strains possessed either the -42 or -32 
mutation, both considered to be key factors in creating a stronger ampC promoter 
by creating a -35 box with greater homology to the E. coli standard promoter 
sequence.5 The -32 mutation was predominant in this study, with 25 strains 
demonstrating this substitution, either alone or in conjunction with other 
mutations. This mutation has been reported to result in an 8- to 46-fold increase in 
over-expression when compared to wild type strains.5 In this study, the geometric 
mean MIC for cefotaxime in the -32 mutation group was 0.6mg/L, compared to 
0.06mg/L for the E. coli control strain (NCTC 12241), showing a ten-fold increase. 
The -42 mutation and -13 spacer insertions have been shown to effect a similar 
impact on the level of over-expression; 20-fold and 24- to 61-fold, respectively.5 
Whilst we found only three strains with the -42 mutation, other studies have 
reported a higher prevalence,13,17–19 with one study finding 100% of isolates with 
this mutation.20 Eight of the 40 strains in our study had insertions of either one or 
two bases at position -13. The inserted bases were either adenine or thymine, and 
increased the spacer region from 16 base pairs to 17 or 18 base pairs. Seven strains 
were found to have mutations in the attenuator region. Although attenuator region 
mutations are thought to increase enzyme production through the destabilisation 
of the stem-loop structure, Tracz et al. (2007) demonstrated that these mutations 
have little actual effect on the level of enzyme production.5 
Resistance to cefoxitin is proposed as a screening test for AmpC production.10 In this 
study, 98% of all strains were resistant by disc susceptibility testing, confirming it’s 
utility as such. Whilst this may represent a good method for detecting AmpC-
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mediated resistance, the specificity of the method is reduced by other means in 
which strains can become resistant to cefoxitin (e.g. membrane permeability).21 
AmpC-producing strains are generally considered to have the antibiogram 
phenotype of cefoxitin-resistant, cefepime-sensitive.8 Here, only 56% of strains met 
the criteria for both, with only 42% having a zone size above the breakpoint of 
32mm for cefepime susceptibility.                                                                                                                                                                              
In this study of 50 uropathogenic strains of cefpodoxime-resistant, ESBL-negative E. 
coli, AmpC beta-lactamase resistance was confirmed in 92% of isolates. Although 
some strains did carry a plasmid ampC gene, the majority of strains possessed one 
of the ampC chromosomal promoter region mutations recognised to cause enzyme 
hyper-production. The -32 mutation, -42 mutation and -13 insertions accounted for 
90% of the resistance in the 40 non-plasmid strains, but were not found together in 
the same strain. Thus, providing further evidence that these represent the key 
mutations responsible for enzyme hyper-production. It was of interest to note a 
predominance of the -32 mutation in the strains, rather than the -42 mutation 
reported elsewhere. Although unlikely to represent a difference in the level of 
clinical resistance, strains carrying the -32 mutation may represent a dominant 
clone in the local population. Further studies are underway to include strains from 
other laboratories and to utilise molecular typing methods to identify the presence 
of different resistant strain populations.   
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Figure 1: Section of ampC promoter region, showing the positions of: 
a) The wild-type hexameric -10 and -35 boxes 
b) C->T transition at position -42 creates a displaced -35 box with a sequence identical to the 
E. coli standard promoter (TTGACA) 
c) T->A transition at position -32 creates an altered wild-type -35 box with a sequence 
identical to the E. coli standard promoter (TTGACA) 
d) Insertion of a single nucleotide at position -13 increases the spacer distance from 16bp to 
17bp 
Numbering of positions is according to Jaurin et al. (1981)
12
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 Disc 
Content 
(μg) 
Zone 
Diameter 
Breakpoints 
(mm) 
S (%) I (%) R (%) 
Cefpodoxime 10 ≤19 0 (0) N/A 50 (100) 
Cefuroxime 30 ≤19 1 (2) N/A 49 (98) 
Cefotaxime 30 ≤23 to ≤29 14 (28) 22 (44) 14 (28) 
Cefoxitin 30 ≤22 1 (2) N/A 49 (98) 
Cefepime 30 ≤26 to ≤31 28 (56) 12 (24) 10 (20) 
Table 1: Disc susceptibility results for the 50 strains to a range of five cephalosporins. The zone 
diameter breakpoints shown are for resistant strains, or for resistant and intermediate strains if a 
range is given. 
S = Resistant, I = Intermediate, R = Resistant   
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Genotype No. of Strains -42 -32 -28 -18 -14 -13 -13ins -1 +6 +17 +23 +34 +37 +58 +63 +70 +81 
Control  C T G G T T - C C C G G G C T C A 
G1 11  A            T C   
G2 8  A                
G3 2  A              T G 
G4 2       T  T         
G5 2 T   A    T      T   G 
G6 2   A    AT           
G7 2   A  A  T   T        
G8 1    A    T      T   G 
G9 1   A               
G10 1   A    T           
G11 1      G TT           
G12 1  A A       T        
G13 1  A A               
G14 1  A  A    T   A   T   G 
G15 1  A           A   T G 
G16 1 T   A    T   A   T   G 
G17 1   A         A  T    
G18 1   A       T        
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Table 2: Details of mutations observed at different positions in the amplified 271bp region of the promoter, attenuator and coding regions of the ampC gene. 
Each genotype is shown, with the corresponding numbers of strains allocated to that group. Genotype numbers were allocated within this study. Position 
numbers for locations on the ampC gene were those used by Jaurin et al. (1981).
12
 The control sequence is derived from the GenBank entry for E. coli NCTC 
12241 (AY899338). 
ins = 1 or 2 bp insertions at position -13. 
 
 
 
 
 
 
 
 
